WO2007000246A1 - Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals - Google Patents

Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals Download PDF

Info

Publication number
WO2007000246A1
WO2007000246A1 PCT/EP2006/005706 EP2006005706W WO2007000246A1 WO 2007000246 A1 WO2007000246 A1 WO 2007000246A1 EP 2006005706 W EP2006005706 W EP 2006005706W WO 2007000246 A1 WO2007000246 A1 WO 2007000246A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
group
pyridin
chosen
substituted
Prior art date
Application number
PCT/EP2006/005706
Other languages
French (fr)
Inventor
Hartmut Strobel
Paulus Wohlfart
Gerhard Zoller
David William Will
Original Assignee
Sanofi-Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AT06754352T priority Critical patent/ATE539072T1/en
Priority to AU2006264049A priority patent/AU2006264049B2/en
Application filed by Sanofi-Aventis filed Critical Sanofi-Aventis
Priority to PL06754352T priority patent/PL1899321T3/en
Priority to MX2008000044A priority patent/MX2008000044A/en
Priority to EP06754352A priority patent/EP1899321B1/en
Priority to JP2008518663A priority patent/JP5149794B2/en
Priority to BRPI0613717-2A priority patent/BRPI0613717A2/en
Priority to RS20120131A priority patent/RS52266B/en
Priority to ES06754352T priority patent/ES2378894T3/en
Priority to NZ565041A priority patent/NZ565041A/en
Priority to SI200631277T priority patent/SI1899321T1/en
Priority to CA002611953A priority patent/CA2611953A1/en
Priority to CN2006800228986A priority patent/CN101208328B/en
Priority to DK06754352.0T priority patent/DK1899321T3/en
Publication of WO2007000246A1 publication Critical patent/WO2007000246A1/en
Priority to US11/958,483 priority patent/US8518976B2/en
Priority to IL188382A priority patent/IL188382A0/en
Priority to NO20080523A priority patent/NO20080523L/en
Priority to HK08113552.5A priority patent/HK1122551A1/en
Priority to HR20120167T priority patent/HRP20120167T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

The present invention relates to N-alkylamides of the formula (I), in which A, Het, X, R1, R2 and R3 have the meanings indicated in the claims, which modulate the transcription of endothelial nitric oxide (NO) synthase and are valuable pharmacologically active compounds. Specifically, the compounds of the formula I upregulate the expression of the enzyme endothelial NO synthase and can be applied in conditions in which an increased expression of said enzyme or an increased NO level or the normalization of a decreased NO level is desired. The invention further relates to processes for the preparation of compounds of the formula I, to pharmaceutical compositions comprising them, and to the use of compounds of the formula I for the manufacture of a medicament for the stimulation of the expression of endothelial NO synthase or for the treatment of various diseases including cardiovascular disorders such as atherosclerosis, thrombosis, coronary artery disease, hypertension and cardiac insufficiency, for example.

Description

Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals
The present invention relates to N-alkylamides of the formula I,
Figure imgf000002_0001
in which A, Het, X, R1, R2 and R3 have the meanings indicated below, which modulate the transcription of endothelial nitric oxide (NO) synthase and are valuable pharmacologically active compounds. Specifically, the compounds of the formula I upregulate the expression of the enzyme endothelial NO synthase and can be applied in conditions in which an increased expression of said enzyme or an increased NO level or the normalization of a decreased NO level is desired. The invention further relates to processes for the preparation of compounds of the formula I1 to pharmaceutical compositions comprising them, and to the use of compounds of the formula I for the manufacture of a medicament for the stimulation of the expression of endothelial NO synthase or for the treatment of various diseases including cardiovascular disorders such as atherosclerosis, thrombosis, coronary artery disease, hypertension and cardiac insufficiency, for example.
Endothelial NO synthase (eNOS, NOS-III) belongs to a group of three isoenzymes which produce nitric oxide (nitrogen monoxide, NO) by oxidation of arginine. Endothelial^ released NO is of central importance in a number of key cardiovascular mechanisms. It has a vasodilating effect and inhibits the aggregation of platelets, the adhesion of leukocytes to the endothelium and the proliferation of intimal smooth muscle cells.
Endothelial NO synthase is subject to physiological and pathophysiological regulation both at the transcriptional and at the post-transcriptional level. Enzyme already present in the endothelium may undergo calcium-dependent and calcium- independent activation through phosphorylation of specific amino acids, but also by direct interactions with specific proteins. Stimulators of this, usually transient, NO release are extracellular arginine, 17β-estrogen and the mechanical stimulus exerted on the luminal surface of the endothelium by the blood flow (shear stress). The latter additionally leads to regulation of eNOS at the transcriptional level. Thus, for example, Sessa et al. (Circ. Research 74 (1994) 349) were able to obtain a marked increase in eNOS by means of exercise training and the increase in shear stress associated therewith.
Whether regulation at the post-transcriptional level is relevant in vivo, has not been unambiguously proven. Thus, for example, administration of a high arginine dose is followed by only a transient improvement in the endothelium-dependent vasorelaxation in patients with coronary heart disease.
On the other hand, the significance of the upregulation of the eNOS protein is scientifically accepted. Thus, there are findings which show that the protective properties of the HMG-CoA reductase inhibitor simvastatin can be attributed, besides to the lipid lowering, also in part to an increase in eNOS expression in vivo (Endres et al., Proc. Natl. Acad. Sci. USA 95 (1998) 8880). It is additionally known that single point mutations in the δ'-flanking region of the eNOS gene ("eNOS promoter"), and the reduction in the rate of eNOS gene transcription associated therewith, in the Japanese population is associated with an increase in the risk of coronary spasms (Nakayama et al., Circulation 99 (1999) 2864).
The current assumption therefore is that the transcriptional and post-transcriptional mechanisms of eNOS regulation are seriously disturbed in a large number of disorders, especially in cardiovascular disorders. Even in very early stages of a wide variety of cardiovascular disorders it is possible for a dysfunction of this type in the endothelium lining the blood vessels to lead to a deficiency of bioactive NO, which is manifested as the disorder progresses in the form of measurable pathophysiological and morphological changes. Thus, critical steps in early atherogenesis are speeded up by a decrease in endothelial NO release, such as, for example, the oxidation of low density lipoproteins, the recruitment and deposition of monocytes in the intima of vessels, and the proliferation of intimal cells. A consequence of atherogenesis is the formation of plaques on the inside of the blood vessels, which may in turn lead, through a diminution in the shear stress, to a further decrease in endothelial NO release and a further deterioration in the pathology. Since endothelial NO is also a vasodilator, a decrease thereof frequently also leads to hypertension which may, as an independent risk factor, cause further organ damage.
The aim of a therapeutic approach to the treatment of these disorders must accordingly be to interrupt this chain of events by increasing the endothelial NO expression. Gene transfer experiments which lead in vitro to overexpression of NO synthase in previously damaged vessels are in fact able to counteract the described processes and are thus evidence of the correctness of this approach (Varenne et al., Hum. Gene Ther. 11 (2000) 1329).
Some low molecular weight compounds which, in cell cultures, may lead to a direct effect on eNOS transcription and expression are disclosed in the literature. For the statins, as has already been mentioned, it has been possible to show such an increase in eNOS in vivo as a side effect. In view of the known range of side effects of this class of substances, however, it is unclear how far use of this effect can be made in a toxicologically unproblematic dose. Liao et al. claim in WO 99/47153 and WO 00/03746 the use of rhoGTPase inhibitors and agents which influence the organization of the actin cytoskeleton for increasing eNOS in endothelial cells and for the therapy of various disorders such as, for example, strokes or pulmonary hypertension without, however, indicating a specific way of achieving this. Certain amide derivatives which upregulate the expression of endothelial NO synthase, in particular N-cycloalkyl amides in which the cycloalkyl ring is fused to a benzene ring or a heteroaromatic ring, have been described in WO 02/064146, WO 02/064545, WO 02/064546, WO 02/064565, WO 2004/014369, WO 2004/014372 and WO 2004/014842. Certain triaza- and tetraaza-anthracenedione derivatives which upregulate the expression of endothelial NO synthase have been described in WO 2004/094425. There still exists a need for further compounds which upregulate the expression of endothelial NO synthase and have a favorable property profile and are useful as pharmaceuticals for the treatment of various diseases such as atherosclerosis, coronary artery disease or cardiac insufficiency, for example. Surprisingly it has now been found that the compounds of the formula I are modulators of the transcription of endothelial NO synthase and in particular stimulate, or upregulate, the expression of eNOS, and are useful for the treatment of various diseases such as the mentioned cardiovascular disorders.
Certain compounds which are encompassed by the formula I have already been described. In JP 2004-262890 compounds are described which inhibit the synthesis of 20-hydroxyeicosatetraenoic acid (= 20-HETE) from arachidonic acid and which contain a substituted central benzene ring or pyridine ring. The central ring carries a heterocyclic group, which in the case of a central pyridine ring is present in the 5- position, and a further group of broad structural variety, which in the case of a central pyridine ring is present in the 2-position. Said further group can, among others, be an unsubstituted imidazolin-2-on-1-yl group, which is assumed to mean a 2- oxoimidazolin-1-yl group, or an unsubstituted 2-oxopyrrolidin-1-yl group which are linked to the central ring via an alkyloxy group. Compounds of the formula I, in which R1 and R2 together with the N-CO group which carries them form a group of the formula
Figure imgf000005_0001
i.e. compounds in which the group -N(R2)-CO-R1 is a phthalimido group which group is also designated as 1 ,3-dioxoisoindol-2-yl group or 1 ,3-dioxo-1 ,3-dihydroisoindol-2- yl group or 1 ,3-dioxo-2,3-dihydro-1 H-isoindol-2-yl group, are described in a number of documents including DE 1913471 , GB 1341375, US 5190589, US 5547972 and Lipinski et al., J. Med. Chem. 29 (1986) 2154. Such phthalimido compounds commonly are intermediates in the synthesis of the respective compounds containing an amino group -NH2 using the Gabriel reaction, or are protected forms of such amino compounds.
In other documents certain compounds comprised by the formula I are described in which R1 and R2, together with the N-CO group which carries them, do not form a ring. For example, In US 5292732 1-(2-acylaminoethyl)pyrroles are described which are intermediates in the synthesis of monoamine oxidase inhibiting pyrrolopyrazines. In JP 44-29656 4-(ω-acylaminoalkyl)isoxazoles are described which exhibit analgesic, antitussive, antipyretic and antiinflammatory activity. In US 3655684 3-(2- acylaminoethyl)-5-phenyl-1 ,2,4-oxadiazoles are described which exhibit anticonvulsant activity. Certain 3-cyanopyhdines which carry an oxaalkylamino, aminoalkylamino, oxaalkyloxy, acyloxyalkylamino, acylaminoalkylamino or acyloxyalkyloxy group in the 2-position and a pyhdin-4-yl group or an alkyloxy- substituted phenyl group in the 5-position and which exhibit cardiotonic activity, including the specific compounds of the formula I in which A is the group NH-CH2-CH2 the nitrogen atom of which is attached to the group Het, Het is a pyridinyl group whose 2-position carries the group A and which is substituted by cyano in the 3-position, X is a direct bond, R3 is pyhdin-4-yl which is attached to the 5-position of the pyridinyl group representing Het, R2 is hydrogen and R1 is either methyl or ethyl or pyridin-3-yl, are described in Hagen et al., Pharmazie 45 (1990) 343 and EP 200024. A stimulating effect of these known compounds of the formula I on the transcription or the expression of eNOS and their use in the treatment of diseases which is based on such effect, has not yet been described.
A subject of the present invention is a compound of the formula I,
Figure imgf000006_0001
in which
A is chosen from -CH2-CH2-, -CH2-CH2-CH2- and -Y-CH2-CH2-, wherein all CH2 groups can be substituted by one or more identical or different substituents R4, and wherein Y is chosen from O, S and NR11 and Y is bonded to the group Het;
Het is a 5-membered or 6-membered, monocyclic aromatic group which contains one or two identical or different hetero ring members chosen from N, NR13, O and S and which can be substituted by one or more identical or different substituents R5;
X is chosen from a direct bond, CH2, O and NH;
R1 and R2, together with the N-CO group which carries them, form a 4-membered to 10-membered, monocyclic or bicyclic, saturated or unsaturated ring which, in addition to the ring nitrogen atom being part of the N-CO group, can contain one or two further hetero ring members chosen from N, NR12, O, S, SO and SO2 which can be identical or different, with the proviso that two ring members from the series O, S, SO and SO2 cannot be present in adjacent ring positions, wherein the ring formed by R1 and R2 and the N-CO group which carries them can be substituted by one or more identical or different substituents R8;
R3 is chosen from phenyl, naphthalenyl and heteroaryl which can all be substituted by one or more identical or different substituents chosen from halogen, (Ci-C4)-alkyl, (Ci-C4)-alkyloxy-(Ci-C2)-alkyl-, OH, (Ci-C4)-alkyloxy which can be substituted by one or more fluorine atoms, (Ci-C2)-alkylenedioxy which can be substituted by one or more fluorine atoms, (Ci-C4)-alkylmercapto, NH2, (Ci-C4)-alkylamino, di((Ci-C4)- alkyl)amino, ((d-C4)-alkyl)-CONH-, di((Ci-C4)-alkyl)aminocarbonyl-, ((CrC4)- alkyl)aminocarbonyl-, ((CrC4)-alkyloxy)carbonyl-, COOH, CONH2, CN, CF3, H2NSO2- and (Ci-C4)-alkyl-SO2-;
R4 is chosen from (Ci-C4)-alkyl and fluorine; R5 is chosen from halogen, (d-C4)-alkyl, (Ci-C4)-alkyloxy-(C1-C2)-alkyl-, OH1 (CrC4)- alkyloxy which can be substituted by one or more fluorine atoms, (CrC4)- alkylmercapto, NH2, (Ci-C4)-alkylamino, di((Ci-C4)-alkyl)amino, ((CrC4)-alkyl)- CONH-, di((CrC4)-alkyl)aminocarbonyl-, ((d-C^-alkyOaminocarbonyl-, ((CrC4)- alkyloxy)carbonyl-, COOH, CONH2, CN, CF3 and (Ci-C4)-alkyl-SO2-;
R8 is chosen from halogen, (CrC4)-alkyl, (C3-C7)-cycloalkyl-CnH2n-, phenyl-CnH2n-, heteroaryl-CnH2n-, (CrC4)-alkyloxy-(CrC2)-alkyl-, OH, oxo, (CrC4)-alkyloxy which can be substituted by one or more fluorine atoms, (CrC2)-alkylenedioxy which can be substituted by one or more fluorine atoms, (CrC4)-alkylmercapto, NH2, (CrC4)- alkylamino, di((CrC4)-alkyl)amino, ((CrC4)-alkyl)-CONH-, di((CrC4)- alkyl)aminocarbonyl-, ((CrC4)-alkyl)aminocarbonyl-, ((CrC4)-alkyloxy)carbonyl-, COOH, CONH2, CN, CF3, H2NSO2- and (CrC4)-alkyl-SO2-, wherein all phenyl groups and heteroaryl groups can independently of each other be substituted by one or more identical or different substituents chosen from halogen, (CrC4)-alkyl, CF3 and (Cr C4)-alkyloxy;
R11 is chosen from hydrogen, (CrC4)-alkyl and ((CrC4)-alkyl)-CO-;
R12 is chosen from hydrogen, (CrC4)-alkyl, (C3-C7)-cycloalkyl-CnH2n-, phenyl-CnH2n-, heteroaryl-CnH2n-, ((CrC4)-alkyl)-CO-, (C3-C7)-cycloalkyl-CnH2n-CO-, phenyl-CnH2n- CO-, heteroaryl-CnH2n-CO-, ((CrC4)-alkyl)-O-CO- and phenyl-CnH2n-O-CO-, wherein all phenyl groups and heteroaryl groups can be substituted by one or more identical or different substituents chosen from halogen, (CrC4)-alkyl, CF3 and (CrC4)- alkyloxy;
R13 is chosen from hydrogen, (CrC4)-alkyl and phenyl-CnH2n-, wherein the phenyl group can be substituted by one or more identical or different substituents chosen from halogen, (CrC4)-alkyl, CF3 and (CrC4)-alkyloxy, where all groups R13 are independent of each other and can be identical or different; heteroaryl is a 5-membered or 6-membered, monocyclic aromatic group which contains one, two or three identical or different hetero ring members chosen from N, NR13, O and S;
n is 0, 1 or 2, where all numbers n are independent of each other and can be identical or different;
in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof;
provided that the group -N(R2)-CO-R1 cannot be an unsubstituted 2-oxopyrrolidin-1-yl group or an unsubstituted 2-oxoimidazolin-1-yl group if simultaneously the group R3-X-Het- is a group of the formula
Figure imgf000009_0001
in which the bond via which the group is connected to the group A is depicted by the line starting in the 2-position of the pyridine ring, and in which R90 is chosen from imidazol-1-yl, isoxazol-5-yl, isothiazol-5-yl, 1 ,2,4-triazoM-yl, pyrazin-2-yl and pyrazol- 3-yl which can all be substituted by (Ci-C4)-alkyl, and which can be substituted in the pyridine ring by up to four substituents chosen from (Ci-C4)-alkyl, (Ci-C4)-alkyloxy and halogen; and provided that the group -N(R2)-CO-R1 cannot be a 1 ,3-dioxoisoindol-2-yl group of the formula
Figure imgf000009_0002
in which the bond via which the group is connected to the group A is depicted by the line starting at the nitrogen atom.
Another subject of the present invention is the use of a compound of the formula Ia
Figure imgf000010_0001
in which A is chosen from -CH2-CH2-, -CH2-CH2-CH2- and -Y-CH2-CH2- wherein all CH2 groups can be substituted by one or more identical or different substituents R4, and wherein Y is chosen from O1 S and NR11 and Y is bonded to the group Het;
Het is 5-membered to 10-membered, monocyclic or bicyclic, aromatic group which contains one or more identical or different hetero ring members chosen from N, NR13, O and S and which can be substituted by one or more identical or different substituents R5;
X is chosen from a direct bond, CH2, O, S, NH and N((Ci-C4)-alkyl), or X is absent and in this case the phenyl, naphthalenyl or heteroaryl group representing the group R3 is fused to the group Het;
R1 and R2 are independently of each other chosen from (C1-Cio)-alkyl, (C3-Ci0)- alkenyl, (C3-Ci0)-alkynyl, (C3-Cio)-cycloalkyl-CnH2n-, phenyl-CnH2n-, naphthalenyl- CnH2n- and heteroaryl-CnH2n-, and R2 can in addition be hydrogen, wherein the groups (Ci-Cio)-alkyl, (C3-Ci0)-cycloalkyl, (C3-Ci0)-alkenyl and (C3-Ci0)-alkynyl can all be substituted by one or more identical or different substituents R6, and the groups CnH2n can all be substituted by one or more identical or different substituents chosen from fluorine and (Ci-C4)-alkyl, and all phenyl, naphthalenyl and heteroaryl groups can independently of each other be substituted by one or more identical or different substituents R7, or R1 and R2, together with the N-CO group which carries them, form a 4-membered to 10-membered, monocyclic or bicyclic, saturated or unsaturated ring which, in addition to the ring nitrogen atom being part of the N-CO group, can contain one or two further hetero ring members chosen from N, NR12, O, S, SO and SO2 which can be identical or different, with the proviso that two ring members from the series O, S, SO and SO2 cannot be present in adjacent ring positions, wherein the ring formed by R1 and R2 and the N-CO group which carries them can be substituted by one or more identical or different substituents R8;
R3 is chosen from phenyl, naphthalenyl and heteroaryl which can all be substituted by one or more identical or different substituents chosen from halogen, (Ci-C6)-alkyl,
Figure imgf000011_0001
OH, (C-ι-C6)-alkyloxy which can be substituted by one or more fluorine atoms, (d-C3)-alkylenedioxy which can be substituted by one or more fluorine atoms, (d-CβJ-alkylmercapto, NH2, (Ci-C6)-alkylamino, di((d-C6)- alkyl)amino, ((d-C6)-alkyl)-CONH-, ((Ci-C6)-alkyl)-SO2NH-, di((C1-C6)- alkyl)aminocarbonyl-, ((Ci-C6)-alkyl)aminocarbonyl-, ((Ci-C6)-alkyloxy)carbonyl-, COOH, CONH2, CN, CF3, ((Ci-C6)-alkyl)NHSO2-, di((Ci-C6)-alkyl)NSO2-, H2NSO2- and (d-C6)-alkyl-SO2-;
R4 is chosen from (Ci-CβJ-alkyl, fluorine and oxo;
R5 is chosen from halogen, (Ci-CβJ-alkyl, phenyl-CnH2n-, (Ci-C6)-alkyloxy-(Ci-C3)- alkyl-, OH, (Ci-C6)-alkyloxy which can be substituted by one or more fluorine atoms, (Ci-C6)-alkylmercapto, NH2, (Ci-C6)-alkylamino, di((C1-C6)-alkyl)amino, ((Ci-C6)- alkyl)-CONH-, di((Ci-C6)-alkyl)aminocarbonyl-, ((C1-C6)-alkyl)aminocarbonyl-, ((C1- C6)-alkyloxy)carbonyl-, COOH, CONH2, CN, CF3, H2NSO2-, ((d-C6)-alkyl)NHSO2-, di((Ci-C6)-alkyl)NSO2- and (C-ι-C6)-alkyl-SO2-, wherein the phenyl group can be substituted by one or more identical or different substituents chosen from halogen, (d-C4)-alkyl, CF3 and (CrC4)-alkyloxy; R6 is chosen from fluorine, OH1 oxo, (CrC6)-alkyloxy, (Ci-C6)-alkylmercapto, di((Ci- C6)-alkyl)amino, ((d-C6)-alkyl)-CONH-, (^((d-CeJ-alkyOaminocarbonyl-, ((Ci-C6)- alkyloxy)carbonyl-, COOH, CONH2, CN and CF3;
R7 is chosen from halogen, (Ci-C6)-alkyl, (Ci-C6)-alkyloxy-(C1-C3)-alkyl-I OH, (Ci-C6)- alkyloxy which can be substituted by one or more fluorine atoms, (Ci-C3)- alkylenedioxy which can be substituted by one or more fluorine atoms, (Ci-C6)- alkylmercapto, NH2, (Ci-C6)-alkylamino, di((Ci-C6)-alkyl)amino, ((Ci-C6)-alkyl)- CONH-, di((Ci-C6)-alkyl)aminocarbonyl-, ((d-C6)-alkyl)aminocarbonyl-, ((C1-C6)- alkyloxy)carbonyl-, COOH, CONH2, CN, CF3, SF5, H2NSO2-, ((Ci-C6)-alkyl)NHSO2-, di((Ci-C6)-alkyl)NSO2- and (CrC6)-alkyl-SO2-;
R8 is chosen from halogen, (Ci-C6)-alkyl, (C3-C7)-cycloalkyl-CnH2n-, phenyl-CnH2n-, heteroaryl-CnH2n-, (CrC6)-alkyloxy-(Ci-C3)-alkyl-, OH, oxo, (Ci-C6)-alkyloxy which can be substituted by one or more fluorine atoms, (Ci-C3)-alkylenedioxy which can be substituted by one or more fluorine atoms, (Ci-C6)-alkylmercapto, NH2, (Ci-C6)- alkylamino, di((Ci-C6)-alkyl)amino, ((Ci-C6)-alkyl)-CONH-, di((Ci-C6)- alkyl)aminocarbonyl-, ((Ci-C6)-alkyl)aminocarbonyl-, ((Ci-C6)-alkyloxy)carbonyl-, COOH, CONH2, CN, CF3, SF5, H2NSO2- and (Ci-C6)-alkyl-SO2-, wherein all phenyl groups and heteroaryl groups can independently of each other be substituted by one or more identical or different substituents chosen from halogen, (Ci-C4)-alkyl, CF3 and (Ci-C4)-alkyloxy;
R11 is chosen from hydrogen, (Ci-C6)-alkyl, (C3-C7)-cycloalkyl-CnH2n-, phenyl-CnH2n-, heteroaryl-CnH2n-, ((Ci-C6)-alkyl)-CO-, (C3-C7)-cycloalkyl-CnH2n-CO-, phenyl-CnH2n- CO- and heteroaryl-CnH2n-CO-, wherein all phenyl groups and heteroaryl groups can be substituted by one or more identical or different substituents chosen from halogen, (Ci-C4)-alkyl, CF3 and (Ci-C4)-alkyloxy;
R12 is chosen from hydrogen, (CrC6)-alkyl, (C3-C7)-cycloalkyl-CnH2n-, phenyl-CnH2n-, heteroaryl-CnH2n-, ((Ci-C6)-alkyl)-CO-, (C3-C7)-cycloalkyl-CnH2n-CO-, phenyl-CnH2n- CO-, heteroaryl-CnH2n-CO-, ((d-C6)-alkyl)-O-CO- and phenyl-CnH2n-O-CO-, wherein all phenyl groups and heteroaryl groups can be substituted by one or more identical or different substituents chosen from halogen, (Ci-C4)-alkyl, CF3 and (CrC4)- alkyloxy;
R13 is chosen from hydrogen, (Ci-C.O-alkyl and phenyl-CnH2n-, wherein the phenyl group can be substituted by one or more identical or different substituents chosen from halogen, (Ci-C4)-alkyl, CF3 and (C1-C4)-alkyloxy, where all groups R13 are independent of each other and can be identical or different;
heteroaryl is a 5-membered to 10-membered, monocyclic or bicyclic aromatic group which contains one or more identical or different hetero ring members chosen from N, NR13, O and S;
n is 0, 1 , 2 or 3, where all numbers n are independent of each other and can be identical or different;
in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, for the manufacture of a medicament for the stimulation of the expression of endothelial NO synthase and for the treatment of a disease in which such a stimulation, or an increase in NO level, is desired, for example a cardiovascular disorder such as atherosclerosis, coronary artery disease or cardiac insufficiency or any other disease mentioned above or below herein.
If in the compounds of the formulae I and Ia any groups, substituents, hetero ring members, numbers or other features such as, for example, R4, R5, R6, R7, R8, R12, R13, alkyl groups, the number n, etc. can occur several times, they can all independently of one another have any of the indicated meanings and can in each case be identical or different from one another. In a dialkylamino group, for example, the alkyl groups can be identical or different.
Alkyl, alkenyl and alkynyl groups can be linear, i.e. straight-chain, or branched. This also applies when they are part of other groups, for example alkyloxy groups (= alkoxy groups, i.e. alkyl-O- groups), alkyloxycarbonyl groups or alkyl-substituted amino groups, or when they are substituted. Substituted alkyl, alkenyl and alkynyl groups can be substituted by one or more, for example one, two, three, four or five, identical or different substituents which can be located in any desired positions. Examples of alkyl groups are methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, the n-isomers of these groups, isopropyl, isobutyl, isopentyl, sec-butyl, tert-butyl, neopentyl or 3,3-dimethylbutyl. Alkenyl groups and alkynyl groups preferably contain one double bond or triple bond, respectively, which can be present in any desired position of the group. Examples of alkenyl and alkynyl are prop-1-enyl, prop-2-enyl (= allyl), but-2-enyl, 2-methylprop-2-enyl, 3-methylbut-2-enyl, hex-3-enyl, hex-4-enyl, 4-methylhex-4-enyl, dec-3-enyl, dec-9-enyl, prop-2-ynyl (= propargyl), but-2-ynyl, but-3-ynyl, hex-4-ynyl or hex-5-ynyl.
As far as applicable, the preceding explanations regarding alkyl groups apply correspondingly to divalent alkyl groups, i.e. alkanediyl groups and alkylene groups, such as the methylene group -CH2- and the polymethylene groups -CH2-CH2- and -CH2-CH2-CH2- occurring in the group A and in divalent alkylenedioxy groups such as -0-CH2-O-, -0-CH2-CH2-O- or -0-CH2-CH2-CH2-O-, and the groups CnH2n, which can also be linear or branched and/or can be substituted by one or more, for example one, two, three, four or five, identical or different substituents which can be located in any desired positions. Of course, the number of substituents can in general not exceed the number of hydrogen atoms in the unsubstituted parent system which can be replaced with a substituent, and can, for example, be only one or two in the case of a CH2 group. Examples of the group CnH2n, in which the number n is 1 , 2, or 3, are -CH2-, -CH2-CH2-, -CH2-CH2-CH2-, -CH(CH3)-, -C(CH3)2-, -CH(CH3)-CH2-,
-CH2-CH(CH3)-. If the number n in the group CnH2n is 0 (= zero), the two groups which are attached to the group CnH2n are directly connected to one another via a single bond. Similarly, if the group X is a direct bond, the groups R3 and Het are directly connected to one another via a single bond.
Examples of cycloalkyl groups are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl and cyclodecyl. Substituted cycloalkyl groups can be substituted by one or more, for example one, two, three, four or five, identical or different substituents which can be located in any desired positions. In general, besides any other specified substituents, all cycloalkyl groups can also carry one or more, for example one, two, three, four or five, identical or different (Ci-C4)-alkyl substituents, for example methyl substituents, which can be located in any desired positions. Examples of alkyl-substituted cycloalkyl groups are 4-methylcyclohexyl, 4- tert-butylcyclohexyl or 2,3-dimethylcyclopentyl.
If a group like phenyl, naphthalenyl and heteroaryl, which can be unsubstituted or substituted, is substituted by one or more substituents, in general it can carry one, two, three, four or five identical or different substituents, for example. The substituents can be located in any desired positions. Substituted heteroaryl groups can be substituted on ring carbon atoms and/or on suitable ring nitrogen atoms, i.e. ring nitrogen atoms which in the parent ring system carry a hydrogen atom, where preferred substituents on such substituted ring nitrogen atoms are alkyl groups, for example (Ci-C4)-alkyl groups, unless stated otherwise. Suitable ring nitrogen atoms, such as the ring nitrogen atoms in a pyridine ring or a quinoline ring, can also be present as N-oxides or as quaternary salts, the latter preferably having a counter- anion which is derived from a physiologically acceptable acid. In monosubstituted phenyl groups the substituent can be located in the 2-position, the 3-position or the 4- position. In a disubstituted phenyl group the substituents can be located in 2,3- position, 2,4-position, 2,5-position, 2,6-position, 3,4-position or 3,5-position. In trisubstituted phenyl groups the substituents can be located in 2, 3,4-position, 2, 3,5- position, 2,3,6-position, 2,4,5-position, 2,4,6-position or 3,4,5-position. Naphthalenyl (= naphthyl) can be naphthalen-1-yl or naphthalen-2-yl. In monosubstituted naphthalen-1-yl groups the substituent can be located in the 2-, 3-, 4-, 5-, 6-, 7-, or 8- position, in monosubstituted naphthalen-2-yl groups the substituent can be located in the 1-, 3-, 4-, 5-, 6-, 7-, or 8-position. In disubstituted naphthalenyl groups the substituents can likewise occur in any desired positions in the ring via which the naphthalenyl group is bonded, and/or in the other ring. Heteroaryl groups are preferably 5-membered or 6-membered monocyclic aromatic heterocyclic groups or 9-membered or 10-membered bicyclic aromatic heterocyclic groups, where the bicyclic groups contain a 6-membered ring fused to a 5-membered or two fused 6-membered rings. In bicyclic heteroaryl groups one or both rings can be aromatic and one or both rings can contain hetero ring members. Preferably heteroaryl groups and other heterocyclic groups contain one, two or three, for example one or two, identical or different hetero ring members. The hetero ring members or ring heteroatoms in heteroaryl groups and other heterocyclic groups are generally chosen from N, O and S wherein N includes ring nitrogen atoms which carry a hydrogen atom or any substituent as is the case in 5-membered aromatic heterocycles such as pyrrole, pyrazole or imidazole, for example. The hetero ring members in heteroaryl groups and other heterocyclic groups can be located in any desired positions provided that the resulting heterocyclic system is known in the art and is stable and suitable as a subgroup in a drug substance. For example, in general two atoms from the series O and S cannot be present in adjacent ring positions. Examples of parent heterocycles of heteroaryl groups and other heterocyclic groups are pyrrole, furan, thiophene, imidazole, pyrazole, 1 ,2,3-triazole, 1 ,2,4-triazole, oxazole (= 1 ,3-oxazole), isoxazole (= 1 ,2-oxazole), thiazole (= 1 ,3- thiazole), isothiazole (= 1 ,2-thiazole), tetrazole, pyridine, pyridazine, pyrimidine, pyrazine, 1 ,2,3-triazine, 1 ,2,4-triazine, 1 ,3,5-triazine, 1 ,2,4,5-tetrazine, indole, benzothiophene, benzofuran, 1 ,3-benzodioxole (= 1 ,2-methylenedioxybenzene), 1 ,3- benzoxazole, 1 ,3-benzothiazole, benzoimidazole, chroman, isochroman, 1 ,4- benzodioxane (= 1 ,2-ethylenedioxybenzene), quinoline, isoquinoline, cinnoline, quinazoline, quinoxaline, phthalazine, thienothiophenes, 1,8-naphthyridine and other naphthyridines, acridine or pteridine. Heteroaryl groups, including heteroaryl groups representing R3, and other heterocyclic groups can be bonded via any desired suitable ring carbon atom and, in the case of nitrogen heterocycles, ring nitrogen atom. Preferably they are bonded via a ring carbon atom. For example, thiophenyl (= thienyl) can be thiophen-2-yl or thiophen-3-yl, pyridinyl (= pyridyl) can be pyridin-2-yl, pyridin-3-yl or pyridin-4-yl, imidazolyl can be, for example, 1 H-imidazol-1-yl, 1 H- imidazol-2-yl, 1 H-imidazol-4-yl or 1 H-imidazol-5-yl, quinolinyl (= quinolyl) can be quinolin-2-yl, quinolin-3-yl, quinolin-4-yl, quinolin-5-yl, quinolin-6-yl, quinolin-7-yl or quinolin-8-yl. In monosubstituted pyridin-2-yl the substituent can be located in the 3- position, 4-position, 5-position or 6-position, in monosubstituted pyridin-3-yl the substituent can be located in the 2-position, 4-position, 5-position or 6-position, in monosubstituted pyridin-4-yl the substituent can be located in the 2-position or 3- position.
As far as applicable, the preceding explanations regarding heteroaryl groups apply correspondingly to divalent heteroaryl groups, i.e. heteroarylene groups, such as the group Het in formulae I and Ia. In general, a divalent heteroaryl group can be bonded to the adjacent groups via any two desired suitable ring atoms including ring carbon atoms and/or, in the case of nitrogen heterocycles, ring nitrogen atoms. Preferably they are bonded via any two ring carbon atoms, in particular in the case of the group Het. In the case of a divalent bicyclic heteroaryl group the positions via which it is bonded to the adjacent groups can be located in the same ring or in different rings. In the case of a divalent group derived from furan or thiophene, for example, the adjacent groups can be bonded in 2,3-position, 2,4-position, 2, 5-position or 3,4- position. A divalent group derived from 1 ,3-thiazole can be 1 ,3-thiazole-2,4-diyl, 1 ,3- thiazole-2,5-diyl or 1 ,3-thiazole-4,5-diyl. A divalent group derived from pyridine can be pyridine-2,3-diyl, pyridine-2,4-diyl, pyridine-2,5-diyl, pyridine-2,6-diyl, pyridine-3,4- diyl or pyridine-3,5-diyl. In the case of an unsymmetrical divalent group the present invention includes all positional isomers, i.e., in the case of a pyridine-2,5-diyl group, for example, it includes the compound in which the one adjacent group is present in the 2-position and the other adjacent group is present in the 5-position as well as the compound in which the one adjacent group is present in the 5-position and the other adjacent group is present in the 2-position. Depending on the ranking order of the adjacent groups in the nomenclature of the compound, in the name of a compound the numbers of the locations of the adjacent groups may differ from the ones indicated above and, for example, a pyridine-2,5-diyl group may be designated as a pyridine-3,6-diyl group.
As far as applicable, the above explanations also apply correspondingly to the aromatic heterocycle which is formed by fusion of the group R3 to the group Het in case the group X is absent. In the respective compounds of the formula Ia the resulting polycyclic heteroaromatic group, which represents the R3-X-Het- moiety in formula Ia which moiety may also be designated as R3-X'-Het- moiety to distinguish it from the R3-X-Het- moiety in the compounds of the formula I1 is a bicyclic or tricyclic or tetracyclic ring system, preferably a bicyclic or tricyclic ring system, more preferably a bicyclic ring system, and contains one or more, for example one, two, three or four, identical or different hetero ring members chosen from N, NR13, O and S. A phenyl or naphthalenyl or heteroaryl group representing R3 can be fused to, or condensed to, the group Het via any suitable bond in R3 and any suitable bond in the group Het, provided that the resulting polycyclic heteroaromatic group is known in the art to be stable and suitable as a subgroup in a drug substance and that in the resulting group at least the ring bonded to the group A can be an aromatic ring, i.e. contain six conjugated pi electrons in case of a 5-membered or 6-membered monocyclic ring. For example, if the group Het in a compound of the formula Ia is a pyridine ring, X is absent and R3 is phenyl, the latter carbocyclic ring can be fused to the bond between positions 2 and 3 or the bond between positions 3 and 4 in the pyridine ring, and the resulting polycyclic heteroaromatic group representing the R3- X-Het- moiety is a quinolinyl or isoquinolinyl group. If a naphthalenyl group representing R3 is fused to a pyridine ring representing Het, the resulting polycyclic heteroaromatic group representing the R3-X-Het- moiety is an aza-anthracenyl or aza-phenanthrenyl group. The polycyclic heteroaromatic which is present in case X is absent, can be bonded to the group A via any suitable ring atom, preferably a ring carbon atom, in an aromatic ring originating from the group Het, and can be substituted by substituents as outlined above for the individual groups R3 and Het.
The heterocyclic ring which can be formed by R1 and R2 together with the N-CO group depicted in formulae I and Ia which carries R1 and R2, which ring is a lactam ring, can be 4-membered, 5-membered, 6-membered, 7-membered, 8-membered, 9- membered or 10-membered, and can be saturated, i.e. contain no double bond within the ring, or unsaturated, including partially unsaturated and aromatic, in particular partially unsaturated, and contain, for example, one, two, three or four double bonds within the ring, provided the respective ring system is known in the art to be stable and suitable as a subgroup in a drug substance. Examples of residues of heterocyclic rings formed by R1 and R2 together with the N-CO group, which residues are bonded to the group A via the nitrogen atom in the said N-CO group depicted in formulae I and Ia, are 2-oxo-azetidin-1-yl, 2-oxo-pyrrolidin-1-yl, 2-oxo-2,5-dihydro-1 H- pyrrol-1-yl, 2-oxo-piperidin-1-yl, 2-oxo-1 ,2)3,4-tetrahydropyridin-1-yl) 2-oxo-1 ,2,5,6- tetrahydropyridin-1-yl, 2-oxo-1 ,2-dihydropyridin-1-yl, 2-oxo-azepan-1-yl, 2-oxo- azocan-1-yl, 2-oxo-azecan-1-yl, 2-oxo-octahydrocyclopenta[b]pyrrol-1-yl, 2-oxo-2,3- dihydro-1 H-indol-1 -yl, 2-oxo-octahydro-1 H-indol-1 -yl, 1 -oxo-2,3-dihydro-1 H-isoindol- 2-yl, i-oxo-octahydro-I H-isoindol-2-yl, 2-oxo-1 ,2-dihydroquinolin-1-yl, 2-oxo-1 ,2,3,4- tetrahydroquinolin-1-yl, 2-oxo-decahydroquinolin-i-yl, 1-oxo-1 ,2-dihydroisoquinolin-2- yl, 3-0X0-1 ,2,3,4-tetrahydroisoquinolin-2-yl, 1-oxo-1 ,2,3,4-tetrahydroisoquinolin-2-yl, 1 -oxo-decahydroisoquinolin-2-yl, 3-oxo-decahydroisoquinolin-2-yl, 4-oxo-4,5,6,7- tetrahydrothieno[3,2-c]pyridin-5-yl, 6-oxo-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-5-yl, 3-oxo-pyrazolidin-2-yl, 2-oxo-imidazolidin-1-yl, 5-oxo-imidazolidin-1-yl, 2-oxo- hexahydropyrimidin-1 -yl, 6-oxo-hexahydropyrimidin-1 -yl, 2-oxo-1 ,2-dihydropyrimidin- 1-yl, 2-oxo-piperazin-1-yl, 2-oxo-[1 ,3]diazepan-1-yl, 7-oxo-[1 ,3]diazepan-1-yl, 2-oxo- [1 ,4]diazepan-1-yl, 7-oxo-[1 ,4]diazepan-1-yl, 2-oxo-oxazolidin-3-yl, 2-oxo- [1 ,3]oxazinan-3-yl, 2-oxo-[1 ,3]oxazepan-3-yl, 3-oxo-morpholin-4-yl, 3-oxo- [1 ,4]oxazepan-4-yl, 5-oxo-[1 ,4]oxazepan-4-yl, 2-oxo-thiazolidin-3-yl, 2-oxo- [1 ,3]thiazinan-3-yl, 3-oxo-thiomorpholin-4-yl, 3-oxo-3,4-dihydro-2H-[1 ,4]thiazin-4-yl, 2-oxo-[1 ,3]thiazepan-3-yl, 3-oxo-[1 ,4]thiazepan-4-yl, 5-oxo-[1 ,4]thiazepan-4-yl. As applies to the ring which can be formed by R1 and R2 together with the N-CO group in general, all listed examples of heterocyclic groups can be unsubstituted or substituted as indicated above, for example by R8. For example, they can be substituted on one or more, for example one, two or three, preferably one or two, more preferably one, ring carbon atoms by further oxo groups in addition to the oxo group mentioned in the listed names, and/or by one or more, for example one, two, three or four, preferably one or two, identical or different alkyl groups such as methyl groups, and/or on one or more ring nitrogen atoms by a (Ci-C4)-alkyl group or a (Cr C-O-alkyl-CO- group such as methyl or acetyl which group represents R12. Examples of groups listed above which are substituted by a further oxo group include 2,5-dioxo- pyrrolidin-1-yl, 2,6-dioxo-piperidin-1-yl, 2,5-dioxo-imidazolidin-1-yl, 2,6-dioxo- hexahydropyrimidin-1-yl, 1 ,3-dioxo-2,3-dihydro-1 H-isoiridol-2-yl (= 1 ,3-dioxo-isoindol- 2-yl) and 2,4-dioxo-thiazolidin-3-yl. Furthermore, as applies to the ring which can be formed by R1 and R2 together with the N-CO group in general, ring sulfur atoms in the listed heterocyclic groups can carry one or two oxo groups, i.e. doubly bonded oxygen atoms, and thus become SO or SO2 groups, i.e. sulfoxide or sulfone groups or S-oxides or S,S-dioxides. For example, the sulfur atom in a 3-oxo-thiomorpholin-4- yl group can carry one or two oxo groups, and besides the 3-oxo-thiomorpholin-4-yl group also the groups 1 ,3-dioxo-thiomorpholin-4-yl and 1 ,1 ,3-trioxo-thiomorpholin-4- yl can be present in a compound of the invention.
Halogen is fluorine, chlorine, bromine or iodine, preferably fluorine, chlorine or bromine, more preferably fluorine or chlorine.
An oxo group, when bonded to a carbon atom, replaces two hydrogen atoms on a carbon atom of the parent system. Thus, if a CH2 group is substituted by oxo, i.e. by a doubly bonded oxygen atom, it becomes a CO group. Evidently, an oxo group cannot occur as a substituent on a carbon atom in an aromatic ring.
The present invention includes all stereoisomeric forms of the compounds of the formulae I and Ia and their salts. With respect to each chiral center, independently of any other chiral center, the compounds of formulae I and Ia can be present in S configuration or substantially S configuration, or in R configuration or substantially R configuration, or as a mixture of the S isomer and the R isomer in any ratio. The invention includes all possible enantiomers and diastereomers and mixtures of two or more stereoisomers, for example mixtures of enantiomers and/or diastereomers, in all ratios. Thus, compounds according to the invention which can exist as enantiomers can be present in enantiomerically pure form, both as levorotatory and as dextrorotatory antipodes, and in the form of mixtures of the two enantiomers in all ratios including racemates. In the case of a E/Z isomerism, or cis/trans isomerism, for example on double bonds or rings, the invention includes both the E form and Z form, or the cis form and the trans form, as well as mixtures of these forms in all ratios. The preparation of individual stereoisomers can be carried out, for example, by separation of a mixture of isomers by customary methods, for example by chromatography or crystallization, by the use of stereochemically uniform starting materials in the synthesis, or by stereoselective synthesis. Optionally a derivatization can be carried out before a separation of stereoisomers. The separation of a mixture of stereoisomers can be carried out at the stage of the compound of the formula I or Ia or at the stage of a starting material or an intermediate during the synthesis. The present invention also includes all tautomeric forms of the compounds of formulae I and Ia and their salts.
In case the compounds of the formulae I and Ia contain one or more acidic and/or basic groups, i.e. salt-forming groups, the invention also comprises their corresponding physiologically or toxicologically acceptable salts, i.e. non-toxic salts, in particular their pharmaceutically acceptable salts. Thus, the compounds of the formulae I and Ia which contain an acidic group can be present on such groups, and can be used according to the invention, for example, as alkali metal salts, alkaline earth metal salts or as ammonium salts. More specific examples of such salts include sodium salts, potassium salts, calcium salts, magnesium salts, quaternary ammonium salts such as tetraalkylammonium salts, or acid addition salts with ammonia or organic amines such as, for example, ethylamine, ethanolamine, triethanolamine or amino acids. Compounds of the formulae I and Ia which contain a basic group, i.e. a group which can be protonated, can be present on such groups, and can be used according to the invention, for example, in the form of their addition salts with inorganic or organic acids. Examples for suitable acids include hydrogen chloride, hydrogen bromide, phosphoric acid, sulfuric acid, nitric acid, methanesulfonic acid, p-toluenesulfonic acid, naphthalenedisulfonic acids, oxalic acid, acetic acid, tartaric acid, lactic acid, salicylic acid, benzoic acid, formic acid, propionic acid, pivalic acid, diethylacetic acid, malonic acid, succinic acid, pimelic acid, fumaric acid, maleic acid, malic acid, sulfamic acid, phenylpropionic acid, gluconic acid, ascorbic acid, nicotinic acid, isonicotinic acid, citric acid, adipic acid, and other acids known to the person skilled in the art. If the compounds of the formulae I and Ia simultaneously contain acidic and basic groups in the molecule, the invention also includes, in addition to the salt forms mentioned, inner salts or betaines or zwitterions. The salts of the compounds of the formulae I and Ia can be obtained by customary methods which are known to the person skilled in the art like, for example, by contacting the compound of the formula I or Ia with an organic or inorganic acid or base in a solvent or diluent, or by anion exchange or cation exchange from another salt. The present invention also includes all salts of the compounds of the formula I which, owing to low physiological compatibility, are not directly suitable for use in pharmaceuticals but which can be used, for example, as intermediates for chemical reactions or for the preparation of physiologically acceptable salts.
The present invention furthermore includes all solvates of compounds of the formulae I and Ia, for example hydrates or adducts with alcohols, active metabolites of the compounds of the formulae I and Ia, and also prodrugs and derivatives of the compounds of the formulae I and Ia which in vitro may not necessarily exhibit pharmacological activity but which in vivo are converted into pharmacologically active compounds, for example esters or amides of carboxylic acid groups.
The group A in the compounds of the formulae I and Ia is preferably chosen from -CH2-CH2-CH2- and -Y-CH2-CH2- wherein Y is chosen from O, S and NR11 and Y is bonded to the group Het, and wherein all CH2 groups can be substituted by one or more identical or different substituents R4. In one embodiment of the present invention the CH2 groups in the group A in the compounds of formulae I and Ia are not substituted by substituents R4. If the CH2 groups in the group A are not substituted, the divalent group -A- in the formulae I and Ia may be replaced with the group -Y'-CH2-CH2- wherein Y1 is bonded to the group Het in formulae I and Ia, and Y' is chosen from a direct bond, CH2, O, S and NR11. Particularly preferably the group A in the compounds of the formulae I and Ia is chosen from -CH2-CH2-CH2-, -NH-CH2-CH2- and -0-CH2-CH2-, more particularly preferably from -CH2-CH2-CH2- and -0-CH2-CH2-, wherein the nitrogen atom and the oxygen atom are bonded to the group Het. In one embodiment of the present invention the group A is the group -0-CH2-CH2- wherein the oxygen atom is bonded to the group Het. The group Y is preferably chosen from O and NR11 and more preferably is O. In the compounds of the formula Ia the divalent group Het is preferably defined as in the compounds of the formula I. More generally, one embodiment of the present invention relates to the use of a compound of the formula I, which is defined as indicated above, in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, for the manufacture of a medicament for the stimulation of the expression of endothelial NO synthase and for the treatment of a disease in which such a stimulation, or an increase in NO level, is desired, for example a cardiovascular disorder such as atherosclerosis, coronary artery disease or cardiac insufficiency or any other diseases mentioned above or below herein.
More preferably, the divalent group Het in the compounds of the formulae I and Ia is a divalent aromatic group of the formula Il
Figure imgf000023_0001
in which G is chosen from N and CH and L is chosen from S, O, NR13, CH=CH, CH=N and N=CH, and which can be substituted by one or more identical or different substituents R5, i.e. in which one or more ring carbon atoms can carry a substituent R5 instead of the hydrogen atoms which are present on the carbon atoms depicted in formula Il or which are specified in the definition of the groups G and L, with the proviso that the ring system depicted in formula Il comprises at least one hetero ring member, i.e. a group NR13 or an N, S or O atom, as a ring member. R5 and R13 in the ring system of the formula Il are defined as indicated above with respect to the compounds of the formulae I and Ia. Particularly preferably the group Het in the compounds of the formulae I and Ia and the group of the formula Il is chosen from the heteroarylene groups pyridinediyl, thiazolediyl, oxazolediyl, imidazolediyl and thiophenediyl, i.e. the divalent residues of pyridine, thiazole, oxazole, imidazole and thiophene, which can all be substituted by one or more identical or different substituents R5 and wherein one of the ring nitrogen atoms of the imidazolediyl group, which represents the nitrogen atom in the group NR13 in the definition of the group L1 carries a group chosen from hydrogen and (Ci-C-O-alkyl. More particularly preferably the group Het in the compounds of the formulae I and Ia and the group of the formula Il is chosen from the heteroarylene groups pyridinediyl, thiazolediyl, imidazolediyl and thiophenediyl, especially preferably from pyridinediyl and thiazolediyl, which can all be substituted by one or more identical or different substituents R5 and wherein one of the ring nitrogen atoms of the imidazolediyl group, which represents the nitrogen atom in the group NR13 in the definition of the group L, carries a group chosen from hydrogen and (CrC4)-alkyl. In one embodiment of the invention the group Het in the compounds of the formulae I and Ia and the group of the formula Il is a pyridinediyl group which can be substituted by one or more identical or different substituents R5.
In one embodiment of the present invention the groups representing the group Het in the compounds of the formulae I and Ia, including the group of the formula Il in which the bonds via which it is connected to the two adjacent groups R3-X and A are represented by the lines intersecting the ring sides, are bonded to the adjacent groups R3-X and A via any two ring carbon atoms. Preferably a pyridinediyl group representing Het or the group of the formula Il is bonded to the adjacent groups via positions 3 and 6 of the pyridine ring, which positions may also be numbered as positions 5 and 2, respectively, depending on the ranking order of the groups bonded to the pyridine ring, where each of the groups R3-X and A can be present in each of the positions. I.e., in the said pyridinediyl group, which is bonded via positions 3 and 6, the group R3-X can be present in position 3 and the group A in position 6, as well as the group R3-X can be present in position 6 and the group A in position 3, and preferably the group R3-X is present in position 6 and the group A in position 3.
Preferably a group of the formula Ha,
Figure imgf000025_0001
which represents Het or the group of the formula Il and in which L is O, S or NR13, i.e. which is a oxazolediyl, thiazolediyl or imidazolediyl group, is bonded to the adjacent groups via positions 2 and 5 or via positions 2 and 4, particularly preferably via positions 2 and 4, where each of the groups R3-X and A can be present in each of the positions and preferably the group R3-X is present in position 4 and the group A in position 2.
Preferably a thiophenediyl group which represents Het or the group of the formula Il is bonded to the adjacent groups via positions 2 and 5 or via positions 2 and 4, which latter positions may also be numbered as positions 5 and 3, particularly preferably via positions 2 and 4, where each of the groups R3-X and A can be present in each of the positions and preferably the group R3-X is present in position 4 and the group A in position 2.
Preferred groups Het or groups of the formula Il thus include the divalent heteroaromatic groups depicted in the following formulae Ilia to MIg which represent preferred embodiments of the structural moiety R3-X-Het-A- in the compounds of the formulae I and Ia, and in which the heteroaromatic group can be unsubstituted or substituted by one or more identical or different substituents R5.
Figure imgf000026_0001
MIa 1Mb IMc
Figure imgf000026_0002
IMd IMe MIf IMg
Particularly preferred groups Het or groups of the formula Il include the divalent heteroaromatic groups depicted in the formulae 1Mb, IMe and MIg, especially the group depicted in formula 1Mb, which represent particularly and especially preferred embodiments of the structural moiety R3-X-Het-A- in the compounds of the formulae I and Ia.
In the compounds of the formula Ia the group X is preferably chosen from a direct bond, CH2, O and NH, or X is absent and in this latter case the phenyl or heteroaryl group representing the group R3 is fused to the group Het. Particularly preferably the group X in the compounds of the formulae I and Ia is chosen from a direct bond and O, or in the compounds of the formula Ia the group X is absent, and more particularly preferably the group X in the compounds of the formulae I and Ia is chosen from a direct bond and O. In one embodiment of the present invention the group X in the compounds of the formulae I and Ia is a direct bond. In another embodiment of the present invention the group X in the compounds of the formula Ia is absent and in this embodiment the phenyl, naphthalenyl or heteroaryl group representing the group R3 is fused to the group Het. In a further embodiment of the present invention the group X in the compounds of the formula Ia cannot be absent, i.e. in this embodiment the group X in the compounds of the formula Ia is chosen from a direct bond, CH2, O, S, NH and N((d-C4)-alkyl). In all cases in which X is absent the phenyl, naphthalenyl or heteroaryl group representing the group R3 is fused to the group Het or the ring system depicted in formula Il which contains the groups G and L. In case X can be absent, in a particularly preferred embodiment of the present invention the structural moiety R3-X-Het- in the compounds of the formulae I and Ia is a bicyclic heteroaryl groups which comprises a monocyclic 5-membered or 6-membered heteroaromatic ring which represents the group Het and to which the group A is bonded, and a benzene ring which is fused to said heteroaromatic ring system and which represents the group R3, where the heteroaromatic ring can be substituted by one or more identical or different substituents R5 and the benzene ring can be substituted as indicated above with respect to R3. In case X is absent, the said structural moiety R3-X-Het- is more particularly preferably chosen from quinolinyl, isoquinolinyl, benzoimidazolyl, benzothiazolyl and benzothienyl, especially preferably from quinolinyl, benzoimidazolyl and benzothiazolyl, which are all bonded to the group A via the heterocyclic ring and which can be substituted as indicated.
If the ring which can be formed by the groups R1 and R2 together with the N-CO group which carries them is a monocyclic ring system, in one embodiment of the invention it is saturated or partially unsaturated. More specifically, in one embodiment it is saturated or contains one or two double bonds within the ring, and in another embodiment it is saturated or contains one double bond within the ring, and in a further embodiment it is saturated. If the said ring is a bicyclic ring system, in one embodiment the specific ring of the bicyclic ring system to which the group A is bonded is saturated or is partially unsaturated, and in a more specific embodiment this ring contains one or two double bonds within the ring of which one double bond can be common to both rings, and the second ring of the bicyclic ring system is a saturated or an aromatic ring, in particular an aromatic ring such as a benzene ring. Preferably, a monocyclic ring formed by the groups R1 and R2 together with the N-CO which carries them contains 4, 5, 6 or 7 ring members and a bicyclic ring system contains 9 or 10 ring members. The ring which can be formed by the groups R1 and R2 together with the N-CO group is preferably a monocyclic ring system. In one embodiment of the present invention, the ring which can be formed by the groups R1 and R2 together with the N-CO group which carries them can contain, in addition to the ring nitrogen atom being part of the N-CO group, one further hetero ring member, i.e. one further ring heteroatom or heteroatom group, which is chosen from N, NR12, O, S, SO and SO2 and preferably is chosen from NR12, S, SO and SO2 and more preferably is chosen from NR12 and S. If the heterocycle formed by R1 and R2 and the N-CO group which carries them is substituted by one or more identical or different substituents R8, it preferably is substituted by one, two, three, four or five, more preferably by one, two, three or four, particularly preferably by one, two or three, more particularly preferably by one or two identical or different substituents R8 on ring carbon atoms, in addition to the oxo group depicted in formulae I and Ia and to oxo groups on ring sulfur atoms and/or groups R12 on ring nitrogen atoms which may be present.
If R1 and R2, together with the N-CO group depicted in formulae I and Ia which carries them, form a ring, in one embodiment of the invention they form a saturated or unsaturated, monocyclic 4-membered to 7-membered ring, for example a monocyclic 5-membered or 6-membered ring, which, in addition to the ring nitrogen atom being part of the N-CO group, can contain one further hetero ring member group chosen from N, NR12, O, S, SO and SO2, wherein the ring formed by R1 and R2 and the N-CO group which carries them can be substituted by one or more identical or different substituents R8. Further hetero ring members which are present in a ring formed by R1 and R2 together with the N-CO group which carries them are preferably chosen from NR12, O and S, more preferably from NR12 and S. The group -N(R2)-CO-R1 in the formulae I and Ia which results if R1 and R2 together with the N-CO group which carries them form a ring, is more preferably chosen from 2-oxo- azetidin-1-yl, 2-oxo-pyrrolidin-1-yl, 2-oxo-piperidin-1-yl, 2-oxo-1 ,2-dihydropyridin-1-yl, 2-oxo-azepan-1-yl, 2-oxo-imidazolidin-1-yl, 2-oxo-hexahydropyrimidin-1-yl, 2-oxo-1 ,2- dihydropyrimidin-1-yl, 2-oxo-piperazin-1-yl, 2-oxo-[1 ,3]diazepan-1-yl, 2-oxo- [1 ,4]diazepan-1-yl, 7-oxo-[1 ,4]diazepan-1-yl, 2-oxo-oxazolidin-3-yl, 2-oxo- [1 ,3]oxazinan-3-yl, 2-oxo-[1 ,3]oxazepan-3-yl, 3-oxo-morpholin-4-yl, 3-oxo- [1 ,4]oxazepan-4-yl, 5-oxo-[1 ,4]oxazepan-4-yl, 2-oxo-thiazolidin-3-yl, 2-oxo-
[1 ,3]thiazinan-3-yl, 3-oxo-thiomorpholin-4-yl, 3-oxo-3,4-dihydro-2H-[1 ,4]thiazin-4-yl, 2-oxo-[1 ,3]thiazepan-3-yl, 3-oxo-[1 ,4]thiazepan-4-yl and 5-oxo-[1 ,4]thiazepan-4-yl, i.e. from the groups depicted in the following formulae
Figure imgf000029_0001
Figure imgf000029_0002
Figure imgf000029_0003
Figure imgf000029_0004
Figure imgf000029_0005
in which the bond via which the group is connected to the group A is depicted by a line starting at a ring nitrogen atom, and which in part may also be named differently as regards the indication of the saturation, for example as 3-oxo-2, 3-d i hydro- [1 ,4]thiazin-4-yl in the case of group 3-oxo-3,4-dihydro-2H-[1 ,4]thiazin-4-yl. Particularly preferably the group which results if R1 and R2 together with the N-CO group which carries them form a ring, is chosen from 2-oxo-azetidin-1-yl, 2-oxo- pyrrolidin-1-yl, 2-oxo-piperidin-1-yl, 2-oxo- 1 ,2-dihyd ropy rid in-1-yl, 2-oxo-azepan-1-yl, 2-oxo-imidazolidin-1-yl, 2-oxo-hexahydropyrimidin-1-yl, 2-oxo-[1 ,3]diazepan-1-yl, 2- oxo-thiazolidin-3-yl, 3-oxo-thiomorpholin-4-yl, 3-oxo-3,4-dihydro-2H-[1 ,4]thiazin-4-yl, i.e. from the groups depicted in the following formulae.
Figure imgf000030_0001
Figure imgf000030_0002
Figure imgf000030_0003
All the specified rings formed by R1 and R2 together with the N-CO group which carries them can be substituted on carbon atoms by one or more identical or different substituents R8, and/or can carry on a ring nitrogen atom which is not bonded to the group A a group R12, and/or can carry on a ring sulfur atom one or two oxo groups, to give a substituted group as indicated above. As examples of such groups which are substituted by an oxo group on a carbon atom or by one or two oxo groups on a sulfur atom, and which can represent the group -N(R2)-CO-R1 in the formulae I and Ia and in which the bond via which the group is connected to the group A is depicted by a line starting at a ring nitrogen atom, the groups 2,5-dioxo-pyrrolidin-1-yl, 2,6-dioxo- piperidin-1-yl, 2,5-dioxo-imidazolidin-1-yl, 2,6-dioxo-hexahydropyrimidin-i-yl, 2,4- dioxo-thiazolidin-3-yl, 1 ,3-dioxo-thiomorpholin-4-yl and 1 ,1 ,3-trioxo-thiomorpholin-4-yl may be mentioned, i.e. groups of the following formulae,
Figure imgf000031_0001
Figure imgf000031_0002
which can all be substituted additionally on carbon atoms by one or more identical or different substituents R8 and/or can carry on a ring nitrogen atoms which is not bonded to the group A a group R12, and which, like all suitable groups in the compounds of formulae I and Ia, can be present in tautomeric forms, for example as a 2,5-dihydroxypyrrol-1-yl group in the case of the 2,5-dioxo-pyrrolidin-1-yl group, as a 2,5-dihydroxyimidazol-1-yl group in the case of the 2,5-dioxo-imidazolidin-1-yl group, or as a 5-hydroxy-1 ,1-dioxo-2,3-dihydro-[1 ,4]thiazin-4-yl group in the case of the 1 ,1 ,3-trioxo-thiomorpholin-4-yl group.
If R1 and R2 do not form a ring together with the N-CO group which carries them, they preferably are independently of each other chosen from (Ci-C4)-alkyl, (C3-C7)- cycloalkyl-CnH2n-, phenyl-CnH2n- and heteroaryl-CnH2n-, more preferably from (Ci-C4)- alkyl, (C3-C7)-cycloalkyl-, phenyl, phenyl-CH2-, heteroaryl and heteroaryl-CH2-, particularly preferably from (CrC-O-alkyl, (C3-C7)-cycloalkyl-, phenyl- and heteroaryl-, and in each case R2 can in addition be hydrogen, wherein the groups (CrC^-alkyl and (C3-C7)-cycloalkyl can both be substituted by one or more identical or different substituents R6, and the groups phenyl and heteroaryl can both be substituted by one or more identical or different substituents R7. If R1 and R2 do not form a ring together with the N-CO group which carries them, in one embodiment of the present invention R2 is hydrogen and R1 is defined as indicated. If R2 is an alkenyl group or an alkynyl group, preferably the nitrogen atom carrying R2 is not in conjugation with a double bond or triple bond, i.e., preferably the nitrogen atom carrying R2 is not directly bonded to a carbon atom in an alkenyl group or alkynyl group which is part of a double bond or triple bond.
In the compounds of the formula Ia the groups R1 and R2 preferably are independently of each other chosen from (Ci-C6)-alkyl, (C3-C6)-alkenyl, (C3-C6)- alkynyl, (C3-C7)-cycloalkyl-CnH2n-, phenyl-CnH2n- and heteroaryl-CnH2n-, and R2 can in addition be hydrogen, wherein the groups (Ci-C6)-alkyl, (C3-C7)-cycloalkyl, (C3-C6)- alkenyl and (C3-Ce)-alkynyl can all be substituted by one or more identical or different substituents R6, and the groups CnH2n can all be substituted by one or more identical or different substituents chosen from fluorine and (Ci-C4)-alkyl, and all phenyl groups and heteroaryl groups can be substituted by one or more identical or different substituents R7, or R1 and R2, together with the N-CO group which carries them, form a 4-membered to 10-membered, monocyclic or bicyclic, saturated or unsaturated ring which, in addition to the ring nitrogen atom being part of the N-CO group, can contain one or two further hetero ring members or heteroatom groups chosen from N, NR12, O, S, SO and SO2 which can be identical or different, with the proviso that two ring members from the series O, S, SO and SO2 cannot be present in adjacent ring positions, wherein the ring formed by R1 and R2 and the N-CO group which carries them can be substituted by one or more identical or different substituents R8.
Particularly preferably, in the compounds of the formula Ia the groups R1 and R2 are chosen from (Ci-C4)-alkyl, (C3-C7)-cycloalkyl-CnH2n-, phenyl-CnH2n- and heteroaryl- CnH2n-, and R2 can in addition be hydrogen, wherein the groups (Ci-C4)-alkyl and (C3-C7)-cycloalkyl can both be substituted by one or more identical or different substituents R6, and all phenyl groups and heteroaryl groups can be substituted by one or more identical or different substituents R7, or R1 and R2, together with the N-CO group which carries them, form a 4-membered to 7-membered, monocyclic, saturated or unsaturated ring which, in addition to the ring nitrogen atom being part of the N-CO group, can contain one further hetero ring member chosen from N, NR12, O, S, SO and SO2, wherein the ring formed by R1 and R2 and the N-CO group which carries them can be substituted by one or more identical or different substituents R8.
In the compounds of the formula I the groups R1 and R2, together with the N-CO group which carries them, preferably form a 4-membered to 7-membered, monocyclic, saturated or unsaturated ring which, in addition to the ring nitrogen atom being part of the N-CO group, can contain one further hetero ring member chosen from N, NR12, O, S, SO and SO2, wherein the ring formed by R1 and R2 and the N-CO group which carries them can be substituted by one or more identical or different substituents R8.
In one embodiment of the present invention, the groups R1 and R2 in the compounds of formulae I and Ia, together with the N-CO group which carries them, form a 4- membered to 10-membered, monocyclic or bicyclic, saturated or unsaturated ring which, in addition to the ring nitrogen atom being part of the N-CO group, can contain one or two further hetero ring members chosen from N, NR12, O, S, SO and SO2 which can be identical or different, with the proviso that two ring members from the series O, S, SO and SO2 cannot be present in adjacent ring positions, wherein the ring formed by R1 and R2 and the N-CO group which carries them can be substituted by one or more identical or different substituents R8, and wherein preferred features of this embodiment are those outlined above. For example, in a preferred feature of this embodiment the ring formed by R1 and R2 together with the N-CO group which carries them is a saturated or unsaturated, monocyclic 4-membered to 7-membered ring, for example a 5-membered or 6-membered ring, which, in addition to the ring nitrogen atom being part of the N-CO group, can contain one further hetero ring member which is preferably chosen from NR12, O and S, more preferably from NR12 and S, and which can be substituted, for example, by an oxo group on a carbon atom. In one embodiment of the present invention the ring formed by R1 and R2 and the N-CO group which carries them does not contain a further hetero ring member in addition to the nitrogen atom which is part of the N-CO group, where in this embodiment the ring can likewise be substituted as indicated.
In the compounds of the formula Ia the group R3 is preferably chosen from phenyl, naphthalenyl and heteroaryl which can all be substituted by one or more identical or different substituents chosen from halogen, (Ci-C4)-alkyl, (Ci-C4)-alkyloxy-(Ci-C2)- alkyl-, OH, (Ci-C4)-alkyloxy which can be substituted by one or more fluorine atoms, (Ci-C2)-alkylenedioxy which can be substituted by one or more fluorine atoms, (Cr C4)-alkylmercapto, NH2, (Ci-C4)-alkylamino, di((Ci-C4)-alkyl)amino, ((Ci-C4)-alkyl)- CONH-, ((Ci-C4)-alkyl)-SO2NH-, di((CrC4)-alkyl)aminocarbonyl-, ((C1-C4)- alkyl)aminocarbonyl-, ((CrC4)-alkyloxy)carbonyl-, COOH, CONH2, CN, CF3, H2NSO2- and (CrC4)-alkyl-SO2-, and more preferably by one or more identical or different substituents chosen from halogen, (Ci-C4)-alkyl, (C1-C4)-alkyloxy-(C1-C2)-alkyl-, OH, (CrC4)-alkyloxy which can be substituted by one or more fluorine atoms, (Ci-C2)- alkylenedioxy which can be substituted by one or more fluorine atoms, (C1-C4)- alkylmercapto, NH2, (d-C4)-alkylamino, di((C1-C4)-alkyl)amino, ((d-C4)-alkyl)- CONH-, di((C1-C4)-alkyl)aminocarbonyl-, ((d-C4)-alkyl)aminocarbonyl-, ((C1-C4)- alkyloxy)carbonyl-, COOH, CONH2, CN, CF3, H2NSO2- and (d-C4)-alkyl-SO2-. Particularly preferably the group R3 in the compounds of the formulae I and Ia is chosen from phenyl, naphthalenyl and heteroaryl, and preferably is a phenyl group or heteroaryl group and more preferably is a phenyl group, which groups can all be substituted by one or more identical or different substituents which are chosen from halogen, (d-C4)-alkyl, (C1-C4)-alkyloxy-(C1-C2)-alkyl-, (d-C4)-alkyloxy which can be substituted by one or more fluorine atoms, (Ci-C4)-alkylmercapto, (Ci-C4)-alkylamino, di((Ci-C4)-alkyl)amino, CONH2, CN, CF3 and (d-C4)-alkyl-SO2-. A heteroaryl group representing R3 is preferably chosen from pyridinyl, quinolinyl, thiophenyl, isoxazolyl and pyrimidinyl, more preferably from pyridinyl, pyrimidinyl, isoxazolyl and thiophenyl, and is thiophenyl in one embodiment of the invention, which groups can all be substituted as indicated. Preferably the optional substituents on the group R3 are chosen from halogen, (Ci-C4)-alkyl, (Ci-C4)-alkyloxy which can be substituted by one or more fluorine atoms, and CF3, more preferably from halogen and (Ci-C4)-alkyl. Particularly preferably R3 is a phenyl group which can be substituted by one or more identical or different substituents which are chosen from halogen, (Ci-C4)-alkyl and CF3. Especially preferably R3 is a phenyl group which is substituted by one or more identical or different substituents chosen from halogen atoms and (Ci-C4)-alkyl groups, in particular from fluorine atoms, chlorine atoms, methyl groups and ethyl groups. A phenyl group representing R3 is preferably a substituted phenyl group. In a substituted group R3 the number of substituents preferably is one, two, three, four or five, more preferably one, two, three or four, particularly preferably one, two or three, more particularly preferably one or two. In one embodiment of the present invention the group R3 is a carbocyclic group, i.e. a phenyl group or a naphthalenyl group, and in another embodiment of the invention the group R3 is a monocyclic group, i.e. a phenyl group or a monocyclic heteroaryl group, for example a thienyl group, and in another embodiment of the invention R3 is a phenyl group, a naphthalenyl group or a monocyclic heteroaryl group, for example a thienyl group, where all these groups can be substituted as indicated. In one embodiment of the present invention the group R3 in the compounds of the formula Ia is chosen from phenyl, naphthalenyl and heteroaryl which can all be substituted by one or more identical or different substituents chosen from halogen, (Ci-C6)-alkyl, (Ci-C6)-alkyloxy-(Ci-C6)-alkyl-, OH, (Ci-CβJ-alkyloxy which can be substituted by one or more fluorine atoms, (Ci-C3)- alkylenedioxy which can be substituted by one or more fluorine atoms, (Ci-Cβ)- alkylmercapto, NH2, (Ci-C6)-alkylamino, di((Ci-C6)-alkyl)amino, ((Ci-C6)-alkyl)- CONH-, diftCrCeJ-alkyOaminocarbonyl-,
Figure imgf000035_0001
((Ci-C6)- alkyloxy)carbonyl-, COOH, CONH2, CN, CF3, ((Ci-C6)-alkyl)NHSO2-, di((d-C6)- alkyl)NSO2-, H2NSO2- and (CrC6)-alkyl-SO2-.
In the compounds of the formula Ia the group R4 is preferably chosen from (Ci-C4)- alkyl and fluorine. Particularly preferably the group R4 in the compounds of the formulae I and Ia is chosen from methyl and fluorine, and especially preferably R4 is fluorine. The total number of substituents R4 in a substituted group A, which in general can be one, two, three, four, five or six, is preferably one, two, three or four, more preferably one or two. In the compounds of the formula Ia the group R5 is preferably chosen from halogen, (Ci-C4)-alkyl, (Ci-C4)-alkyloxy-(C1-C2)-alkyl-, OH, (Ci-C4)-alkyloxy which can be substituted by one or more fluorine atoms, (Ci-C4)-alkylmercapto, NH2, (Ci-C4)- alkylamino, di((Ci-C4)-alkyl)amino, ((Ci-C4)-alkyl)-CONH-, di((d-C4)- alkyl)aminocarbonyl-, ((Ci-C4)-alkyl)aminocarbonyl-, ((Ci-C4)-alkyloxy)carbonyl-, COOH, CONH2, CN, CF3 and (CrC4)-alkyl-SO2-. Particularly preferably the group R5 in the compounds of the formulae I and Ia is chosen from halogen, (Ci-C4)-alkyl, (Ci- C4)-alkyloxy-(CrC2)-alkyl-, OH, (Ci-C4)-alkyloxy which can be substituted by one or more fluorine atoms, (Ci-C4)-alkylmercapto, NH2, (Ci-C4)-alkylamino, di((Ci-C4)- alkyl)amino, ((CrC4)-alkyl)-CONH-, CONH2, CN, CF3 and (Ci-C4)-alkyl-SO2-, more particularly preferably from halogen, (Ci-C4)-alkyl and CF3. Especially preferably the group Het in the compounds of the formulae I and Ia is unsubstituted or substituted by one or more identical or different substituents chosen from fluorine, chlorine, methyl and CF3, in particular fluorine, chlorine and methyl, for example fluorine substituents, and more especially preferably the group Het is unsubstituted. The number of substituents R5, which are present on a substituted group Het, preferably is one, two, three or four, more preferably one, two or three, particularly preferably one or two, more particularly preferably one.
In the compounds of the formula Ia the group R6 is preferably chosen from fluorine, OH, oxo, (Ci-C4)-alkyloxy, (Ci-C4)-alkylmercapto, di((Ci-C4)-alkyl)amino, ((C1-C4)- alkyl)-CONH-, di((Ci-C4)-alkyl)aminocarbonyl-, ((Ci-C4)-alkyloxy)carbonyl-, COOH, CONH2, CN and CF3. Particularly preferably the group R6 in the compounds of the formulae I and Ia is chosen from fluorine, (Ci-C4)-alkyloxy, di((Ci-C4)-alkyl)amino, ((Ci-C4)-alkyl)-CONH-, di((Ci-C4)-alkyl)aminocarbonyl-, ((Ci-C4)-alkyloxy)carbonyl-, COOH and CF3, more particularly preferably from fluorine, ((Ci-C4)- alkyloxy)carbonyl- and COOH, especially preferably from ((Ci-C4)-alkyloxy)carbonyl- and COOH. The number of substituents R6 preferably is one, two or three, more preferably one or two, particularly preferably one.
In the compounds of the formula Ia the group R7 is preferably chosen from halogen, (Ci-C4)-alkyl, (Ci-C4)-alkyloxy-(Ci-C2)-alkyl-, OH, (Ci-C4)-alkyloxy which can be substituted by one or more fluorine atoms, (CrC2)-alkylenedioxy which can be substituted by one or more fluorine atoms, (Ci-C^-alkylmercapto, NH2, (Ci-C4)- alkylamino, di((C1-C4)-alkyl)amino, ((d-C4)-alkyl)-CONH-, di((d-C4)- alkyl)aminocarbonyl-, ((Ci-C4)-alkyl)aminocarbonyl-, ((Ci-C4)-alkyloxy)carbonyl-, COOH, CONH2, CN, CF3, H2NSO2- and (Ci-C4)-alkyl-SO2-. Particularly preferably the group R7 in the compounds of the formulae I and Ia is chosen from halogen, (Ci-C4)- alkyl, (Ci-C4)-alkyloxy-(Ci-C2)-alkyl-, OH, (CrC4)-alkyloxy which can be substituted by one or more fluorine atoms, (Ci-C2)-alkylenedioxy which can be substituted by one or more fluorine atoms, NH2, (Ci-C4)-alkylamino, di((Ci-C4)-alkyl)amino, ((Ci-C4)- alkyl)-CONH-, CONH2, CN, CF3 and (Ci-C4)-alkyl-SO2-, more particularly preferably from halogen, (d-C4)-alkyl, NH2, (Ci-C4)-alkylamino, di((Ci-C4)-alkyl)amino, ((Ci-C4)- alkyl)-CONH- and CF3, especially preferably from fluorine, chlorine, methyl, NH2 and CF3. The number of substituents R7 preferably is one, two, three or four, more preferably one, two or three, particularly preferably one or two, more particularly preferably one.
In the compounds of the formula Ia the group R8 is preferably chosen from halogen, (CrC4)-alkyl, (C3-C7)-cycloalkyl-CnH2n-, phenyl-CnH2n-, heteroaryl-CnH2n-, (Ci-C4)- alkyloxy-(Ci-C2)-alkyl-, OH, oxo, (Ci-C4)-alkyloxy which can be substituted by one or more fluorine atoms, (Ci-C2)-alkylenedioxy which can be substituted by one or more fluorine atoms, (Ci-C4)-alkylmercapto, NH2, (Ci-C4)-alkylamino, di((Ci-C4)- alkyl)amino, ((Ci-C4)-alkyl)-CONH-, di((Ci-C4)-alkyl)aminocarbonyl-, ((CrC4)- alkyl)aminocarbonyl-, ((Ci-C4)-alkyloxy)carbonyl-, COOH, CONH2, CN, CF3, H2NSO2- and (Ci-C4)-alkyl-SO2-, wherein all phenyl groups and heteroaryl groups can independently of each other be substituted by one ore more identical or different substituents chosen from halogen, (Ci-C4)-alkyl, CF3 and (Ci-C4)-alkyloxy. Particularly preferably the group R8 in the compounds of the formulae I and Ia is chosen from halogen, (Ci-C4)-alkyl, phenyl-CnH2n-, heteroaryl-CnH2n-, (Ci-C4)- alkyloxy-(Ci-C2)-alkyl-, OH, oxo, (CrC4)-alkyloxy which can be substituted by one or more fluorine atoms, (Ci-C2)-alkylenedioxy which can be substituted by one or more fluorine atoms, (Ci-C4)-alkylmercapto, (Ci-C4)-alkylamino, di((Ci-C4)-alkyl)amino, ((CrC4)-alkyl)-CONH-, di((Ci-C4)-alkyl)aminocarbonyl-, ((CrC4)-alkyloxy)carbonyl-, CONH2, CN and CF3, wherein all phenyl groups and heteroaryl groups can independently of each other be substituted by one ore more identical or different substituents chosen from halogen, (Ci-C4)-alkyl, CF3 and (d-C4)-alkyloxy. More particularly preferably the group R8 in the compounds of the formulae I and Ia is chosen from halogen, (Ci-C4)-alkyl,
Figure imgf000038_0001
oxo, (Ci-C4)- alkyloxy which can be substituted by one or more fluorine atoms, (Ci-C2)- alkylenedioxy which can be substituted by one or more fluorine atoms, (Ci-C4)- alkylmercapto, ((Ci-C4)-alkyl)-CONH-, di((Ci-C4)-alkyl)aminocarbonyl- and CF3, especially preferably from halogen, (Ci-C4)-alkyl, oxo, (Ci-C4)-alkyloxy which can be substituted by one or more fluorine atoms, and CF3, more especially preferably from halogen, (Ci-C4)-alkyl, oxo and CF3. Substituents R8 which are present in a non- aromatic ring in the heterocycle formed by R1 and R2 together with the N-CO group which carries them, in particular in the ring which contains the said N-CO group, for example in a non-aromatic monocyclic heterocycle formed by R1 and R2 together with the N-CO group, are preferably chosen from (Ci-C4)-alkyl, (C3-C7)-cycloalkyl- CnH2n-, phenyl-CnH2n-, heteroaryl-CnH2n-, (Ci-C4)-alkyloxy-(Ci-C2)-alkyl-, OH, oxo, NH2, (Ci-C4)-alkylamino, di((Ci-C4)-alkyl)amino and ((Ci-C4)-alkyl)-CONH-, more preferably from (Ci-C4)-alkyl, (C3-C7)-cycloalkyl-CnH2n-, phenyl-CnH2n-, heteroaryl- CnH2n- and oxo, particularly preferably from (CrC4)-alkyl and oxo, wherein all phenyl groups and heteroaryl groups can independently of each other be substituted by one ore more identical or different substituents chosen from halogen, (Ci-C4)-alkyl, CF3 and (CrC4)-alkyloxy. The number of substituents R8 preferably is one, two, three, four or five, more preferably one, two, three or four, particularly preferably one, two or three, more particularly preferably one or two.
In the compounds of the formula Ia the group R11 is preferably chosen from hydrogen, (Ci-C4)-alkyl and ((Ci-C4)-alkyl)-CO-. Particularly preferably the group R11 in the compounds of the formulae I and Ia is chosen from hydrogen and (Ci-C4)-alkyl, more particularly preferably from hydrogen and methyl. Especially preferably R11 is hydrogen. In the compounds of the formula Ia the group R12 is preferably chosen from hydrogen, (Ci-C4)-alkyl, (C3-C7)-cycloalkyl-CnH2n-, phenyl-CnH2n-, heteroaryl-CnH2n-, ((d-C4)-alkyl)-CO-, (C3-C7)-cycloalkyl-CnH2n-CO-, phenyl-CnH2n-CO-, heteroaryl- CnH2n-CO-, ((Ci-C4)-alkyl)-O-CO- and phenyl-CnH2n-O-CO-, wherein all phenyl groups and heteroaryl groups can be substituted by one or more identical or different substituents chosen from halogen, (Ci-C4)-alkyl, CF3 and (Ci-C4)-alkyloxy. Particularly preferably the group R12 in the compounds of the formulae I and Ia is chosen from hydrogen, (d-C4)-alkyl, (C3-C7)-cycloalkyl-CnH2n-, ((CrC4)-alkyl)-CO-, (C3-C7)-cycloalkyl-CnH2n-CO-, ((Ci-C4)-alkyl)-O-CO- and phenyl-CnH2n-O-CO-, more particularly preferably from hydrogen, (Ci-C4)-alkyl, (C3-C7)-cycloalkyl-CnH2n-, ((Cr C4)-alkyl)-CO-, (C3-C7)-cycloalkyl-CnH2n-CO- and ((Ci-C4)-alkyl)-O-CO-, especially preferably from hydrogen, (Ci-C4)-alkyl and (C3-C7)-cycloalkyl-CnH2n-, more especially preferably from hydrogen and (CrC4)-alkyl. In one embodiment of the present invention the group R12 is hydrogen.
In the compounds of the formulae I and Ia the group R13 is preferably chosen from hydrogen and (C-ι-C4)-alkyl and more preferably from hydrogen and methyl. Particularly preferably R13 is hydrogen.
In the compounds of the formula Ia a heteroaryl group is preferably a 5-membered or 6-membered, monocyclic aromatic group which contains one, two or three identical or different hetero ring members chosen from N, NR13, O and S. Particularly preferably a heteroaryl group in the compounds of the formulae I and Ia is a 5- membered or 6-membered, monocyclic aromatic group which contains one or two identical or different hetero ring members chosen from N, NR13, O and S.
In the compounds of the formula Ia the number n is preferably 0, 1 or 2, wherein all numbers n are independent of each other and can be identical or different. Particularly preferably the number n in the compounds of the formulae I and Ia is 0 or 1 , wherein all numbers n are independent of each other and can be identical or different. An example of the group phenyl-CnH2n- in which the number n is 1 is the benzyl group (= phenyl-CH2-). In preferred embodiments of the present invention one or more or all of the groups contained in the compounds of formulae I and Ia can independently of each other have any of the preferred definitions of the groups specified above or any one or some of the specific denotations which are comprised by the definitions of the groups and specified above, all combinations of preferred definitions and/or specific denotations being a subject of the present invention. Also with respect to all preferred embodiments the invention includes the compounds of the formulae I and Ia in all stereoisomeric forms and mixtures of stereoisomeric forms in all ratios, and their physiologically acceptable salts, as well as their tautomeric forms.
For example, one such embodiment of the present invention relates to compounds of the formula Ia in which simultaneously
A is chosen from -CH2-CH2-CH2- and -Y-CH2-CH2- wherein all CH2 groups can be substituted by one or more identical or different substituents R4, and wherein Y is chosen from O, S and NR11 and Y is bonded to the group Het;
Het is chosen from pyridinediyl, thiazolediyl, oxazolediyl, imidazolediyl and thiophenediyl which can all be substituted by one or more identical or different substituents R5 and wherein one of the ring nitrogen atoms of the imidazolediyl group carries a group chosen from hydrogen and (C-i-C-O-alkyl;
X is chosen from a direct bond and O;
R1 and R2 are independently of each other chosen from (C1-C4)-alkyl, (C3-C7)- cycloalkyl-CnH2n-, phenyl-CnH2n-, and heteroaryl-CnH2n-, and R2 can in addition be hydrogen, wherein the groups (Ci-C4)-alkyl and (C3-C7)-cycloalkyl can both be substituted by one or more identical or different substituents R6, and all phenyl groups and heteroaryl groups can be substituted by one or more identical or different substituents R7, or R1 and R2, together with the N-CO group which carries them, form a 4-membered to 7-membered, monocyclic, saturated or unsaturated heterocycle which, in addition to the ring nitrogen atom being part of the N-CO group, can contain one further hetero ring member chosen from N, NR12, O, S, SO and SO2, wherein the ring formed by R1 and R2 and the N-CO group which carries them can be substituted by one or more identical or different substituents R8;
R3 is phenyl which can be substituted by one or more identical or different substituents which are chosen from halogen, (Ci-C4)-alkyl, (Ci-C4)-alkyloxy-(CrC2)- alkyl-, (C1-C4)-alkyloxy which can be substituted by one or more fluorine atoms, (Cr C4)-alkylmercapto, (Ci-C4)-alkylamino, di((Ci-C4)-alkyl)amino, CONH2, CN, CF3 and (d-C4)-alkyl-SO2-;
R4 is chosen from methyl and fluorine;
R5 is chosen from halogen, (Ci-C4)-alkyl, (Ci-C4)-alkyloxy-(Ci-C2)-alkyl-, OH, (Ci-C4)- alkyloxy which can be substituted by one or more fluorine atoms, (Ci-C4)- alkylmercapto, NH2, (Ci-C4)-alkylamino, di((Ci-C4)-alkyl)amino, ((Ci-C4)-alkyl)- CONH-, CONH2, CN, CF3 and (Ci-C4)-alkyl-SO2-;
R6 is chosen from fluorine, (Ci-C4)-alkyloxy, di((Ci-C4)-alkyl)amino, ((Ci-C4)-alkyl)- CONH-, di((Ci-C4)-alkyl)aminocarbonyl-, ((Ci-C4)-alkyloxy)carbonyl-, COOH and CF3;
R7 is chosen from halogen, (Ci-C4)-alkyl, (Ci-C4)-alkyloxy-(Ci-C2)-alkyl-, OH, (Ci-C4)- alkyloxy which can be substituted by one or more fluorine atoms, (Ci-C2)- alkylenedioxy which can be substituted by one or more fluorine atoms, NH2, (CrC4)- alkylamino, di((CrC4)-alkyl)amino, ((Ci-C4)-alkyl)-CONH-, CONH2, CN, CF3 and (d- C4)-alkyl-SO2-;
R8 is chosen from halogen, (CrC4)-alkyl, phenyl-CnH2n-, heteroaryl-CnH2n-, (Ci-C4)- alkyloxy-(Ci-C2)-alkyl-, OH, oxo, (Ci-C4)-alkyloxy which can be substituted by one or more fluorine atoms, (Ci-C2)-alkylenedioxy which can be substituted by one or more fluorine atoms, (Ci-C4)-alkylmercapto, (Ci-C4)-alkylamino, di((Ci-C4)-alkyl)amino, ((CrC4)-alkyl)-CONH-, di((CrC4)-alkyl)aminocarbonyl-, ((d-C4)-alkyloxy)carbonyl-, CONH2, CN and CF3, wherein all phenyl groups and heteroaryl groups can independently of each other be substituted by one ore more identical or different substituents chosen from halogen, (C-ι-C4)-alkyl, CF3 and (Ci-C4)-alkyloxy;
R11 is chosen from H and (C-ι-C4)-alkyl;
R12 is chosen from H, (Ci-C4)-alkyl, (C3-C7)-cycloalkyl-CnH2n-, ((CrC4)-alkyl)-CO-, (C3-C7)-cycloalkyl-CnH2n-CO- and ((CrC4)-alkyl)-O-CO-;
R13 is chosen from hydrogen and (Ci-C4)-alkyl;
heteroaryl is a 5-membered or 6-membered, monocyclic aromatic group containing one or two identical or different hetero ring members chosen from N, NR13, O and S;
n is 0 or 1 , wherein all numbers n are independent of each other and can be identical or different;
in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof.
Another such embodiment of the present invention relates to compounds of the formula Ia, in which simultaneously
A is chosen from -CH2-CH2-CH2- and -Y-CH2-CH2- wherein all CH2 groups can be substituted by one or more identical or different substituents R4, and wherein Y is chosen from O, S and NR11 and Y is bonded to the group Het;
Het is chosen from pyridinediyl and thiazolediyl which can all be substituted by one or more identical or different substituents R5; X is a direct bond;
and the other groups are defined as in any other definition of the compounds of the formula Ia above or below;
in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof.
Another such embodiment of the present invention relates to compounds of the formulae I and Ia in which simultaneously
A is chosen from -CH2-CH2-CH2- and -Y-CH2-CH2- wherein all CH2 groups can be substituted by one or more identical or different substituents R4, and wherein Y is chosen from O, S and NR11 and Y is bonded to the group Het;
Het is chosen from pyridinediyl, thiazolediyl, oxazolediyl, imidazolediyl and thiophenediyl which can all be substituted by one or more identical or different substituents R5 and wherein one of the ring nitrogen atoms of the imidazolediyl group carries a group chosen from hydrogen and (Ci-C4)-alkyl;
X is chosen from a direct bond and O;
R1 and R2, together with the N-CO group which carries them, form a 4-membered to 7-membered, monocyclic, saturated or unsaturated heterocycle which, in addition to the ring nitrogen atom being part of the N-CO group, can contain one further hetero ring member chosen from N, NR12, O, S, SO and SO2, wherein the ring formed by R1 and R2 and the N-CO group which carries them can be substituted by one or more identical or different substituents R8;
R3 is phenyl which can be substituted by one or more identical or different substituents which are chosen from halogen, (Ci-C4)-alkyl, (C1-C4^aIKyIoXy-(Ci-C2)- alkyl-, (Ci-C4)-alkyloxy which can be substituted by one or more fluorine atoms, (Ci- C4)-alkylmercapto, (d-C^-alkylamino, di((CrC4)-alkyl)amino, CONH2, CN, CF3 and (Ci-C4)-alkyl-SO2-;
R4 is chosen from methyl and fluorine;
R5 is chosen from halogen, (Ci-C4)-alkyl, (Ci-C4)-alkyloxy-(Ci-C2)-alkyl-, OH, (Ci-C4)- alkyloxy which can be substituted by one or more fluorine atoms, (C1-C4)- alkylmercapto, NH2, (d-C4)-alkylamino, di((Ci-C4)-alkyl)amino, ((CrC4)-alkyl)- CONH-, CONH2, CN, CF3 and (CrC4)-alkyl-SO2-;
R8 is chosen from halogen, (C-i-C4)-alkyl, phenyl-CnH2n-, heteroaryl-CnH2n-, (Ci-C4)- alkyloxy-(Ci-C2)-alkyl-, OH, oxo, (Ci-C4)-alkyloxy which can be substituted by one or more fluorine atoms, (Ci-C2)-alkylenedioxy which can be substituted by one or more fluorine atoms, (Ci-C4)-alkylmercapto, (Ci-C4)-alkylamino, di((Ci-C4)-alkyl)amino, ((CrC4)-alkyl)-CONH-, di((Ci-C4)-alkyl)aminocarbonyl-, ((C1-C4)-alkyloxy)carbonyl-, CONH2, CN and CF3, wherein all phenyl groups and heteroaryl groups can independently of each other be substituted by one ore more identical or different substituents chosen from halogen, (Ci-C4)-alkyl, CF3 and (Ci-C4)-alkyloxy;
R11 is chosen from H and (Ci-C4)-alkyl;
R12 is chosen from H, (d-C4)-alkyl, (C3-C7)-cycloalkyl-CnH2n-, ((Ci-C4)-alkyl)-CO-, (C3-C7)-cycloalkyl-CnH2n-CO- and ((CrC4)-alkyl)-O-CO-;
R13 is chosen from hydrogen and (Ci-C4)-alkyl;
heteroaryl is a 5-membered or 6-membered, monocyclic aromatic group containing one or two identical or different hetero ring members chosen from N, NR13, O and S;
n is 0 or 1 , wherein all numbers n are independent of each other and can be identical or different; in any of its stereoisomer^ forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof.
Another such embodiment of the present invention relates to compounds of the formulae I and Ia in which simultaneously
A is chosen from -CH2-CH2-CH2- and -Y-CH2-CH2- wherein Y is chosen from O and
NH and wherein Y is bonded to the group Het;
Het is chosen from pyridinediyl, thiazolediyl, oxazolediyl, imidazolediyl and thiophenediyl which can all be substituted by one or more identical or different substituents R5 and wherein one of the ring nitrogen atoms of the imidazolediyl group carries a group chosen from hydrogen and (Ci-C4)-alkyl;
X is chosen from a direct bond and O;
R1 and R2, together with the N-CO group which carries them, form a 4-membered to 7-membered, monocyclic, saturated or unsaturated heterocycle which, in addition to the nitrogen atom being part of the N-CO group, can contain one further hetero ring member chosen from NR12, O and S, wherein the ring formed by R1 and R2 and the N-CO group which carries them can be substituted by one or more identical or different substituents R8;
R3 is phenyl which can be substituted by one or more identical or different substituents which are chosen from halogen, (Ci-C4)-alkyl, (Ci-C4)-alkyloxy-(Ci-C2)- alkyl-, (Ci-C4)-alkyloxy which can be substituted by one or more fluorine atoms, (C1- C4)-alkylmercapto, (CrC4)-alkylamino, di((Ci-C4)-alkyl)amino, CONH2, CN, CF3 and (Ci-C4)-alkyl-SO2-;
R5 is chosen from halogen, (d-C4)-alkyl, (Ci-C4)-alkyloxy-(Ci-C2)-alkyl-, OH, (Ci-C4)- alkyloxy which can be substituted by one or more fluorine atoms, (Ci-C4)- alkylmercapto, NH2, (CVC^-alkylamino, di((Ci-C4)-alkyl)amino, ((CrC4)-alkyl)- CONH-, CONH2, CN, CF3 and (d-C4)-alkyl-SO2-;
R8 is chosen from (C-i-C4)-alkyl and oxo;
R12 is chosen from H and (C-i-C4)-alkyl-;
in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof.
Another such embodiment of the present invention relates to compounds of the formulae I and Ia in which simultaneously
A is chosen from -CH2-CH2-CH2- and -Y-CH2-CH2- wherein Y is chosen from O and NH and Y is bonded to the group Het;
Het is a pyridinediyl or thiazolediyl group which can all be substituted by one or more identical or different substituents R5;
X is a direct bond;
R1 and R2, together with the N-CO group which carries them, form a saturated or unsaturated, monocyclic 4-membered to 7-membered ring which, in addition to the ring nitrogen atom being part of the N-CO group, can contain one further hetero ring member chosen from NR12, O and S, wherein the ring formed by R1 and R2 and the N-CO group which carries them can be substituted by one or more identical or different substituents R8;
R3 is phenyl which can be substituted by one or more identical or different substituents which are chosen from halogen, (CrC4)-alkyl, (Ci-C4)-alkyloxy-(CrC2)- alkyl-, (CrC4)-alkyloxy which can be substituted by one or more fluorine atoms, (Ci- C-O-alkylmercapto, (Ci-C4)-alkylamino, di((Ci-C4)-alkyl)amino, CONH2, CN1 CF3 and (Ci-C4)-alkyl-Sθ2-;
R5 is chosen from halogen, (Ci-C4)-alkyl,
Figure imgf000047_0001
OH1 (Ci-C4)- alkyloxy which can be substituted by one or more fluorine atoms, (Ci-C4)- alkylmercapto, NH2, (Ci-C4)-alkylamino, di((Ci-C4)-alkyl)amino, ((Ci-C4)-alkyl)- CONH-, CONH2, CN, CF3 and (Ci-C4)-alkyl-SO2-;
R8 is chosen from (Ci-C4)-alkyl and oxo;
R12 is chosen from H and (Ci-C4)-alkyl-; in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof;
where in this embodiment the group Het preferably is a pyridinediyl group which can be substituted by one or more identical or different substituents R5.
Another such embodiment of the present invention relates to novel compounds of the formula I
Figure imgf000047_0002
in which
A is chosen from -CH2-CH2-, -CH2-CH2-CH2- and -Y-CH2-CH2-, wherein all CH2 groups can be substituted by one or more identical or different substituents R4, and wherein Y is chosen from O, S and NR11 and Y is bonded to the group Het; Het is a 5-membered or 6-membered, monocyclic aromatic group which contains one or two identical or different hetero ring members chosen from N, NR13, O and S and which can be substituted by one or more identical or different substituents R5;
X is chosen from a direct bond, CH2, O and NH;
R1 and R2 are independently of each other chosen from (Ci-C6)-alkyl, (C3-C6)- alkenyl, (C3-C6)-alkynyl, (C3-C7)-cycloalkyl-CnH2n-, phenyl-CnH2n- and heteroaryl- CnH2n-, and R2 can in addition be hydrogen, wherein the groups
Figure imgf000048_0001
(C3- C7)-cycloalkyl, (C3-Ce)-alkenyl and (C3-C6)-alkynyl can all be substituted by one or more identical or different substituents R6, and the groups CnH2n can all be substituted by one or more identical or different substituents chosen from fluorine and (Ci-C4)-alkyl, and all phenyl groups and heteroaryl groups can independently of each other be substituted by one or more identical or different substituents R7, or R1 and R2, together with the N-CO group which carries them, form a 4-membered to 10-membered, monocyclic or bicyclic, saturated or unsaturated ring which, in addition to the ring nitrogen atom being part of the N-CO group, can contain one or two further hetero ring members chosen from N, NR12, O, S, SO and SO2 which can be identical or different, with the proviso that two ring members from the series O, S, SO and SO2 cannot be present in adjacent ring positions, wherein the ring formed by R1 and R2 and the N-CO group which carries them can be substituted by one or more identical or different substituents R8;
R3 is chosen from phenyl, naphthalenyl and heteroaryl which can all be substituted by one or more identical or different substituents chosen from halogen, (Ci-C4)-alkyl, (Ci-C4)-alkyloxy-(Ci-C2)-alkyl-, OH, (CrC4)-alkyloxy which can be substituted by one or more fluorine atoms, (Ci-C2)-alkylenedioxy which can be substituted by one or more fluorine atoms, (Ci-C4)-alkylmercapto, NH2, (Ci-C4)-alkylamino, di((CrC4)- alkyl)amino, ((Ci-C4)-alkyl)-CONH-, di((Ci-C4)-alkyl)aminocarbonyl-, ((Ci-C4)- alkyl)aminocarbonyl-,
Figure imgf000048_0002
COOH, CONH2, CN, CF3, H2NSO2- and (Ci-C4)-alkyl-SO2-; R4 is chosen from (CrC4)-alkyl and fluorine;
R5 is chosen from halogen, (Ci-C4)-alkyl, (C1-C4)-alkyloxy-(C1-C2)-alkyl-I OH, (CrC4)- alkyloxy which can be substituted by one or more fluorine atoms, (CrC4)- alkylmercapto, NH2, (Ci-C4)-alkylamino, di((Ci-C4)-alkyl)amino, ((CrC4)-alkyl)- CONH-, di((Ci-C4)-alkyl)aminocarbonyl-, ((d-C^-alky^aminocarbonyl-, ((Ci-C4)- alkyloxy)carbonyl-, COOH, CONH2, CN, CF3 and (Ci-C4)-alkyl-SO2-;
R6 is chosen from fluorine, OH, oxo, (Ci-C4)-alkyloxy, (Ci-C4)-alkylmercapto, di((C1- C4)-alkyl)amino, ((Ci-C4)-alkyl)-CONH-, di((d-C4)-alkyl)aminocarbonyl-, ((CrC4)- alkyloxy)carbonyl-, COOH, CONH2, CN and CF3;
R7 is chosen from halogen, (Ci-C4)-alkyl,
Figure imgf000049_0001
OH, (CrC4)- alkyloxy which can be substituted by one or more fluorine atoms, (CrC2)- alkylenedioxy which can be substituted by one or more fluorine atoms, (CrC4)- alkylmercapto, NH2, (Ci-C4)-alkylamino, di((Ci-C4)-alkyl)amino, ((CrC4)-alkyl)- CONH-, di((Ci-C4)-alkyl)aminocarbonyl-, ((CrC^-alkyOaminocarbonyl-, ((CrC4)- alkyloxy)carbonyl-, COOH, CONH2, CN, CF3, H2NSO2- and (CrC4)-alkyl-SO2-;
R8 is chosen from halogen, (Ci-C4)-alkyl, (C3-C7)-cycloalkyl-CnH2n-, phenyl-CnH2n-, heteroaryl-CnH2n-, (Ci-C4)-alkyloxy-(Ci-C2)-alkyl-, OH, oxo, (Ci-C4)-alkyloxy which can be substituted by one or more fluorine atoms, (Ci-C2)-alkylenedioxy which can be substituted by one or more fluorine atoms, (Ci-C4)-alkylmercapto, NH2, (CrC4)- alkylamino, di((CrC4)-alkyl)amino, ((CrC4)-alkyl)-CONH-, di((Ci-C4)- alkyl)aminocarbonyl-, ((CrC^-alkyOaminocarbonyl-, ((CrC4)-alkyloxy)carbonyl-,
COOH, CONH2, CN, CF3, H2NSO2- and (CrC4)-alkyl-SO2-, wherein all phenyl groups and heteroaryl groups can independently of each other be substituted by one or more identical or different substituents chosen from halogen, (CrC4)-alkyl, CF3 and (Cr C4)-alkyloxy;
R11 is chosen from hydrogen, (CrC4)-alkyl and ((CrC4)-alkyl)-CO-; R12 is chosen from hydrogen, (Ci-C4)-alkyl, (C3-Cy)-CyClOaIKyI-CnH2n-, phenyl-CnH2n-, heteroaryl-CnH2n-, ((CrC4)-alkyl)-CO-, (C3-C7)-cycloalkyl-CnH2n-CO-, phenyl-CnH2n- CO-, heteroaryl-CnH2n-CO-, ((C1-C4)-alkyl)-O-CO- and phenyl-CnH2n-O-CO-, wherein all phenyl groups and heteroaryl groups can be substituted by one or more identical or different substituents chosen from halogen, (Ci-C4)-alkyl, CF3 and (Ci-C4)- alkyloxy;
R13 is chosen from hydrogen, (Ci-C-O-alkyl and phenyl-CnH2n-, wherein the phenyl group can be substituted by one or more identical or different substituents chosen from halogen, (Ci-C4)-alkyl, CF3 and (Ci-C4)-alkyloxy, where all groups R13 are independent of each other and can be identical or different;
heteroaryl is a 5-membered or 6-membered, monocyclic aromatic group which contains one, two or three identical or different hetero ring members chosen from N, NR13, O and S;
n is 0, 1 or 2, where all numbers n are independent of each other and can be identical or different;
in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof;
excluding compounds comprised by this definition which have already been described such as 2-(2-acetylaminoethylamino)-3-cyano-5-(pyridin-4-yl)pyridine, 2- (2-propionylaminoethylamino)-3-cyano-5-(pyridin-4-yl)pyridine and 3-cyano-2-(2- nicotinoylaminoethylamino)-5-(pyridin-4-yl)pyridine.
Another such embodiment of the present invention relates to compounds of the formula Ia in which simultaneously
A is chosen from -CH2-CH2-CH2- and -Y-CH2-CH2- wherein Y is chosen from O and NH and wherein Y is bonded to the group Het; Het is chosen from the pyridinediyl, thiazolediyl, oxazolediyl, imidazolediyl and thiophenediyl which can all be substituted by one or more identical or different substituents R5 and wherein one of the ring nitrogen atoms of the imidazolediyl group carries a group chosen from hydrogen and (Ci-C4)-alkyl;
X is absent and the phenyl group representing the group R3 is fused to the group Het;
R1 and R2, together with the N-CO group which carries them, form a 4-membered to 7-membered, monocyclic, saturated or unsaturated heterocycle which, in addition to the ring nitrogen atom being part of the N-CO group, can contain one further hetero ring member chosen from NR12, O and S, wherein the ring formed by R1 and R2 and the N-CO group which carries them can be substituted by one or more identical or different substituents R8;
R3 is phenyl which can be substituted by one or more identical or different substituents which are chosen from halogen, (Ci-C4)-alkyl, (Ci-C4)-alkyloxy-(Ci-C2)- alkyl-, (C-ι-C4)-alkyloxy which can be substituted by one or more fluorine atoms, (C-i- C4)-alkylmercapto, (Ci-C4)-alkylamino, di((Ci-C4)-alkyl)amino, CONH2, CN, CF3 and (CrC4)-alkyl-SO2-;
R5 is chosen from halogen, (Ci-C4)-alkyl, (Ci-C4)-alkyloxy-(Ci-C2)-alkyl-, OH, (Ci-C4)- alkyloxy which can be substituted by one or more fluorine atoms, (CrC4)- alkylmercapto, NH2, (CrC4)-alkylamino, di((Ci-C4)-alkyl)amino, ((Ci-C4)-alkyl)- CONH-, CONH2, CN, CF3 and (Ci-C4)-alkyl-SO2-;
R8 is chosen from (C-ι-C4)-alkyl and oxo;
R12 is chosen from H and (Ci-C4)-alkyl-;
in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof. Besides the use of the compounds of the formula Ia defined afore in which the group X is absent, for the manufacture of a medicament for the stimulation of the expression of endothelial NO synthase and for the treatment of a disease in which such a stimulation, or an increase in NO level, is desired, for example cardiovascular disorders such as atherosclerosis, coronary artery disease or cardiac insufficiency or any other diseases mentioned above or below herein, also the novel compounds of the formula Ia defined afore in which the group X is absent, themselves, i.e. the novel compounds per se, are a subject of the present invention.
As in any embodiment of the invention, in the preceding embodiments, which contain exemplary definitions of compounds according to the invention, one or more or all of the groups can have any of its preferred definitions specified above or any one or some of the specific denotations which are comprised by its definitions and are specified above.
A further embodiment of the present invention relates to any of the individual compounds of the formulae I and Ia which are specifically disclosed herein, including the compounds of all examples described below, in the form of the respective free compound as well as in the form of the physiologically acceptable salts thereof in general and, if a specific salt is disclosed herein, in the form of this specific salt, as well as to all tautomeric forms of the free compounds and their salts if tautomeric forms exist. I.e., this embodiment encompasses the physiologically acceptable salts in general of any individual compound specifically disclosed herein, irrespective thereof whether the compound is specifically disclosed as the free compound or as a specific salt. For example, as regards the compound 1-(3-(6-(2-fluorophenyl)pyridin- 3-yl)propyl)piperidin-2-one which is specifically disclosed as the free compound, subjects of the present invention are "1-(3-(6-(2-fluorophenyl)pyridin-3- yl)propyl)piperidin-2-one" and "1 -(3-(6-(2-fluorophenyl)pyridin-3-yl)propyl)piperidin-2- one or a physiologically acceptable salt thereof. As regards the compound 4-(3-(6- phenylpyridin-3-yl)propyl)thiomorpholin-3-one which is specifically disclosed as its trifluoroacetic acid salt, subjects of the present invention are "4-(3-(6-phenylpyridin-3- yl)propyl)thiomorpholin-3-one", "4-(3-(6-phenylpyridin-3-yl)propyl)thiomorpholin-3-one or a physiologically acceptable salt thereof and "4-(3-(6-phenylpyridin-3- yl)propyl)thiomorpholin-3-one trifluoroacetic acid salt". Thus, a subject of the present invention is a compound chosen from all individual compounds which are specifically disclosed herein, irrespective thereof whether they are disclosed as the free compound or as a specific salt, including the compounds
1-(3-(6-(2-fluorophenyl)pyridin-3-yl)propyl)-1H-pyhdin-2-one,
1-(3-(6-(2-fluorophenyl)pyhdin-3-yl)propyl)pipehdin-2-one,
4-(3-(6-phenylpyridin-3-yl)propyl)thiomorpholin-3-one, 1-(3-(6-(2-fluorophenyl)pyridin-3-yl)propyl)pyrrolidin-2-one,
1-(3-(6-(2-fluorophenyl)pyridin-3-yl)propyl)piperidine-2,6-dione,
1-(3-(6-(2-fluorophenyl)pyridin-3-yl)propyl)azepan-2-one,
4-(3-(6-(2-chlorophenyl)pyridin-3-yl)propyl)thiomorpholin-3-one,
4-(3-(6-(4-fluorophenyl)pyridin-3-yl)propyl)thiomorpholin-3-one, 4-(3-(6-(2-fluorophenyl)pyridin-3-yl)propyl)thiomorpholin-3-one,
1-(3-(6-(2-fluorophenyl)pyridin-3-yl)propyl)pyrrolidine-2,5-dione,
3-(3-(6-(2-fluorophenyl)pyridin-3-yl)propyl)thiazolidine-2,4-dione,
1-(3-(6-(4-fluorophenyl)pyridin-3-yl)propyl)pyrrolidin-2-one,
1-(3-(6-(4-fluorophenyl)pyhdin-3-yl)propyl)pyrrolidine-2,5-dione, 3-(3-(6-(4-fluorophenyl)pyridin-3-yl)propyl)imidazolidine-2,4-dione,
1-(3-(6-(4-fluorophenyl)pyridin-3-yl)propyl)azetidin-2-one,
1-(3-(6-(4-fluorophenyl)pyridin-3-yl)propyl)piperidin-2-one,
1-(3-(6-(4-fluorophenyl)pyridin-3-yl)propyl)azepan-2-one,
4-(3-(6-(2-fluorophenyl)pyhdin-3-yl)propyl)-4H-[1 ,4]thiazin-3-one, 3-(3-(6-(2-fluorophenyl)pyridin-3-yl)propyl)imidazolidine-2,4-dione,
1-(3-(6-(4-fluorophenyl)pyridin-3-yl)propyl)piperidine-2,6-dione,
3-(3-(6-(4-fluorophenyl)pyridin-3-yl)propyl)thiazolidine-2,4-dione,
1-(3-(6-(2-fluorophenyl)pyridin-3-yl)propyl)azetidin-2-one,
1-(3-(6-(4-fluorophenyl)pyridin-3-yl)propyl)-1 H-pyridin-2-one, 4-(3-(6-(4-fluorophenyl)pyridin-3-yl)propyl)-4H-[1 ,4]thiazin-3-one,
1-(2-(6-(2-fluorophenyl)pyridin-3-yloxy)ethyl)piperidin-2-one,
1-(2-(6-(2-fluorophenyl)pyridin-3-yloxy)ethyl)azetidin-2-one, 1-(2-(6-(2-fluorophenyl)pyridin-3-yloxy)ethyl)pyrrolidine-2,5-dione, 3-(2-(4-(4-fluorophenyl)thiazol-2-ylamino)ethyl)imidazolidine-2,4-dione, 3-(2-(6-(2-fluorophenyl)pyridin-3-yloxy)ethyl)imidazolidine-2,4-dione, 1-(2-(5-(2-fluorophenyl)pyridin-2-yloxy)ethyl)pyrrolidin-2-one, 1-(2-(4-(4-fluorophenyl)thiazol-2-ylamino)ethyl)pyrrolidine-2,5-dione, 1-(2-(6-(4-fluorophenyl)pyridin-3-yloxy)ethyl)pyrrole-2,5-dione, 1-(2-(6-(4-fluorophenyl)pyridin-3-yloxy)ethyl)pyrrolidine-2,5-dione, 1-(2-(6-(4-fluorophenyl)pyridin-3-yloxy)ethyl)-1 H-pyridin-2-one, 1-(2-(4-(4-fluorophenyl)thiazol-2-ylamino)ethyl)imidazolidin-2-one, 3-(2-(6-(4-fluorophenyl)pyridin-3-yloxy)ethyl)imidazolidine-2,4-dione,
3-(3-(6-(4-fluorophenyl)pyridin-3-yl)propyl)-5,5-dimethylimidazolidine-2,4-dione, 3-(3-(6-(4-fluorophenyl)pyridin-3-yl)propyl)oxazolidin-2-one, i^^θ-CS-chloro^-fluorophenyOpyridin-S-yloxyJethyOpyrrolidine^.δ-dione, 1-(2-(6-(6-fluoropyridin-3-yl)pyridin-3-yloxy)ethyl)pyrrolidine-2,5-dione, 1-(2-(6-(4-methylthiophen-2-yl)pyridin-3-yloxy)ethyl)pyrrolidine-2,5-dione, 1-(2-(6-(3,4,5-trifluorophenyl)pyridin-3-yloxy)ethyl)pyrrolidine-2,5-dione, 1-(2-(6-(3-trifluoromethoxyphenyl)pyridin-3-yloxy)ethyl)pyrrolidine-2,5-dione, 1-(2-(6-(2-trifluoromethoxyphenyl)pyridin-3-yloxy)ethyl)pyrrolidine-2,5-dione, 1-(2-(6-(6-methoxypyridin-3-yl)pyridin-3-yloxy)ethyl)pyrrolidine-2,5-dione, 1-(2-(6-(pyridin-3-yl)pyridin-3-yloxy)ethyl)pyrrolidine-2,5-dione,
1-(2-(6-(4-trifluoromethoxyphenyl)pyridin-3-yloxy)ethyl)pyrrolidine-2,5-dione, 1-(2-(6-(2,3-dichlorophenyl)pyridin-3-yloxy)ethyl)pyrrolidine-2,5-dione, 1-(2-(6-(2,4-difluorophenyl)pyridin-3-yloxy)ethyl)pyrrolidine-2,5-dione, 1-(2-(6-(3,4-dimethoxyphenyl)pyridin-3-yloxy)ethyl)pyrrolidine-2,5-dione, 1-(2-(6-(4-cyanophenyl)pyridin-3-yloxy)ethyl)pyrrolidine-2,5-dione, 1-(2-(6-(3-cyanophenyl)pyridin-3-yloxy)ethyl)pyrrolidine-2,5-dione, 1-(2-(6-(naphthalen-2-yl)pyridin-3-yloxy)ethyl)pyrrolidine-2,5-dione, 1-(2-(6-(naphthalen-1-yl)pyridin-3-yloxy)ethyl)pyrrolidine-2,5-dione, 1-(2-(6-(3-acetylaminophenyl)pyridin-3-yloxy)ethyl)pyrrolidine-2,5-dione, 1-(2-(6-(2-trifluoromethylphenyl)pyridin-3-yloxy)ethyl)pyrrolidine-2,5-dione, 1-(2-(6-(4-trifluoromethylphenyl)pyridin-3-yloxy)ethyl)pyrrolidine-2,5-dione, 1-(2-(6-(3,5-dichlorophenyl)pyridin-3-yloxy)ethyl)pyrrolidine-2,5-dione, 1-(2-(6-(3-trifluoromethylphenyl)pyridin-3-yloxy)ethyl)pyrrolidine-2,5-dione, 1-(2-(6-(3,4-difluorophenyl)pyridin-3-yloxy)ethyl)pyrrolidine-2,5-dione, 1-(2-(6-(3,5-difluorophenyl)pyridin-3-yloxy)ethyl)pyrrolidine-2,5-dione, 1-(2-(6-(4-tert-butylphenyl)pyridin-3-yloxy)ethyl)pyrrolidine-2,5-dione, 1-(2-(6-(4-ethoxyphenyl)pyridin-3-yloxy)ethyl)pyrrolidine-2,5-dione, 1-(2-(6-(2-fluoropyridin-3-yl)pyridin-3-yloxy)ethyl)pyrrolidine-2,5-dione, 1-(2-(6-(2,5-difluorophenyl)pyridin-3-yloxy)ethyl)pyrrolidine-2,5-dione, 1-(2-(6-(4-dimethylaminophenyl)pyridin-3-yloxy)ethyl)pyrrolidine-2,5-dione, 1-(2-(6-(3-chloropyridin-4-yl)pyridin-3-yloxy)ethyl)pyrrolidine-2,5-dione, 1 -(2-(6-(5-cyanothiophen-2-yl)pyridin-3-yloxy)ethyl)pyrrolidine-2,5-dione, 1-(2-(6-(3,5-dimethylisoxazol-4-yl)pyridin-3-yloxy)ethyl)pyrrolidine-2,5-dione) 1-(2-(6-(3-fluoropyridin-4-yl)pyridin-3-yloxy)ethyl)pyrrolidine-2,5-dione, 1-(2-(6-(4-fluoro-2-methylphenyl)pyridin-3-yloxy)ethyl)pyrrolidine-2,5-dionel 1-(2-(6-(4-fluoro-3-methylphenyl)pyridin-3-yloxy)ethyl)pyrrolidine-2,5-dione, 1-(2-(6-(pyrimidin-5-yl)pyridin-3-yloxy)ethyl)pyrrolidine-2,5-dionel 4-(3-(6-(4-fluorophenyl)pyridin-3-yl)propylcarbamoyl)butyric acid, 2-(2-(4-(4-fluorophenyl)thiazol-2-ylamino)ethyl)isoindole-1 ,3-dione, 1 -(2-(5-(1 -methyl-1 H-benzoimidazol-2-yl)pyridin-2-yloxy)ethyl)pyrrolidin-2-one, N-(2-(4-(4-fluorophenyl)thiazol-2-ylamino)ethyl)acetamide, 2-(2-(6-(2-fluorophenyl)pyridin-3-yloxy)ethyl)isoindole-1 ,3-dione, 4-chloro-N-(2-(4-(4-fluorophenyl)thiazol-2-ylamino)ethyl)benzamide, 4-aminofurazan-3-carboxylic acid (2-(4-(4-fluorophenyl)thiazol-2- ylamino)ethyl)amide, N-(2-(4-(4-fluorophenyl)thiazol-2-ylamino)ethyl)isonicotinamide, N-(2-(6-(2-fluorophenyl)pyridin-3-yloxy)ethyl)acetamide, N-(2-(6-(2-fluorophenyl)pyridin-3-yloxy)ethyl)benzamide, cyclopropanecarboxylic acid (2-(6-(2-fluorophenyl)pyridin-3-yloxy)ethyl)amide, 1-(2-(6-(quinolin-8-yll)pyridin-3-yloxy)ethyl)pyrrolidine-2,5-dione, 1-(2-(6-(4-methylsulfonylaminophenyl)pyridin-3-yloxy)ethyl)pyrrolidine-2,5-dione, and 1-(2-(6-(3-methylsulfonylaminophenyl)pyridin-3-yloxy)ethyl)pyrrolidine-2,5-dione, or a physiologically acceptable salt thereof. A further subject of the present invention are processes of preparation by which the compounds of the formulae I and Ia or salts thereof are obtainable. There are several ways of preparing the compounds by piecing suitable building blocks together. According to one of the processes, by which compounds of the formulae I and Ia can be synthesized in which the group A denotes -Y-CH2-CH2-, i.e. compounds of the formula Ib in which the groups Het, X, Y, R1, R2 and R3 are defined as in the compounds of the formulae I and Ia1 a compound of the formula IV and a compound of the formula V are linked in a standard alkylation reaction.
Figure imgf000056_0001
VIII
VII
In the compounds of the formulae IV and V the groups Het, X, Y, R1, R2 and R3 are defined as in the compounds of the formulae I and Ia and, in addition, any functional groups can be present in protected form or in the form of precursor groups which are later converted into the desired groups. The compounds of the formulae IV and V can also be employed in the form of salts. The group L1 in the compounds of the formula V is a leaving group which is nucleophilically substitutable by the amino group, hydroxyl group or mercapto group representing the group -Y-H in the compounds of the formula IV. Examples of suitable leaving groups L1 are halogen, in particular chlorine and bromine, and arylsulfonyloxy groups and alkylsulfonyloxy groups such as benzenesulfonyloxy, toluenesulfonyloxy, nitrobenzenesulfonyloxy, methanesulfonyloxy and trifluoromethanesulfonyloxy. When compounds of the formula V containing such leaving groups L1 are employed, for binding the liberated acid of the formula L1-H and/or enhancing the nucleophilicity of the compound of the formula IV in the alkylation reaction it is often advantageous to employ a suitable base such as an amine, for example a tertiary amine like triethylamine, ethyldiisopropylamine, pyridine, an amide salt, for example sodium amide or lithium diisopropylamide, an organometallic compound, for example an organolithium compound like n-butyllithium, an alkali metal or alkaline earth metal hydride, for example lithium hydride, sodium hydride or calcium hydride, an alkali metal or alkaline earth metal hydroxide or quaternary ammonium hydroxide, for example lithium hydroxide, sodium hydroxide, potassium hydroxide, calcium hydroxide, benzyltrimethylammonium hydroxide, an alkali metal or alkaline earth metal alkoxide, for example sodium methoxide, sodium ethoxide, potassium methoxide, potassium ethoxide, potassium tert-butoxide, or another basic alkaline metal or earth alkaline metal compound, for example a carbonate like sodium carbonate, potassium carbonate, cesium carbonate, a hydrogencarbonate like sodium hydrogencarbonate, potassium hydrogencarbonate, or another basic salt, or a mixture of two or more bases. The base can be employed before the actual alkylation reaction is performed in order to convert the compound of the formula IV into its corresponding salt. The reaction of the compounds of the formulae IV and V is usually carried out in an inert solvent, which can be protic or aprotic and aqueous or non-aqueous, such as a hydrocarbon or chlorinated hydrocarbon, for example n-heptane, toluene, xylene, chlorobenzene, dichloromethane, an ether, for example diethyl ether, diisopropyl ether, 1 ,2-dimethoxyethane (= DME), tetrahydrofuran (= THF), dioxane, an ester, for example ethyl acetate, butyl acetate, an amide, for example N,N-dimethylformamide (= DMF), N-methylpyrrolidin-2-one (= NMP), a nitrile, for example acetonitrile, an alcohol, for example methanol, ethanol, isopropanol, n-butanol, or another solvent, for example water, pyridine, dimethyl sulfoxide (= DMSO), or a mixture of two or more solvents, including a mixture of water and an organic solvent which is miscible or immiscible with water. The reaction of the compounds of the formulae IV and V can be carried out in a wide temperature range. Usually it is advantageous to perform the reaction at temperatures from about -20 0C to about the boiling point of the solvent used, preferably at from about 0 0C to about 100 0C. As is usual, the detailed conditions of a specific preparation, including the solvent, the base, the temperature, the order of addition, the molar ratios and other parameters, are routinely chosen by the person skilled in the art in view of the characteristics of the starting compounds and the target compound.
Besides halogen or a sulfonyloxy group, the leaving group L1 can also be a hydroxyl group, for example, and the linking of the compounds of the formulae IV and V be effected under the conditions of the Mitsunobu reaction. In such a reaction a hydroxyl compound is activated by reaction with an azodicarboxylic acid ester like diethyl azodicarboxylate (DEAD) or diisopropyl azodicarboxylate (DIAD) and a phosphane like triphenylphosphane or tributylphosphane, and becomes susceptible to nucleophilic substitution. The reaction can usually be carried under mild conditions in an aprotic solvent like an ether, for example tetrahydrofuran or dioxane, at temperatures from about 0° C to about room temperature. Details on the Mitsunobu reaction are given, for example, in Mitsunobu, Synthesis (1981) 1.
Instead of reacting the compound of the formula IV with the compound of the formula V and thereby simultaneously introducing the group -CH2-CH2- and the group -N(R2)-CO-R1, these two groups can also be introduced stepwise by first reacting a compound of the formula IV with a compound of the formula Vl and then reacting the obtained compound of the formula VII, or a compound generated from the compound of the formula VII, with a compound of the formula VIII. In the compounds of the formulae IV, Vl, VII and VIII the groups Het, X, Y, R1, R2, R3 and L1 are defined as in the compounds of the formulae I and Ia and the compounds of the formula V and, in addition, any functional groups can be present in protected form or in the form of precursor groups which are later converted into the desired groups. The compounds of the formulae IV, Vl and VII can also be employed in the form of salts. The group L2 in the compounds of the formulae Vl and VII can be a nucleophilically substitutable leaving group like the group L1 and be defined as the group L1 in the compound of the formula V, and be identical to or different from L1. If L2 is a leaving group, the formation of the desired product of the formula VII in the reaction of the compounds of the formulae IV and Vl can be achieved by employing suitable reaction conditions, for example employing an excess of the compound of the formula Vl, or by employing a compound of the formula Vl which contains two leaving groups L1 and L2 of different reactivity. The group L2 in the compound of the formula Vl, instead of being a leaving group, can also be a protected form of a leaving group or a precursor of a leaving group which is converted into a leaving group in the compound of the formula VII. For example, the group L2 in the compound of the formula Vl can be a hydroxyl group, or the group L2 in the compound of the formula Vl can be an esterified or etherified hydroxyl group which in the compound of the formula VII is converted into a hydroxyl group, and the hydroxyl group representing the group L2 in the obtained compound of the formula VII can be converted into a halogen atom or a sulfonyloxy group, for example a bromine atom by treatment with hydrogen bromide or phosphorus tribromide or a methanesulfonyloxy group by treatment with methanesulfonyl chloride. Such conversions can be performed under standard conditions known to the skilled person. Another example of such a compound of the formula Vl is a 2-halogen-substituted acetic acid ester, for example a 2-bromoacetic acid (Ci-C4)-alkyl ester. After alkylation of the compound of the compound of the formula IV with such an ester to give a compound of the formula VII in which the -CH2-CH2-L2 moiety is replaced with a -CH2-CO-O-(Ci-C4)-alkyl moiety, the ester group can be reduced to a hydroxyl group, for example with a complex hydride reducing agent such as lithium borohydride, to give a compound of the formula VII in which L2 is hydroxyl, which can then be converted into a compound of the formula VII in which L2 is methanesulfonyloxy, for example. All the above explanations on the reaction of the compounds of the formulae IV and V, for example with respect to bases which may be added, apply correspondingly to the reactions of the compounds of the formulae IV and Vl and the reaction of the compounds of the formulae VII and VIII.
Instead of introducing the group Y by means of the same starting compound which introduces the R3-X-Het- moiety, the group Y can also be introduced by means of the starting compound which introduces the -N(R2)-CO-R1 moiety, and a compound of the formula Ib prepared by reaction of suitable compounds of the formulae IX and X.
Figure imgf000060_0001
In the compounds of the formulae IX and X the groups Het, X, Y, R1, R2 and R3 are defined as in the compounds of the formulae I and Ia and, in addition, any functional groups can be present in protected form or in the form of precursor groups which are later converted into the desired groups. The group L3 in the compounds of the formula IX is a leaving group which can be replaced with the group Y in a nucleophilic aromatic substitution reaction. Examples of leaving groups L3 in a compound of the formula IX which can undergo such a reaction, are halogen, for example chlorine, bromine or iodine, and sulfonyloxy groups such as trifluoromethanesulfonyloxy. The compounds of the formulae IX and X can also be employed in the form of salts. All the above explanations on the reaction of the compounds of the formulae IV and V, for example with respect to bases which may be added, apply to the reaction of the compounds of the formulae IX and X correspondingly.
The starting compounds of the formulae IV, V, Vl, VIII, IX and X, as well as other starting compounds for the preparation of the compounds of the invention discussed herein, are commercially available or can be prepared according to, or analogously to, procedures which are described in the literature and familiar to the person skilled in the art. Compounds of the formulae IV and IX, for example, in which the group X is O, S, NH or N((Ci-C4)-alkyl), can be obtained in a nucleophilic aromatic substitution reaction, similarly to the reaction of the compounds of the formulae IX and X, from a respective compound of the formula R3-X-H and a suitable heteroaromatic compound containing a leaving group. Compounds of the formulae IV and IX in which the group X is CH2 can be obtained by reaction of a metalated heteroaromatic compound comprising the group Het with an alkylating agent which introduces the R3-CH2- moiety, or by reduction of a compound which contains a R3-CO-Het- or R3-CH(OH)-Het- moiety which can in turn be obtained by an acylation reaction or by reaction of an aldehyde with a metalated heteroaromatic compound. Compounds of the formula IV and IX in which the group X is a direct bond, can be obtained in a transition metal-catalyzed Suzuki coupling reaction from a halogen-substituted heteroaromatic compound comprising the group Het and a boronic acid derivative. Compounds of the formulae V and X can be obtained by acylating amines of the formulae L1-CH2-CH2-N(R2)-H and H-Y-CH2-CH2-N(R2)-H or alkylating amides of the formula VIII and optionally modifying a group in a desired manner, for example converting a hydroxyl group representing the group H-Y- into a halogen atom or a sulfonyloxy group representing the group L1, such as a bromine atom by treatment with hydrogen bromide or phosphorus tribromide or a methanesulfonyloxy group by treatment with methanesulfonyl chloride under standard conditions (cf., for example, the preparation of methanesulfonic acid 2-(2,5-dioxopyrrolidin-1 -yl)ethyl ester from methanesulfonyl chloride and 1-(2-hydroxyethyl)pyrrolidine-2,5-dione described in WO 2004/089903). Compounds of the formula VIII can be obtained by acylation of amines of the formula R2-NH2 or, in case R1 and R2 together with the N-CO group which carries them form a ring, from suitable bifunctional starting compounds such as from amino-substituted carboxylic acids by cyclization or from dicarboxylic acids by conversion into the imides, for example.
Compounds of the formulae I and Ia in which the group A denotes -CH2-CH2- or -CH2-CH2-CH2-, i.e. compounds of the formula Ic in which the number p is 0 or 1 and all other groups are defined as in the compounds of the formulae I and Ia, can be prepared by reacting a compound of the formula IX with an amide of the formula Xl or XIII which comprises a terminal alkenyl or alkynyl moiety, respectively, in the unsaturated substituent on the nitrogen atom to give an intermediate of the formula XII or XIV which can then be converted into a compound of the formula Ic by catalytic hydrogenation, for example in the presence of a palladium catalyst.
Figure imgf000062_0001
In the compounds of the formulae IX and Xl to XIV the groups Het, X, R1, R2 and R3 are defined as in the compounds of the formulae I and Ia and, in addition, any functional groups can be present in protected form or in the form of precursor groups which are later converted into the desired groups. The number p in the compounds of the formulae Xl to XIV is 0 or 1. Like the -CH2-CH2-CH2- and -CH2-CH2- groups representing the group A in the compounds of the formulae I and Ia, the alkenyl and alkynyl group in the compounds of the formulae Xl to XIV can optionally be substituted by suitable substituents, for example alkyl substituents. The group L3 in the compounds of the formula IX is a leaving group such as halogen, for example chlorine, bromine or iodine, or a sulfonyloxy group, for example trifluoromethanesulfonyloxy, as explained above. The reaction of a compound of the formula IX with a compound of the formula Xl or XIII is carried out under the conditions of the well-known Heck reaction and Sonogashira reaction, respectively, in the presence of a transition metal catalyst such as a palladium catalyst and, in the case of the Sonogashira reaction, a copper co-catalyst such as copper iodide (cf. de Meijere et al., Angew. Chem. Int. Ed. 33 (1994) 2379). A further process for the preparation of compounds of the formulae I and Ia in which the group A denotes -CH2-CH2- or -CH2-CH2-CH2-, i.e. compounds of the formula Ic in which the number p is 0 or 1 and the other groups are defined as in the compounds of the formulae I and Ia, starts from heteroaromatic aldehydes of the formula XV in which the carbon chain can be elongated to give the hydroxyalkyl compounds of the formula XVI which, after conversion of the hydroxyl group into a leaving group to give the compounds of the formula XVII, can be used for the alkylation of compounds of the formula VIII to give compounds of the formula Ic.
Figure imgf000063_0001
In the compounds of the formulae VIII and XV to XVII the groups Het, X, R1, R2 and R3 are defined as in the compounds of the formulae I and Ia and, in addition, any functional groups can be present in protected form or in the form of precursor groups which are later converted into the desired groups. The number p in the compounds of the formulae XVI and XVII is 0 or 1. Like the -CH2-CH2-CH2- and -CH2-CH2- groups representing the group A in the compounds of the formulae I and Ia, the carbon chains in the compounds of the formulae XV to XVII can optionally be substituted by suitable substituents, for example alkyl substituents. In case the carbon atom adjacent to the group Het carries an alkyl group, the starting compound of the formula XV can thus also be a ketone instead of an aldehyde. The group L4 in the compounds of the formula XVII is a nucleophilically substitutable leaving group. Similarly as explained above with respect to the leaving group L1, examples of suitable leaving groups L4 are halogen, in particular chlorine and bromine, and arylsulfonyloxy groups and alkylsulfonyloxy groups such as benzenesulfonyloxy, toluenesulfonyloxy, nitrobenzenesulfonyloxy, methanesulfonyloxy and trifluoromethanesulfonyloxy.
For elongating the carbon chain by two carbon atoms, the compound of the formula
XV can be condensed under the conditions of the Knoevenagel reaction with a malonic acid derivative, or under the conditions of the Wittig-Horner reaction with a di((Ci-C4)-alkyl) ((Ci-C4)-alkyloxy)carbonylmethylphosphonate, for example. In the intermediate heteroaromatic cinnamic acid derivative of the formula R3-X-Het- CH=CH-COOR30, in which R30 can be (Ci-C4)-alkyl or hydrogen, the -CH=CH- moiety can be converted into a -CH2-CH2- moiety by catalytic hydrogenation, for example in the presence of a palladium catalyst, and the COOR30 moiety reduced to a -CH2-OH moiety, for example by reduction with a complex borohydride or aluminum hydride such as lithium borohydride, to give a compound of the formula XVI in which p is 1. For elongating the carbon chain by one carbon atom, a compound of the formula XV can be condensed under the conditions of the Wittig reaction with a methoxymethyltriphenylphosphonium salt, for example, and in the intermediate compound of the formula R3-X-Het-CH=CH-OCH3 the vinyl ether moiety -CH=CH-OCH3 can be hydrolyzed under acidic conditions to give the aldehyde moiety -CH2-CHO which can be reduced to a -CH2-CH2-OH moiety by means of a complex borohydride or by catalytic hydrogenation to give a compound of the formula
XVI in which p is 0. Similarly as outlined above with respect to the compounds of the formula V and VII, the conversion of the hydroxyalkyl compound of the formula XVI into the compound of the formula XVII can be accomplished by means of a halogenating agent such as thionyl chloride, phosphorus tribromide or hydrogen bromide in case L4 is halogen, or a sulfonyl chloride or a sulfonic acid anhydride such as methanesulfonyl chloride or trifluoromethanesulfonyl anhydride, for example, in case L4 is a sulfonyloxy group. All the above explanations on the reaction of the compounds of the formulae IV and V, for example with respect to bases which may be added, apply correspondingly to the reaction of the compounds of the formulae
XVII and VIII. The compounds of the formulae XVII and VIII can also be employed in the form of their salts. Instead of starting in the preparation of a target compound of the formula I or Ia from a compound which already comprises all the groups R3, X and Het, such as a compound of the formula IV or IX or XVI, it is also possible to start from a compound which only comprises the group Het or the groups X and Het, for example, and to introduce the group R3 or the moiety R3-X- in a later step, or in the last step of the reaction sequence, after having assembled the -X-Het-A-N(R2)-CO-R1 moiety or the -Het-A-N(R2)-CO-R1 moiety. Thus, for example, when preparing a compound of the formula Ib which is defined as indicated above, instead of reacting a compound of the formula IV with a compound of the formula V, also a compound of the formula XVIII can be reacted with a compound of the formula V and the resulting intermediate of the formula XIX reacted with a compound of the formula XX which introduces the R3-X- moiety.
Figure imgf000065_0001
VIII
XXI
In the compounds of the formulae V, XVIII, XIX and XX the groups Het, X, Y, R1, R2 and R3 are defined as in the compounds of the formulae I and Ia and, in addition, any functional groups can be present in protected form or in the form of precursor groups which are later converted into the desired groups. The compounds can also be employed in the form of their salts. The leaving group L1 in the compounds of the formula V is defined as indicated above. Similarly as explained above with respect to the compounds of the formulae IV and V, the reaction of the compounds of the formulae XVIII and V is preferably carried out in the presence of a base. All the above explanations on the reaction of the compounds of the formulae IV and V correspondingly apply to the reaction of the compounds of the formulae XVIII and V. The group L5 in the compounds of the formulae XVIII and XIX is a leaving group which can be replaced with the group R3-X- in a nucleophilic aromatic substitution reaction or a reaction of another type as it is performed when reacting the compounds of the formulae XIX and XX. Examples of suitable leaving groups L5 in the compounds of the formulae XVIII and XIX are halogen, in particular chlorine, bromine and iodine, and sulfonyloxy groups such as trifluoromethanesulfonyloxy. The group G in the compounds of the formula XX can be hydrogen in case the group X is O, S, NH or N((Ci-C4)-alkyl). In such case the nucleophilic aromatic substitution reaction between the compounds of the formulae XIX and XX can be carried out as indicated above with respect to the reaction of the compounds IX and X. In case the group X is a direct bond and the group G thus is attached directly to the group R3 via a single bond, the group G can be a boronic acid derivative, for example a boronic acid group, and the compound of the formula XX thus be a compound of the formula R3-B(OH)2 in which R3 is defined as in the compounds of the formulae I and Ia and, in addition, any functional groups can be present in protected form or in the form of precursor groups. The reaction of the boronic acid derivative with a compound of the formula XIX to give a compound of the formula Ib, in which X is a direct bond, can be carried out under the conditions of the well known Suzuki coupling, or Suzuki- Miyaura coupling, in the presence of a transition metal catalyst such as a palladium catalyst, for example palladium acetate or tetrakis(thphenylphosphane)palladium, in an aqueous or non-aqueous solvent. Details on such coupling reactions of boronic acid derivatives, which can advantageously be used also in other processes for the preparation of the compounds of the invention, and intermediates therefor are explained in Kotha et al., Tetrahedron 58 (2002) 9633, Miyaura, Topics in Current Chemistry 219 (2002) 11 , or Walker et al., Angew. Chem. Ind. Ed. 43 (2004) 1871 , for example.
In a similar manner as described above, instead of reacting compounds of the formulae IV and Vl and reacting the resulting compound of the formula VII with a compound of the formula VIII, compounds of formula Ib can also be prepared by reacting compounds of the formulae XVIII and Vl, reacting the resulting compound of the formula XXI with a compound of the formula VIII to give a compound of the formula XIX, and finally introducing the group R3-X- into the latter compound by reacting it with a compound of the formula XX. The groups Het, Y and L2 in the compounds of the formula XXI are defined as in the compounds of the formula VII, the group L5 in the compounds of the formula XXI is defined as the group L5 in the compounds of the formulae XVIII and XIX. With respect to the other compounds involved in this process, including examples of compounds of the formula Vl such as 2-bromoacetic acid esters, and suitable reaction conditions the above statements apply correspondingly.
Just so, instead of reacting compounds of the formulae IX and X, compounds of the formulae XXII and X can be reacted to give a compound of the formula XXIII which can then be reacted with a compound of the formula XX to give a compound of the formula Ib.
XXIII
Ib
Figure imgf000067_0001
The group L5 in the compounds of the formulae XXII and XXIII can be a nucleophilically substitutable leaving group like the group L3 and defined as the group L3, i.e. be a halogen atom, for example chlorine, bromine or fluorine, or a sulfonyloxy group such as trifluoromethanesulfonyloxy, for example, and be identical to or different from L3. If L5 is a leaving group, the formation of the desired product of the formula XXIII in the reaction of the compounds of the formulae XXII and X can be achieved by employing suitable reaction conditions, or by employing a compound of the formula XXII which contains two leaving groups L3 and L5 of different reactivity, or by taking advantage of different reactivities of leaving groups which are present in different positions of the group Het in case L3 and L5 are identical. The latter situation applies to a compound of the formula XXII such as 2,5-dibromopyridine, for example, in which the bromine atom in the 2-position is more reactive than the bromine atom in the 5-position and which will yield a compound of the formula XXIII containing a 5- bromopyridin-2-yl moiety in which the bromine atom in the 5-position can then be replaced with the group R3-X- (cf. Tilley et al., J. Org. Chem. 53 (1988) 386). The group L5 in the compound of the formula XXII, instead of being a leaving group, can also be a protected form of a leaving group or a precursor of a leaving group which is converted into a leaving group in the compound of the formula XXIII. With respect to the other groups in the compounds of the formulae XXII and XXIII and the other compounds involved in this process as well as suitable reaction conditions the statements on the above-discussed processes apply correspondingly. The compounds can also be employed in the form of their salts.
Like in the preparation of compounds of the formulae I and Ia which contain a group Y within the group A, just so in the preparation of compounds in which the group A is -CH2-CH2- or -CH2-CH2-CH2- the group R3 or the group R3-X- can be introduced in a later step, or in the last step of the reaction sequence, after having assembled the -Het-A-N(R2)-CO-R1 moiety or the -X-Het-A-N(R2)-CO-R1 moiety. Accordingly, instead of reacting a compound of the formula IX with a compound of the formulae Xl or XIII, just so a compound of the formula XXII can be reacted with a compound of the formulae Xl or XIII to give an analog of the compound of the formulae XII or XIV in which the group R3-X- is replaced with the group L5, in the latter compounds the double bond or triple bond can be hydrogenated, and the resulting analog of the compound of the formula Ic in which the group R3-X- is replaced with the group L5, can be reacted with a compound of the formula XX to give a compound of the formula Ic. The above-discussed preparation of compounds of the formula Ic from heteroaromatic aldehydes of the formula XV can accordingly be modified to start from an heteroaromatic aldehyde of the formula XXIV,
Figure imgf000069_0001
XXIV XXV XXVI
Figure imgf000069_0002
XXVII Ic
which, via the compounds of the formulae XXV1 XXVI and XXVII, can be converted into a compound of the formula Ic. The group L6 in the compounds of the formulae XXIV to XXVII is a leaving group such as halogen, in particular chlorine, bromine or iodine, or a sulfonyloxy group, for example a trifluoromethanesulfonyloxy group, which in the final step of the reaction sequence can be replaced with the group R3-X- introduced by the compound of the formula XX. With respect to the other groups in the compounds of the formulae XXIV to XXVII and the other compounds involved in this process, as well as with respect to reaction conditions and examples of reactions for elongating the carbon chain, the above statements all apply correspondingly. Taking the preparation of a compound of the formula Ic in which the number p is 1 as an example, more specifically a compound of the formula XXIV in which L6 can be a bromine atom, for example, can be reacted in a Wittig-Horner reaction with a di((Cr C-O-alkyl) ((CrC4)-alkyloxy)carbonylmethylphosphonate, for example, to give an intermediate heteroaromatic cinnamic acid derivative of the formula L6-Het-CH=CH- COOR30, in which R30 can be (Ci-C4)-alkyl, and which can be converted by catalytic hydrogenation into an intermediate of the formula L6-Het-CH2-CH2-COOR30 in which R30 can be (Ci-C4)-alkyl. In the latter compound the ester group can be reduced to an alcohol group, for example by treatment with lithium borohydride, to give a compound of the formula XXV in which the number p is 1 and which can be converted into a compound of the formula XXVI in which the number p is 1 and the group L4 is a bromine atom or a methanesulfonyloxy group, for example, by treatment with hydrogen bromide or with methanesulfonyl chloride, respectively. The compound of the formula XXVI can be reacted with a compound of the formula VIII, for example in the presence of sodium hydride, to give a compound of the formula XXVII in which the number p is 1 and in which the group L6, for example a bromine atom, can be replaced with the group R3-X- by reaction with a compound of the formula XX, for example by reaction with a boronic acid in the presence of palladium catalyst in case the group X is a direct bond. Instead of introducing the group R3-X- in the last step of preparation of the compound of the invention, it can also be introduced into any prior intermediate in the course of the synthesis. In the synthesis of compounds of the formula Ic in which the number p is 1 , for example, the compound of the formula L6-Het-CH2-CH2-COOR30, in which R30 can be (Ci-C4)-alkyl, can be reacted with a compound of the formula XX to give a compound of the formula R3-X-Het-CH2-
CH2-COOR30, in which R30 can be (CrC4)-alkyl, and in which the ester group can be reduced to an alcohol group to give a compound of the formula R3-X-Het-CH2- CH2-CH2OH which, after conversion of the hydroxy group into a leaving group such as the group L4 in the compounds of the formula XXVI, can then be reacted with a compound of the formula VIII. Such variations of the synthetic strategies outlined above are familiar to the person skilled in the art and allow to adapt the preparation of a compound of the formulae I or Ia to the particulars of the specific case.
Further synthetic strategies for the preparation of compounds of the formulae I and Ia include the assembly of the group Het in a ring-forming reaction from starting compounds which can contain the groups R3-X- and -A-N(R2)-CO-R1 or part of these groups or protected forms or precursors thereof which are then modified in subsequent reaction steps. For example, compounds of the formulae I and Ia in which the group Het is a thiazole ring, the group X is a direct bond and the group A is the group -NH-CH2-CH2-, i.e. compounds of the formula Id in which the groups R1, R2 and R3 are defined as indicated above with respect to the compounds of the formulae I and Ia, can be prepared by reacting a 2-bromo-1-R3-ethanone of the formula XXVIII, in which the CH2 group can optionally be substituted by a suitable substituent, for example an alkyl substituent, with a thiocyanate, for example an alkali metal thiocyanate such as sodium thiocyanate or potassium thiocyanate, to give a 2- thiocyanato-1-R3-ethanone which can also be isolated if desired, and with an N-(2- aminoethyl)amide of the formula Xa.
Figure imgf000071_0001
The groups R1 to R3 in the compounds of the formulae Xa and XXVIII are defined as in the compounds of the formulae I and Ia and, in addition, any functional groups can be present in protected form or in the form of precursor groups which are later converted into the desired groups. The reaction of a compound of the formula XXVIII with a thiocyanate and a compound of the formula Xa is generally carried out in a solvent, for example an alcohol such as methanol or ethanol, at elevated temperatures, for example at temperatures from about 40 0C to about 80 0C, for example at about 50 0C. The NH group attached to the thiazole ring in the compounds of the formula Id and, in general, an NH group representing the group Y in a compound of the formulae I and Ia, can further be modified, for example by treatment with an acylating agent such as a carboxylic acid chloride or anhydride to give a compound of the formulae I or Ia in which the group Y is the group NR11 and R11 is an acyl group. Compounds of the formulae I and Ia in which the group Y is the group NR11 and R11 is another group than hydrogen and an acyl group, can be prepared according to the process described afore by employing an analog of the compound of the formula Xa which contains a respective group R11HN- instead of the group H2N-.
The amide moiety -N(R2)-CO-R1 in the compounds of the formula Id, as well as in compounds of the formulae I and Ia as defined above in general, can be hydrolyzed under standard conditions to give an amino compound of the formula XXIX in which the group R3 is defined as in the compounds of the formulae I and Ia and, in addition, any functional groups can be present in protected form or in the form of precursor groups, or, depending on the meaning of the group R2 in the compounds of the formula Id, to give an analog of the compound of the formula XXIX which contains a group -NHR2 instead of the -NH2 group, which amino compounds can again be converted into further compounds of the formula Id and thus are valuable intermediate compounds. Such hydrolysis can be carried out by treating a compound of the formula Id or a suitable compound of the formulae I or Ia, for example a compound in which R1 is a methyl group and R2 is hydrogen or more generally a compound of the formula R3-X-Het-A-NH2 which is acylated on the NH2 group and in which R3, X, Het and A are defined as above, with a dilute acid, for example hydrochloric acid, or an alkali metal hydroxide, for example a sodium hydroxide solution. In case R1 and R2, together with the N-CO group which carries them, in the compound of the formula Id or the compound of the formulae I or Ia or more generally in the acylated derivative of the compound of the formula R3-X-Het-A-NH2, form a 1 ,3-dioxoisoindol-2-yl group (= phthalimido group), the conversion into the compound of the formula Id or into the compound of the formula R3-X-Het-A-NH2 can conveniently be performed by treatment with hydrazine, for example in a solvent such as ethanol under reflux, i.e. analogously to the well known Gabriel synthesis of amines. Compounds of the formula XXIX can furthermore be prepared by reacting a compound of the formula XXVIII as outlined above with a thiocyanate, for example sodium thiocyanate, and a protected 1 ,2-diaminoethane of the formula XXX to give a compound of the formula XXXI in which the group R3 is defined as in the compounds of the formulae I and Ia and, in addition, any functional groups can be present in protected form or in the form of precursor groups, and in which the amino group is deprotected under standard conditions to give a compound of the formula XXIX. The amino-protecting group PG can be an acyl group or an alkyloxycarbonyl group, for example a tert-butyloxycarbonyl group (= Boc) which can be removed by treatment with trifluoroacetic acid (= TFA), a benzyloxycarbonyl group which can be removed by catalytic hydrogenation, or a fluoren-9-ylmethoxycarbonyl group which can be removed by treatment with piperidine, for example.
The conversion of compounds of the formula XXIX into compounds of the formula Id, or in general of compounds of the formula R3-X-Het-A-NH2 into compounds of the formulae I and Ia, can be carried out according to standard procedures. For example, for the introduction of an acyl group of the formula R1-CO- the amine can be reacted with a carboxylic acid chloride of the formula R1-CO-CI or an anhydride of the formula (R1-CO)2O, or with a carboxylic acid of the formula R1-COOH by means of a activating reagent or coupling reagent as are commonly used in the preparation of amides. Suitable such reagents include carbodiimides such as N1N'- dicyclohexylcarbodiimide (= DCC) or diisopropylcarbodiimide (= DIC), O-((cyano(ethoxycarbonyl)methylene)amino)-1 ,1 ,3,3-tetramethyluronium tetrafluoroborate (= TOTU), N,N)N',N'-tetramethyl-O-(7-azabenzotriazol-1-yl)uronium hexafluorophosphate (= HATU), propanephosphonic acid anhydride (PPA), N, N1- carbonyldiimidazole (CDI), and chloroformic acid alkyl esters such as ethyl chloroformate or isobutyl chloroformate. The acylation is generally carried in a solvent such as, for example, toluene, dichloromethane, THF, dioxane, DMF, NMP, in the presence of a base such as, for example, triethylamine, ethyldiisopropylamine, sodium carbonate, at a temperature from about 0 0C to about 80 0C, for example at room temperature. The NH2 group in the compounds of the formula XXIX, or in general in compounds of the formula R3-X-Het-A-NH2, can also be incorporated into a ring, as can be formed in the compounds of the formulae I and Ia by R1 and R2 together with the N-CO group which carries them, for example by reaction with an ω-halogen-substituted alkanecarboxylic acid derivative such as a 4-chlorobutyric acid derivative to give a 2-oxopyrrolidin-1-yl ring system or a 5-chloropentanoic acid derivative to give a 2-oxopiperidin-1-yl ring system, or an α,ω-dicarboxylic acid derivative such as succinic anhydride or phthalic anhydride to give a 2,5- dioxopyrrolidin-1-yl ring system or a 1,3-dioxoisoindol-2-yl ring system, respectively.
Further compounds of the formulae I and Ia can be obtained from suitable compounds prepared according to the above-described processes by functionalization or modification of contained functional groups according standard procedures, for example by esterification, amidation, hydrolysis, etherification, alkylation, acylation, sulfonylation, reduction, oxidation, conversion into salts, and others.
All reactions used in the above-described syntheses of the compounds of the formulae I and Ia are per se well-known to the skilled person and can be carried out under standard conditions according to or analogously to procedures described in the literature, for example in Houben-Weyl, Methoden der Organischen Chemie (Methods of Organic Chemistry), Thieme-Verlag, Stuttgart, or Organic Reactions, John Wiley & Sons, New York. As already indicated above, depending on the circumstances of the individual case, in order to avoid an unwanted course of a reaction or side reactions during the synthesis of a compound, it can generally be necessary or advantageous to temporarily block functional groups by introducing protective groups and deprotect them at a later stage of the synthesis, or introduce functional groups in the form of precursor groups which later are converted into the desired functional groups. As a further example of protecting groups, besides the above-mentioned amino-protecting groups, ester protecting groups of carboxylic acid groups may be mentioned, such as tert-butyl esters which can be deprotected by treatment with trifluoroacetic acid, or benzyl esters which can be deprotected by catalytic hydrogenation. As an example of a precursor group the nitro group may be mentioned which can be converted into an amino group by reduction, for example by catalytic hydrogenation. Such synthesis strategies, and protective groups and precursor groups which are suitable in a specific case, are known to the skilled person. If desired, the obtained compounds of formulae I and Ia, as well as any intermediate compounds, can be purified by customary purification procedures, for example by recrystallization or chromatography.
The compounds of the formulae I and Ia are useful pharmacologically active, or pharmaceutically active compounds which modulate the expression of endothelial NO synthase, and more specifically upregulate, or stimulate, the expression, or transcription, of endothelial NO synthase, and which can be employed as pharmaceuticals, or active ingredients of medicaments, for the treatment of various diseases. In the context of the present invention, treatment is understood as comprising both therapy, including alleviation and cure, of diseases and disease symptoms and prevention and prophylaxis of diseases and disease symptoms, such as, for example, the prevention of the appearance of asthmatic disease symptoms or the prevention of myocardial infarction or of myocardial reinfarction in affected patients. The diseases or disease symptoms can be acute or chronic. Diseases which can be treated with the compounds of the formulae I and Ia include, for example, cardiovascular diseases like stable and unstable angina pectoris, coronary heart disease, coronary artery disease, Prinzmetal angina (spasm), acute coronary syndrome, cardiac insufficiency, heart failure, myocardial infarction, stroke, thrombosis, peripheral artery occlusive disease (= PAOD), endothelial dysfunction, atherosclerosis, restenosis, endothel damage after PTCA (= percutaneous transluminal coronary angioplasty), hypertension including essential hypertension, pulmonary hypertension and secondary hypertension (renovascular hypertension, chronic glomerulonephritis), erectile dysfunction, and ventricular arrhythmia. Further, the compounds of the formulae I and Ia lower the cardiovascular risk of postmenopausal women or after intake of contraceptives. Compounds of the formulae I and Ia can additionally be used in the treatment, including therapy and prevention, of diabetes and diabetes complications such as nephropathy or retinopathy, angiogenesis, asthma bronchiale, chronic renal failure, cirrhosis of the liver, osteoporosis, restricted memory performance or a restricted ability to learn. Preferred indications are stable angina pectoris, coronary heart disease, hypertension, endothelial dysfunction, atherosclerosis and diabetes complications.
The compounds of the formulae I and Ia can be used in combination with other pharmacologically active compounds or pharmaceuticals, preferably with compounds which are able to enhance the effect of the compounds according to the formulae I and Ia . Examples of such other compounds include statins; ACE inhibitors; AT1 antagonists; argininase inhibitors; PDE V inhibitors; calcium antagonists; alpha blockers; beta blockers; metimazol and analogous compounds; arginine; tetrahydrobiopterin; vitamins, in particular vitamin C and vitamin B6; niacine.
The compounds of the formulae I and Ia and their physiologically acceptable salts, optionally in combination with other pharmacologically active compounds, can be administered to animals, preferably to mammals, and in particular to humans, as pharmaceuticals by themselves, in mixtures with one another, or in the form of pharmaceutical compositions. Further subjects of the present invention therefore also are the compounds of the formulae I and Ia and their physiologically acceptable salts for use as pharmaceuticals, their use as modulating agents, and more specifically as stimulating agents or upregulating agents, of the expression or transcription of endothelial NO synthase, for example in conditions in which an increased expression of said enzyme or an increased NO level or the normalization of a decreased NO level in a patient is desired, and in particular their use in the treatment, including therapy and prevention, of the above-mentioned diseases or syndromes, as well as their use for the preparation or manufacture of medicaments for these purposes. Furthermore, a subject of the present invention are pharmaceutical compositions, or pharmaceutical preparations, which comprise an effective dose of at least one compound of the formulae I or Ia and/or a physiologically acceptable salt thereof and a pharmaceutically acceptable carrier, i.e. one or more pharmaceutically acceptable carrier substances and/or additives. The pharmaceuticals according to the invention can be administered orally, for example in the form of pills, tablets, lacquered tablets, sugar-coated tablets, granules, hard and soft gelatin capsules, aqueous, alcoholic or oily solutions, syrups, emulsions or suspensions, or rectally, for example in the form of suppositories. Administration can also be carried out parenterally, for example subcutaneously, intramuscularly or intravenously, for example in the form of solutions for injection or infusion. Other suitable administration forms are, for example, percutaneous or topical administration, for example in the form of ointments, tinctures, sprays or transdermal therapeutic systems, or the inhalative administration in the form of nasal sprays or aerosol mixtures, or, for example, microcapsules, implants or rods. The preferred administration form depends, among others, on the disease to be treated and on its severity.
The amount of a compound of the formulae I or Ia and/or its physiologically acceptable salts present in the pharmaceutical compositions normally ranges from about 0.2 to about 800 mg, preferably from about 0.5 to about 500 mg, in particular from about 1 to about 200 mg, per dose, but depending on the type of the pharmaceutical composition it may also be higher. The pharmaceutical compositions usually comprise from about 0.5 to about 90 percent by weight of the compounds of the formulae I or Ia and/or their physiologically acceptable salts. The production of the pharmaceutical compositions can be carried out in a manner known per se. To this end, one or more compounds of the formulae I or Ia and/or their physiologically acceptable salts together with one or more solid or liquid pharmaceutical carrier substances (or vehicles) and/or additives (or auxiliary substances) and, if a combination medicament is desired, other pharmacologically active compounds having therapeutic or prophylactic action are brought into a suitable administration form or dosage form which can then be used as a pharmaceutical in human or veterinary medicine.
For the production of pills, tablets, sugar-coated tablets and hard gelatin capsules it is possible to use, for example, lactose, starch, for example maize starch, starch derivatives, talc, stearic acid or its salts, etc. Soft gelatin capsules and suppositories can comprise, for example, fats, waxes, semisolid and liquid polyols, natural or hardened oils, etc. Suitable carrier substances for the preparation of solutions, for example of solutions for injection, or of emulsions or syrups are, for example, water, physiologically sodium chloride solution, alcohols such as ethanol, glycerol, polyols, sucrose, invert sugar, glucose, mannitol, vegetable oils, etc. It is also possible to lyophilize the compounds of the formulae I and Ia and their physiologically acceptable salts and to use the resulting lyophilisates, for example, for preparing compositions for injection or infusion. Suitable carriers for microcapsules, implants or rods are, for example, copolymers of glycolic acid and lactic acid. Besides the compound or compounds according to the invention and carrier substances, the pharmaceutical compositions can also contain additives such as, for example, fillers, disintegrants, binders, lubricants, wetting agents, stabilizers, emulsifiers, dispersants, preservatives, sweeteners, colorants, flavorings, aromatizers, thickeners, diluents, buffer substances, solvents, solubilizers, agents for achieving a depot effect, salts for altering the osmotic pressure, coating agents or antioxidants.
The dosage of the compound of the formulae I or Ia to be administered and/or of a physiologically acceptable salt thereof depends on the individual case and, as is customary, has to be adapted to the individual circumstances to achieve an optimum effect. Thus, it depends on the nature and the severity of the disorder to be treated, and also on the sex, age, weight and individual responsiveness of the human or animal to be treated, on the efficacy and duration of action of the compounds used, on whether the use is for the therapy of a acute or chronic disease or prophylactic, or on whether other active compounds are administered in addition to compounds of the formulae I or Ia. In general, a daily dose from about 0.01 mg/kg to about 100 mg/kg, preferably from about 0.1 mg/kg to about 10 mg/kg, in particular from about 0.3 mg/kg to about 5 mg/kg (in each case mg per kg of bodyweight) is appropriate for administration to an adult weighing about 75 kg in order to obtain the desired results. The daily dose can be administered in a single dose or, in particular when larger amounts are administered, divided into several, for example two, three or four individual doses. In some cases, depending on the individual response, it may be necessary to deviate upwards or downwards from the given daily dose.
The compounds of the formulae I and Ia can also be used for other purposes than those indicated in the foregoing. Non-limiting examples include the use as diagnostics, for example the use in methods for determining the activity of endothelial NO synthase in biological samples, the use as biochemical tools and the use as intermediates for the preparation of further compounds, for example further pharmacologically active compounds.
Examples
Compounds containing a basic group which were purified by preparative HPLC using an eluent which contained thfluoroacetic acid, were in part obtained in the form of acid addition salts with trifluoroacetic acid (TFA) which is not depicted in the formulae in the examples. The compounds were characterized by analytical high pressure liquid chromatography (HPLC) and/or mass spectrometry (MS) and/or nuclear magnetic resonance spectrometry (NMR). The MS data were obtained by electron spray ionization (ESI). The HPLC conditions were as follows.
Method HPLC A (LC/MS): Column: YMC J'sphere 33 x 2 mm; 4 μ. Flow rate: 1 ml/min. Eluent A1 : water containing 0.1 % TFA. Eluent A2: acetonitrile containing 0.1 % TFA. Gradient: from 95 % eluent A1 + 5 % eluent A2 to 5 % eluent A1 + 95 % eluent A2 in 3.7 min.
Example 1 1-(3-(6-(2-Fluorophenyl)pyridin-3-yl)propyl)-1H-pyridin-2-one
Figure imgf000079_0001
a) 3-(6-(2-Fluorophenyl)pyridin-3-yl)propionic acid ethyl ester
A mixture of 1000 mg (3.87 mmol) of 3-(6-bromopyridin-3-yl)propionic acid ethyl ester, 596.3 mg (4.26 mmol) of 2-fluorophenylboronic acid, 43.5 mg (0.19 mmol) of palladium acetate, 101.6 mg (0.38 mmol) of triphenylphosphane, 3.88 ml of a 1 M sodium carbonate solution, 23 ml of toluene and 6 ml of ethanol was heated under reflux for 5 h and, after cooling, poured into water. The resulting mixture was extracted with ethyl acetate. The organic phase was separated and concentrated, and the residue was purified by chromatography (silica gel, n-heptane/ethyl acetate 5:1). Yield: 782 mg (74 %).
b) 3-(6-(2-Fluorophenyl)pyridin-3-yl)propan-1 -ol
Under argon, 400 mg (1.46 mmol) of 3-(6-(2-fluorophenyl)pyridin-3-yl)propionic acid ethyl ester and 63.8 mg (2.93 mmol) of lithium borohydride were stirred in 20 ml of THF at 40 0C for 3 h. After cooling, the mixture was cautiously hydrolyzed with water, the precipitate was filtered off with suction, and water and methylene chloride were added to the filtrate. The organic phase was separated, washed with water and concentrated. Yield: 241 mg (71 %).
c) 5-(3-Bromopropyl)-2-(2-fluorophenyl)pyridine
230 mg (0.99 mmol) of 3-(6-(2-fluorophenyl)pyridin-3-yl)propan-1-ol were stirred in 10 ml of hydrobromic acid (33 % in acetic acid) at 60 0C for 6 h. After concentrating, a sodium hydrogencarbonate solution was added, the resulting mixture was extracted with ethyl acetate, and the organic phase was separated and concentrated. Yield: 707 mg (71 %).
d) 1 -(3-(6-(2-Fluorophenyl)pyhdin-3-yl)propyl)-1 H-pyridin-2-one 8.2 mg (0.18 mmol) of sodium hydride (55 % suspension in mineral oil) were added to 17.8 mg (0.19 mmol) of 2-hydroxypyridine in 5 ml of DMF, and the mixture was stirred at room temperature for 30 min. Subsequently, 50 mg (0.17 mmol) of 5-(3- bromopropyl)-2-(2-fluorophenyl)pyridine were added. The reaction mixture was stirred for 4 h, concentrated, admixed with water and extracted with methylene chloride. The organic phase was separated and concentrated, and the residue was purified by preparative HPLC (RP18, acetonitrile/water containing 0.1 % TFA) Yield: 11 mg (22 %). MS: M+H+ = 309.1.
Example 2 1-(3-(6-(2-Fluorophenyl)pyridin-3-yl)propyl)piperidin-2-one
Figure imgf000081_0001
50 mg (0.17 mmol) of 5-(3-bromopropyl)-2-(2-fluorophenyl)pyridine were reacted with 18.5 mg (0.18 mmol) of piperidin-2-one analogously to example 1d). Yield: 16 mg (31
MS: M+H+ = 313.1.
Example 3
4-(3-(6-Phenylpyhdin-3-yl)propyl)thiomorpholin-3-one, trifluoroacetic acid salt
Figure imgf000081_0002
a) 3-(6-Bromopyridin-3-yl)propan-1-ol
Under argon, 560 mg (2.17 mmol) of 3-(6-bromopyridin-3-yl)propionic acid ethyl ester and 94.6 mg (4.34 mmol) of lithium borohydride were stirred in 40 ml of THF at 40 0C for 3 h. After cooling, the mixture was cautiously hydrolyzed with water, the precipitate was filtered off with suction, and the filtrate was concentrated and admixed with water and ethyl acetate. The organic phase was separated, washed with water and concentrated. Yield: 450 mg (96 %). MS: M+H+ = 216.1.
b) 2-Bromo-5-(3-bromopropyl)pyridine
300 mg (1.38 mmol) of 3-(6-bromopyhdin-3-yl)propan-1-ol were stirred in 5 ml of hydrobromic acid (33 % in acetic acid) at 80 0C for 6 h. After concentrating, a potassium carbonate solution was added, the resulting mixture was extracted with ethyl acetate, and the organic phase was separated and concentrated. Yield: 368 mg (95 %).
c) 4-(3-(6-Bromopyridin-3-yl)propyl)thiomorpholin-3-one
60.2 mg (1.38 mmol) of sodium hydride (55 % suspension in mineral oil) were added to 161.7 mg (1.38 mmol) of thiomorpholin-3-one in 5 ml of DMF, and the mixture was stirred at room temperature for 15 min. Subsequently, 350 mg (1.25 mmol) of 2- bromo-5-(3-bromopropyl)pyridine were added. The reaction mixture was stirred for 3.5 h, concentrated, admixed with water and extracted with ethyl acetate. The organic phase was separated and concentrated. Yield: 421 mg.
d) 4-(3-(6-Phenylpyridin-3-yl)propyl)-thiomorpholin-3-one, trifluoroacetic acid salt Under argon, a mixture of 100 mg (0.32 mmol) of 4-(3-(6-bromopyridin-3- yl)propyl)thiomorpholin-3-one, 46.4 mg (0.38 mmol) of phenylboronic acid, 3.6 mg of (0.016 mmol) palladium acetate, 8.3 mg (0.03 mmol) of triphenylphosphane, 320 μl of a 1 M sodium carbonate solution and 20 ml of toluene was heated under reflux for 5 h. After cooling, the mixture was poured into water, the resulting mixture was extracted with ethyl acetate, and the organic phase was separated and concentrated. The residue was purified by preparative HPLC (RP18, acetonitrile/water containing 0.1 % TFA). Yield: 10 mg (7 %). MS: M+H+ = 313.0.
Example 4
1-(3-(6-(2-Fluorophenyl)pyridin-3-yl)propyl)pyrrolidin-2-one, trifluoroacetic acid salt
Figure imgf000083_0001
100 mg (0.34 mmol) of 5-(3-bromopropyl)-2-(2-fluorophenyl)pyτidine were reacted with 34.7 mg (0.41 mmol) of pyrrolidin-2-one analogously to example 1d). Yield: 50 mg (35 %). MS: M+H+ = 299.1.
Example 5 1-(3-(6-(2-Fluorophenyl)pyridin-3-yl)propyl)piperidine-2,6-dione, trifluoroacetic acid salt
Figure imgf000083_0002
100 mg (0.34 mmol) of 5-(3-bromopropyl)-2-(2-fluorophenyl)pyridine were reacted with 46.1 mg (0.41 mmol) of piperidine-2,6-dione analogously to example 1d). Yield: 38 mg (25 %). MS: M+H+ = 327.1.
Example 6
1-(3-(6-(2-Fluorophenyl)pyridin-3-yl)propyl)azepan-2-one, trifluoroacetic acid salt
Figure imgf000084_0001
100 mg (0.34 mmol) of 5-(3-bromopropyl)-2-(2-fluorophenyl)pyridine were reacted with 46.2 mg (0.41 mmol) of azepan-2-one analogously to example 1d). Yield: 31 mg (23 %).
MS: M+H+ = 327.1.
Example 7
4-(3-(6-(2-Chlorophenyl)pyridin-3-yl)propyl)thiomorpholin-3-one, trifluoroacetic acid salt
Figure imgf000084_0002
101.5 mg (0.32 mmol) of 4-(3-(6-bromopyridin-3-yl)propyl)thiomorpholin-3-one were reacted with 60.2 mg (0.38 mmol) of 2-chlorophenylboronic acid analogously to example 3d). Yield: 10 mg (7 %). MS: M+H+ = 347.0.
Example 8 4-(3-(6-(4-Fluorophenyl)pyridin-3-yl)propyl)thiomorpholin-3-one, trifluoroacetic acid salt
Figure imgf000085_0001
96 mg (0.3 mmol) of 4-(3-(6-bromopyridin-3-yl)propyl)thiomorpholin-3-one were reacted with 59.7 mg (0.42 mmol) of 4-fluorophenylboronic acid analogously to example 3d). Yield: 12 mg (9 %). MS: M+H+ = 331.0.
Example 9
4-(3-(6-(2-Fluorophenyl)pyridin-3-yl)propyl)thiomorpholin-3-one, trifluoroacetic acid salt
Figure imgf000085_0002
100 mg (0.34 mmol) of 5-(3-bromopropyl)-2-(2-fluorophenyl)pyridine were reacted with 47.8 mg (0.41 mmol) of thiomorpholin-3-one analogously to example 1d). Yield: 37 mg (24 %). MS: M+H+ = 331.0.
Example 10 1-(3-(6-(2-Fluorophenyl)pyridin-3-yl)propyl)pyrrolidine-2,5-dione, trifluoroacetic acid salt
Figure imgf000086_0001
100 mg (0.34 mmol) of 5-(3-bromopropyl)-2-(2-fluorophenyl)pyridine were reacted with 40.4 mg (0.41 mmol) of pyrrolidine-2,5-dione analogously to example 1d). Yield: 67 mg (46 %). MS: M+H+ = 313.1.
Example 11
3-(3-(6-(2-Fluorophenyl)pyridin-3-yl)propyl)thiazolidine-2,4-dione, trifluoroacetic acid salt
Figure imgf000086_0002
100 mg (0.34 mmol) of 5-(3-bromopropyl)-2-(2-fluorophenyl)pyridine were reacted with 47.8 mg (0.41 mmol) of thiazolidine-2,4-dione analogously to example 1d). Yield: 20 mg (13 %). MS: M+H+ = 331.1.
Example 12 1-(3-(6-(4-Fluorophenyl)pyridin-3-yl)propyl)pyrrolidin-2-one, trifluoroacetic acid salt
Figure imgf000086_0003
a) Methanesulfonic acid 3-(6-(4-fluorophenyl)pyridin-3-yl)propyl ester
544.8 mg (4.75 mmol) of methanesulfonyl chloride were added dropwise with cooling to 1000 mg (4.32 mmol) of 3-(6-(4-fluorophenyl)pyridin-3-yl)propan-1-ol (prepared analogously to example 1a), starting from 3-(6-bromopyridin-3-yl)propionic acid ethyl ester and 4-fluorophenylboronic acid) and 656.3 mg (6.48 mmol) of triethylamine in 50 ml of methylene chloride. After 5 h at room temperature, the mixture was extracted with water, and the organic phase was separated and concentrated. Yield: 1.3 g (97 %). MS: M+H+ = 310.1.
b) 1-(3-(6-(4-Fluorophenyl)pyridin-3-yl)propyl)pyrrolidin-2-one, trifluoroacetic acid salt 110 mg (0.36 mmol) of methanesulfonic acid 3-(6-(4-fluorophenyl)pyridin-3-yl)propyl ester were reacted with 36.1 mg (0.42 mmol) of pyrrolidin-2-one analogously to example 1d). Yield: 46 mg (31 %). MS: M+H+ = 299.2.
Example 13
1-(3-(6-(4-Fluorophenyl)pyridin-3-yl)propyl)pyrrolidine-2,5-dione, trifluoroacetic acid salt
Figure imgf000087_0001
136 mg (0.44 mmol) of methanesulfonic acid 3-(6-(4-fluorophenyl)pyridin-3-yl)propyl ester were reacted with 52.3 mg (0.52 mmol) of pyrrolidine-2,5-dione analogously to example 1d). Yield: 35 mg (19 %). MS: M+H+ = 313.2.
Example 14 3-(3-(6-(4-Fluorophenyl)pyridin-3-yl)propyl)imidazolidine-2,4-dione, trifluoroacetic acid salt
Figure imgf000088_0001
136 mg (0.44 mmol) of methanesulfonic acid 3-(6-(4-fluorophenyl)pyridin-3-yl)propyl ester were reacted with 52.8 mg (0.52 mmol) of imidazolidine-2,4-dione analogously to example 1d). Yield: 8 mg (4 %). MS: M+H+ = 314.2.
Example 15
1-(3-(6-(4-Fluorophenyl)pyridin-3-yl)propyl)azetidin-2-one, trifluoroacetic acid salt
Figure imgf000088_0002
136 mg (0.44 mmol) of methanesulfonic acid 3-(6-(4-fluorophenyl)pyridin-3-yl)propyl ester were reacted with 37.5 mg (0.52 mmol) of azetidin-2-one analogously to example 1d). Yield: 8 mg (5 %). MS: M+H+ = 285.1.
Example 16
1-(3-(6-(4-Fluorophenyl)pyridin-3-yl)propyl)piperidin-2-one, trifluoroacetic acid salt
Figure imgf000088_0003
136 mg (0.44 mmol) of methanesulfonic acid 3-(6-(4-fluorophenyl)pyridin-3-yl)propyl ester were reacted with 52.3 mg (0.52 mmol) of piperidin-2-one analogously to example 1d). Yield: 19 mg (10 %). MS: M+H+ = 313.2.
Example 17
4-(3-(6-(4-Fluorophenyl)pyridin-3-yl)propylcarbamoyl)butyric acid, trifluoroacetic acid salt
Figure imgf000089_0001
136 mg (0.44 mmol) of methanesulfonic acid 3-(6-(4-fluorophenyl)pyridin-3-yl)propyl ester were reacted with 59.7 mg (0.52 mmol) of piperidine-2,6-dione analogously to example 1d). Yield: 18 mg (8 %). MS: M+H+ = 345.2.
Example 18
1-(3-(6-(4-Fluorophenyl)pyridin-3-yl)propyl)azepan-2-one, trifluoroacetic acid salt
Figure imgf000089_0002
136 mg (0.44 mmol) of methanesulfonic acid 3-(6-(4-fluorophenyl)pyridin-3-yl)propyl ester were reacted with 59.7 mg (0.52 mmol) of azepan-2-one analogously to example 1d). Yield: 78 mg (40 %). MS: M+H+ = 327.3. Example 19
4-(3-(6-(2-Fluorophenyl)pyridin-3-yl)propyl)-4H-[1 ,4]thiazin-3-one, trifluoroacetic acid salt
Figure imgf000090_0001
100 mg (0.32 mmol) of methanesulfonic acid 3-(6-(2-fluorophenyl)pyridin-3-yl)propyl ester (prepared from 3-(6-(2-fluorophenyl)pyridin-3-yl)propan-1-ol analogously to example 12a) were reacted with 44.7 mg (0.39 mmol) of 4H-[1 ,4]thiazin-3-one analogously to example 1d). Yield: 56 mg (40 %). MS: M+H+ = 329.2.
Example 20
3-(3-(6-(2-Fluorophenyl)pyridin-3-yl)propyl)imidazolidine-2,4-dione, trifluoroacetic acid salt
Figure imgf000090_0002
100 mg (0.32 mmol) of methanesulfonic acid 3-(6-(2-fluorophenyl)pyridin-3-yl)propyl ester (prepared from 3-(6-(2-fluorophenyl)pyridin-3-yl)-propan-1-ol analogously to example 12a) were reacted with 38.8 mg (0.39 mmol) of imidazolidine-2,4-dione analogously to example 1d). Yield: 51 mg (37 %). MS: M+H+ = 314.2.
Example 21 1-(3-(6-(4-Fluorophenyl)pyridin-3-yl)propyl)piperidine-2)6-dione, trifluoroacetic acid salt
Figure imgf000091_0001
136 mg (0.44 mmol) of methanesulfonic acid 3-(6-(4-fluorophenyl)pyridin-3-yl)propyl ester were reacted with 69.6 mg (0.61 mmol) of piperidine-2,6-dione analogously to example 1d). Yield: 77 mg (40 %). MS: M+H+ = 327.2.
Example 22
3-(3-(6-(4-Fluorophenyl)pyridin-3-yl)propyl)thiazolidine-2,4-dione, trifluoroacetic acid salt
Figure imgf000091_0002
136 mg (0.44 mmol) of methanesulfonic acid 3-(6-(4-fluorophenyl)pyridin-3-yl)propyl ester were reacted with 61.8 mg (0.52 mmol) of thiazolidine-2,4-dione analogously to example 1d). Yield: 53 mg (27 %). MS: M+H+ = 331.2.
Example 23
1-(3-(6-(2-Fluorophenyl)pyridin-3-yl)propyl)azetidin-2-one, trifluoroacetic acid salt
Figure imgf000092_0001
100 mg (0.32 mmol) of methanesulfonic acid 3-(6-(2-fluorophenyl)pyridin-3-yl)propyl ester (prepared from 3-(6-(2-fluorophenyl)pyridin-3-yl)propan-1-ol analogously to example 12a) were reacted with 32.2 mg (0.45 mmol) of azetidin-2-one analogously to example 1d). Yield: 8 mg (5 %). MS: M+H+ = 285.2.
Example 24 1-(3-(6-(4-Fluorophenyl)pyridin-3-yl)propyl)-1 H-pyridin-2-one, trifluoroacetic acid salt
Figure imgf000092_0002
136 mg (0.44 mmol) of methanesulfonic acid 3-(6-(4-fluorophenyl)pyridin-3-yl)propyl ester were reacted with 50.2 mg (0.52 mmol) of 1 H-pyridin-2-one analogously to example 1d). Yield: 98 mg (52 %). MS: M+H+ = 309.2.
Example 25 4-(3-(6-(4-Fluorophenyl)pyridin-3-yl)propyl)-4H-[1 ,4]thiazin-3-one, trifluoroacetic acid salt
Figure imgf000092_0003
136 mg (0.44 mmol) of methanesulfonic acid 3-(6-(4-fluorophenyl)pyridin-3-yl)propyl ester were reacted with 60.7 mg (0.52 mmol) of 4H-[1 ,4]thiazin-3-one analogously to example 1d). Yield: 17 mg (9 %). MS: M+H+ = 329.2.
Example 26
1-(2-(6-(2-Fluorophenyl)pyridin-3-yloxy)ethyl)piperidin-2-one, trifluoroacetic acid salt
Figure imgf000093_0001
a) (6-(2-Fluorophenyl)pyridin-3-yloxy)acetic acid methyl ester
Under argon, 157.3 mg (3.6 mmol) of sodium hydride (55 % suspension in mineral oil) were added to 620 mg (3.27 mmol) of 6-(2-fluorophenyl)pyridin-3-ol in 25 ml of DMF. After stirring at room temperature for 60 min, 551.4 mg (3.6 mmol) of bromoacetic acid methyl ester were added, and the reaction mixture was stirred at room temperature for 2 h. After concentrating, water was added, and the mixture was extracted with ethyl acetate. The organic phase was separated and concentrated. Yield: 687 mg (80 %). MS: M+H+ = 262.1.
b) 2-(6-(2-Fluorophenyl)pyridin-3-yloxy)ethanol
Under argon, 675 mg (2.58 mmol) of (6-(2-fluorophenyl)pyridin-3-yloxy)acetic acid methyl ester and 112.5 mg (5.17 mmol) of lithium borohydride were stirred in 20 ml of THF at 60 0C for 2 h. After cooling, the mixture was cautiously hydrolyzed with water and concentrated, and water and ethyl acetate were added. The organic phase was separated, washed with water and concentrated. Yield: 350 mg (58 %). MS: M+H+ =234.1. c) Methanesulfonic acid 2-(6-(2-fluorophenyl)pyridin-3-yloxy)ethyl ester
217.1 mg (1.89 mmol) of methanesulfonyl chloride were added dropwise with cooling to 340 mg (1.46 mmol) of 2-(6-(2-fluorophenyl)pyridin-3-yloxy)ethanol and 442.5 mg (4.37 mmol) of triethylamine in 25 ml of methylene chloride. After 7 h at room temperature, the mixture was extracted with water, and the organic phase was separated and concentrated. Yield: 394 mg (87 %). MS: M+H+ = 312.2.
d) 1-(2-(6-(2-Fluorophenyl)pyridin-3-yloxy)-ethyl)piperidin-2-one, trifluoroacetic acid salt
100 mg (0.32 mmol) of methanesulfonic acid 2-(6-(2-fluorophenyl)pyridin-3- yloxy)ethyl ester were reacted with 38.2 mg (0.38 mmol) of piperidin-2-one analogously to example 1d). Yield: 15 mg (11 %). MS: M+H+ = 315.1.
Example 27
1-(2-(6-(2-Fluorophenyl)pyridin-3-yloxy)ethyl)azetidin-2-one, trifluoroacetic acid salt
Figure imgf000094_0001
100 mg (0.32 mmol) of methanesulfonic acid 2-(6-(2-fluorophenyl)pyridin-3- yloxy)ethyl ester were reacted with 27.4 mg (0.38 mmol) of azetidin-2-one analogously to example 1d). Yield: 4 mg (3 %).
MS: M+H+ = 287.1.
Example 28
1-(2-(6-(2-Fluorophenyl)pyridin-3-yloxy)ethyl)pyrrolidine-2,5-dione, trifluoroacetic acid salt
Figure imgf000095_0001
100 mg (0.32 mmol) of methanesulfonic acid 2-(6-(2-fluorophenyl)pyridin-3- yloxy)ethyl ester were reacted with 38.2 mg (0.38 mmol) of pyrrolidine-2,5-dione analogously to example 1d). Yield: 52 mg (38 %). MS: M+H+ = 315.1.
Example 29
3-(2-(4-(4-Fluorophenyl)thiazol-2-ylamino)ethyl)imidazolidine-2,4-dione, trifluoroacetic acid salt
Figure imgf000095_0002
200 mg (0.92 mmol) of 2-bromo-1-(4-fluorophenyl)ethanone and 74.7 mg (0.92 mmol) of sodium thiocyanate were stirred in ethanol at 50 0C for 2 h. 165.5 mg (0.92 mmol) of 3-(2-aminoethyl)imidazolidine-2,4-dione hydrochloride and 102.6 mg (1.01 mmol) of triethylamine were added, and the reaction mixture was stirred at 50 0C for 9 h. After concentrating, water was added, and the mixture was extracted with ethyl acetate. The organic phase was separated and concentrated, and the residue was purified by preparative HPLC (RP18, acetonithle/water containing 0.1 % TFA). Yield: 82 mg (20 %). MS: M+H+ = 321.0.
Example 30 3-(2-(6-(2-Fluorophenyl)pyridin-3-yloxy)ethyl)imidazolidine-2,4-dioneI trifluoroacetic acid salt
Figure imgf000096_0001
90 mg (0.29 mmol) of methanesulfonic acid 2-(6-(2-fluorophenyl)pyτidin-3-yloxy)ethyl ester were reacted with 34.7 mg (0.35 mmol) of imidazolidine-2,4-dione analogously to example 1d). Yield: 4 mg (3 %). MS: M+H+ = 316.2.
Example 31 2-(2-(4-(4-Fluorophenyl)thiazol-2-ylamino)ethyl)isoindole-1 ,3-dione, trifluoroacetic acid salt
Figure imgf000096_0002
a) (2-(4-(4-Fluorophenyl)thiazol-2-ylamino)ethyl)carbamic acid tert-butyl ester
2.5 g (11.52 mmol) of 2-bromo-1-(4-fluorophenyl)ethanone and 0.93 g (11.52 mmol) of sodium thiocyanate were stirred in ethanol at 50 0C for 2 h. 1.845 g (11.52 mmol) of (2-aminoethyl)carbamic acid tert-butyl ester were added, and the reaction mixture was stirred at 50 0C for 2 h. After concentrating, water was added, and the mixture was extracted with ethyl acetate. The organic phase was separated and concentrated. Yield: 3.04 g (78 %).
b) N-(4-(4-Fluorophenyl)thiazol-2-yl)ethane-1 ,2-diamine, trifluoroacetic acid salt A mixture of 996 mg (2.95 mmol) of (2-(4-(4-fluorophenyl)thiazol-2- ylamino)ethyl)carbamic acid tert-butyl ester and 5 ml of 90 % aqueous trifluoroacetic acid was allowed to stand at room temperature for 4 h. After concentrating, the residue was purified by preparative HPLC (RP18, acetonitrile/water containing 0.1 % TFA). Yield: 122 mg (9 %). MS: M+H+ = 238.1.
c) 2-(2-(4-(4-Fluorophenyl)thiazol-2-ylamino)ethyl)isoindole-1 ,3-dione, trifluoroacetic acid salt
A mixture of 54.3 mg (0.11 mmol) of N-(4-(4-fluorophenyl)thiazol-2-yl)ethane-1 ,2- diamine, trifluoroacetic acid salt, 35.4 mg (0.35 mmol) of triethylamine, 17.3 mg (0.11 mmol) of phthalic anhydride, 5 ml of toluene and 1 ml of DMF was heated under reflux for 3 h. After concentrating, the residue was extracted with an aqueous solution of sodium hydrogensulfate (pH 5) and a sodium hydrogencarbonate solution and concentrated, and the residue was purified by preparative HPLC (RP18, acetonitrile/water containing 0.1 % TFA). Yield: 16 mg (28 %). MS: M+H+ = 368.1.
Example 32
1-(2-(5-(2-Fluorophenyl)pyridin-2-yloxy)ethyl)pyrrolidin-2-one, trifluoroacetic acid salt
Figure imgf000097_0001
a)1-(2-(5-Bromopyridin-2-yloxy)ethyl)pyrrolidin-2-one
2.45 g (19 mmol) of 1-(2-hydroxyethyl)-pyrrolidin-2-one and 0.83 g (19 mmol) of sodium hydride (55 % in mineral oil) in 10 ml of NMP were stirred at room temperature for 1 h. 3.0 g (12.7 mmol) of 2,5-dibromopyridine were added, and the mixture was heated to 80 0C for 2 h. Water was added, and the mixture was extracted with ethyl acetate. The combined organic phases were dried and concentrated. The remaining oil was taken up in 200 ml of tert-butyl methyl ether and treated with a solution of hydrogen chloride in diethyl ether. The resulting greasy solid was isolated by decantation of the solvent and treated with a 25 % aqueous sodium hydroxide solution. The product was extracted with ethyl acetate, and the combined organic phases were dried and concentrated. Yield: 2.75 g.
b) 1-(2-(5-(2-Fluorophenyl)pyridin-2-yloxy)ethyl)pyrrolidin-2-one, trifluoroacetic acid salt
88.3 mg (0.62 mmol) of 2-fluorobenzeneboronic acid, 150 mg (0.53 mmol) of 1-(2-(5- bromopyridin-2-yloxy)ethyl)pyrrolidin-2-one, 249 mg (0.79 mmol) of barium hydroxide octahydrate and 20 mg of tetrakis(triphenylphosphane)palladium were dissolved in 10 ml 1 ,2-dimethoxyethane and 10 ml water, and the mixture was heated to 800C for 5 h. The solvent was evaporated, and the residue taken up in water and extracted with methylene chloride. The combined organic phases were dried and concentrated, and the residue was purified by preparative HPLC (RP18, acetonitrile/water containing 0.01 % TFA). Yield: 60 mg.
Example 33
1-(2-(5-(1-Methyl-1 H-benzoimidazol-2-yl)pyridin-2-yloxy)ethyl)pyrrolidin-2-one, trifluoroacetic acid salt
Figure imgf000098_0001
The compound was prepared analogously to example 32a) by reaction of 500 mg (2.1 mmol) of 2-(6-chloropyridin-3-yl)-1-methyl-1 H-benzoimidazole with 1-(2- hydroxyethyl)pyrrolidin-2-one. Yield: 370 mg. MS: M+H+ = 337.
Example 34 1-(2-(4-(4-Fluorophenyl)thiazol-2-ylamino)ethyl)pyrrolidine-2,5-dione, trifluoroacetic acid salt
Figure imgf000099_0001
a) (4-(4-Fluorophenyl)thiazol-2-ylamino)acetic acid methyl ester
14.5 g (66.8 mmol) of 2-bromo-1-(4-fluorophenyl)ethanone and 5.42 g (66.8 mmol) of sodium thiocyanate were stirred in 250 ml of ethanol at 50 °C for 3 h. 5.95 g (66.8 mmol) of aminoacetic acid methyl ester (prepared from its hydrochloride) in 25 ml of ethanol were added, and the reaction mixture was stirred at room temperature for 4 h and allowed to stand overnight. After concentrating, water and ethyl acetate were added to the residue. The organic phase was separated, washed with water, dried and concentrated. Yield: 8.6 g (48 %). MS: M+H+ = 266.3.
b) (tert-Butoxycarbonyl-(4-(4-fluorophenyl)thiazol-2-yl)-amino)acetic acid methyl ester 360 mg (8.3 mmol) of sodium hydride (55 % suspension in mineral oil) were added to 2 g (7.5 mmol) of (4-(4-fluorophenyl)thiazol-2-ylamino)acetic acid methyl ester in 25 ml of DMF, and the mixture was stirred at room temperature for 60 min. Subsequently 1.8 g (8.3 mmol) of di-tert-butyl-dicarbonate were added, and the reaction mixture was stirred for 2 h. After concentrating, water was added and the mixture extracted with ethyl acetate. The organic phase was concentrated, and the residue was purified by chromatography (silica gel, n-heptane/ethyl acetate 5:1). Yield: 440 mg (16 %). MS: M+H+ = 367.2.
c) (4-(4-Fluorophenyl)thiazol-2-yl)-(2-hydroxyethyl)-carbamic acid tert-butyl ester Under argon, 435 mg (1.18 mmol) of (tert-butoxycarbonyl-(4-(4-fluorophenyl)thiazol- 2-yl)-amino)acetic acid methyl ester and 51.7 mg (2.37 mmol) of lithium borohydride were stirred in 20 ml of THF at 600C for 1 h. After cooling, the mixture was cautiously hydrolyzed with water, the precipitate was filtered off with suction, and water and ethyl acetate were added to the filtrate. The organic phase was separated, washed with water and concentrated. Yield: 273 mg (68 %).
d) Methanesulfonic acid 2-(tert-butoxycarbonyl-(4-(4-fluorophenyl)thiazol-2- yl)amino)ethyl ester 98.7 mg (0.86 mmol) of methanesulfonyl chloride were added dropwise with cooling to 265 mg (0.78 mmol) of (4-(4-fluorophenyl)thiazol-2-yl)-(2-hydroxyethyl)-carbamic acid tert-butyl ester and 237.7 mg (2.35 mmol) of triethylamine in 25 ml of methylene chloride. After 4 h at room temperature, the mixture was extracted with water and the organic phase was concentrated. Yield: 241 mg (74 %).
e) 1-(2-(4-(4-Fluorophenyl)thiazol-2-ylamino)ethyl)pyrrolidine-2,5-dione, trifluoroacetic acid salt
23 mg (0.52 mmol) of sodium hydride (55 % suspension in mineral oil) were added to 52.3 mg (0.52 mmol) of pyrrolidine-2,5-dione in 5 ml of DMF, and the mixture was stirred at room temperature for 60 min. Subsequently 100 mg (0.24 mmol) of methanesulfonic acid 2-(tert-butoxycarbonyl-(4-(4-fluorophenyl)thiazol-2-yl)- amino)ethyl ester were added and the reaction mixture was stirred for 3 h. After concentrating, water was added, and the mixture was extracted with ethyl acetate. The organic phase was separated and concentrated, and the residue was purified by preparative HPLC (RP18, acetonitrile/water containing 0.1 % TFA). Yield: 5 mg (5 %). MS: M+H+ = 320.1.
Example 35 N-(2-(4-(4-Fluorophenyl)thiazol-2-ylamino)ethyl)acetamide
Figure imgf000101_0001
2-Bromo-1-(4-fluorophenyl)ethanone was reacted with N-(2-aminoethyl)acetamide analogously to example 31a). Yield: 65 %. MS: M+H+ = 280.2.
Example 36
1 -(2-(6-(4-Fluorophenyl)pyridin-3-yloxy)ethyl)pyrrole-2,5-dione, trifluoroacetic acid salt
Figure imgf000101_0002
80 mg (0.42 mmol) of 6-(4-fluorophenyl)pyridin-3-ol, 61.2 mg (0.43 mmol) of 1-(2- hydroxyethyl)pyrrole-2,5-dione and 155.3 mg (0.59 mmol) of triphenylphosphane were dissolved in 20 ml of THF. After cooling to 00C, 136.2 mg (0.59 mmol) of azodicarboxylic acid di-tert-butyl ester in 3 ml THF were slowly added. The mixture was stirred at room temperature for 6 h, evaporated and treated with ethyl acetate and diluted hydrochloric acid. The aqueous layer was evaporated and purified by chromatography (RP18, acetonitrile/water containing 0.1 % TFA). Yield: 17 mg. MS: M+H+ = 313.1.
Example 37 2-(2-(6-(2-Fluorophenyl)pyridin-3-yloxy)ethyl)isoindole-1 ,3-dione
Figure imgf000102_0001
500 mg (2.64 mmol) of 6-(2-fluorophenyl)pyridin-3-ol (prepared from 2-bromo-5- nitropyridine and 2-fluorophenylboronic acid; the nitro group was converted into the hydroxy group according to the method described in WO 98/25920), 730.6 mg (5.28 mmol) of potassium carbonate and 738.6 mg (2.91 mmol) of 2-(2-bromoethyl)- isoindole-1 ,3-dione in 10 ml of DMF were stirred at room temperature for 4 h. The solvent was removed by evaporation and the residue treated with ethyl acetate and water. The organic layer was evaporated and the residue purified by chromatography. Yield: 189 mg. MS: M+H+ = 363.2.
Example 38
1-(2-(6-(4-Fluorophenyl)pyridin-3-yloxy)ethyl)pyrrolidine-2,5-dione, trifluoroacetic acid salt
Figure imgf000102_0002
128.7 mg (0.58 mmol) of methanesulfonic acid 2-(2,5-dioxopyrrolidin-1-yl)ethyl ester and 100 mg (0.53 mmol) of 6-(4-fluorophenyl)pyridin-3-ol were reacted analogously to example 1d). Yield: 30 mg . MS: M+H+ = 315.1.
Example 39 1 -(2-(6-(4-Fluorophenyl)pyridin-3-yloxy)ethyl)-1 H-pyridin-2-one, trifluoroacetic acid salt
Figure imgf000103_0001
100 mg (0.63 mmol) of 1-(2-chloroethyl)-1 H-pyridin-2-one and 100 mg (0.53 mmol) of 6-(4-fluorophenyl)pyridin-3-ol were reacted analogously to example 1d). Yield: 11 mg. MS: M+H+ = 311.1.
Example 40 1-(2-(4-(4-Fluorophenyl)thiazol-2-ylamino)ethyl)imidazolidin-2-one, trifluoroacetic acid salt
Figure imgf000103_0002
a) 1-(4-Fluorophenyl)-2-thiocyanatoethanone
10 g (46 mmol) of 2-bromo-1-(4-fluorophenyl)ethanone and 3.74 g (46 mmol) of sodium thiocyanate were stirred in 80 ml ethanol at 50 0C for 2 h. After addition of water the separated solid was isolated by filtration, washed and dried. Yield: 8.96 g.
MS: M+H+ = 196.2.
b) 1 -(2-(4-(4-Fluorophenyl)thiazol-2-ylamino)ethyl)imidazolidin-2-one, trifluoroacetic acid salt
65.8 mg (0.5 mmol) of 1-(4-fluorophenyl)-2-thiocyanatoethanone and 99.5 mg (0.5 mmol) of 1-(2-aminoethyl)imidazolidin-2-one were stirred in 5 ml of ethanol at 50 0C for 4 h. The solvent was evaporated and the residue purified by chromatography
(RP18, acetonitrile/water containing 0.1 % TFA). Yield: 17 mg.
MS: M+H+ = 307.1. Example 41
4-Chloro-N-(2-(4-(4-fluorophenyl)thiazol-2-ylamino)ethyl)benzamide, trifluoroacetic acid salt
Figure imgf000104_0001
The compound was prepared analogously to example 40b). Yield: 30 mg. MS: M+H+ = 376.1.
Example 42
4-Aminofurazan-3-carboxylic acid (2-(4-(4-fluorophenyl)thiazol-2- ylamino)ethyl)amide, trifluoroacetic acid salt
Figure imgf000104_0002
The compound was prepared analogously to example 40b). Yield: 54 mg. MS: M+H+ = 349.1.
Example 43
N-(2-(4-(4-Fluorophenyl)thiazol-2-ylamino)ethyl)isonicotinamide, trifluoroacetic acid salt
Figure imgf000104_0003
The compound was prepared analogously to example 40b). Yield: 52 mg. MS: M+H+ = 343.1.
Example 44
3-(2-(6-(4-Fluorophenyl)pyridin-3-yloxy)ethyl)imidazolidine-2,4-dione, hydrochloride
Figure imgf000105_0001
100 mg (0.32 mmol) of methanesulfonic acid 2-(6-(4-fluorophenyl)pyridin-3- yloxy)ethyl ester and 35.4 mg (0.35 mmol) of imidazolidine-2,4-dione were reacted analogously to example 1d). The hydrochloride salt was prepared by dissolution of the product in hydrochloric acid and lyophilization. Yield: 58 mg. MS: M+H+ = 316.1.
Example 45
N-(2-(6-(2-Fluorophenyl)pyridin-3-yloxy)ethyl)acetamide, trifluoroacetic acid salt
Figure imgf000105_0002
a) 2-(6-(2-Fluorophenyl)pyridin-3-yloxy)ethylamine
189 mg (0.52 mmol) of (2-(2-(6-(2-fluorophenyl)pyridin-3-yloxy)ethyl)isoindole-1 ,3- dione and 236 mg (4.72 mmol) of hydrazine hydrate (24 %) were stirred in 10 ml of ethanol under reflux for 7 h. After cooling the residue was filtered, washed and dried. Yield: 165 mg.
MS: M+H+ = 233.3. b) N-(2-(6-(2-Fluorophenyl)pyridin-3-yloxy)ethyl)acetamide, trifluoroacetic acid salt 59.9 mg (0.26 mmol) of 2-(6-(2-fluorophenyl)pyridin-3-yloxy)ethylamine and 52.2 mg (0.52 mmol) of triethylamine were stirred in 5 ml of methylene chloride at room temperature. 31.6 mg (0.31 mmol) of acetic acid anhydride were slowly added. The mixture was stirred for 4 h, washed with water, evaporated and purified by chromatography (RP18, acetonithle/water containing 0.1 % TFA). Yield: 17 mg. MS: M+H+ = 275.1.
Example 46 3-(3-(6-(4-Fluorophenyl)pyridin-3-yl)propyl)-5,5-dimethylimidazolidine-2,4-dione, trifluoroacetic acid salt
Figure imgf000106_0001
69 mg (0.226 mmol) of methanesulfonic acid 3-(6-(4-fluorophenyl)pyridin-3-yl)propyl ester were reacted with 43.44 mg (0.339 mmol) of 5,5-dimethylimidazolidine-2,4- dione in the presence of 2.7 mg (0.34 mmol) of lithium hydride analogously to example 1d). Yield: 37 mg. MS: M+H+ = 342.12.
Example 47
N-(2-(6-(2-Fluorophenyl)pyridin-3-yloxy)ethyl)benzamide, trifluoroacetic acid salt
Figure imgf000106_0002
28.9 mg (0.24 mmol) of benzoic acid, 49.9 mg (0.21 mmol) of 2-(6-(2- fluorophenyl)pyridin-3-yloxy)ethylamine, 89.9 mg (0.27 mmol) of N.N.N'.N'- tetramethyl-O-(7-azabenzotriazol-1-yl)uronium hexafluorophosphate and 65.2 mg (0.64 mmol) of triethylamine were stirred in 8 ml of DMF at room temperature for 2 h and at 40 0C for 3 h. The solvent was removed by evaporation and the residue treated with ethyl acetate and water. The organic layer was evaporated and purified by chromatography (RP18, acetonitrile/water containing 0.1 % TFA). Yield: 27 mg. MS: M+H+ = 337.1.
Example 48
Cyclopropanecarboxylic acid (2-(6-(2-fluorophenyl)pyridin-3-yloxy)ethyl)amide, trifluoroacetic acid salt
Figure imgf000107_0001
20.36 mg (0.24 mmol) of cyclopropanecarboxylic acid and 49.94 mg (0.21 mmol) of 2-(6-(2-fluorophenyl)pyridin-3-yloxy)ethylamine were reacted analogously to example 47. Yield: 15 mg. MS: M+H+ = 301.2.
Example 49
3-(3-(6-(4-Fluorophenyl)pyridin-3-yl)propyl)oxazolidin-2-one, trifluoroacetic acid salt
Figure imgf000107_0002
The compound was prepared analogously to example 12b). Yield: 22 mg. MS: M+H+ = 301.0. Example 50
1-(2-(6-(3-Chloro-4-fluorophenyl)pyridin-3-yloxy)ethyl)pyrrolidine-2,5-dione, trifluoroacetic acid salt
Figure imgf000108_0001
a) 1-(2-(6-Bromopyridin-3-yloxy)ethyl)pyrrolidine-2,5-dione
10 g (58 mmol) of 3-hydroxy-6-bromopyridine were dissolved in 40 ml of DMF and treated with 2.76 g (69 mmol) of sodium hydride (60 % suspension in mineral oil). After stirring at room temperature for 1 h, 20 mg of 4-dimethylaminopyridine were added and the mixture was treated with 16.53 g (74.8 mmol) of methanesulfonic acid 2-(2,5-dioxopyrrolidin-1-yl)ethyl ester and heated to 100 0C for 3 h. Subsequently, the solvent was evaporated and the residue was taken up in water and extracted 4 times with ethyl acetate. The combined organic phases were dried and evaporated to dryness. The remaining material was purified by chromatography (silica gel, dichloromethane/methanol 98 : 2) followed by preparative HPLC (RP18, acetonitrile/water containing 0.1 % TFA) to yield 10.8 g of the title compound.
b) 1-(2-(6-(3-Chloro-4-fluorophenyl)pyridin-3-yloxy)ethyl)pyrrolidine-2,5-dione, trifluoroacetic acid salt
150 mg (0.5 mmol) of 1-(2-(6-bromopyridin-3-yloxy)ethyl)pyrrolidine-2,5-dione, 96 mg (0.55 mmol) of 3-chloro-4-fluorophenylboronic acid and 152 mg (0.5 mmol) of cesium fluoride were dissolved under an argon atmosphere in 5 ml of a mixture of 2 parts of absolute 1 ,2-dimethoxyethane and 1 part of absolute methanol and treated with 34.2 mg (0.09 mmol) of tetrakis(triphenylphosphane)palladium. The mixture was heated for 3 min at 150 0C in a microwave reactor (Smith Synthesizer, Personal Chemistry), the solvent was evaporated and the residue dissolved in 20 ml of ethyl acetate. The solution was extracted once with sodium hydrogencarbonate solution, dried and evaporated to dryness. The remaining material was purified by preparative HPLC (RP18, acetonithle/water containing 0.1 % TFA). Yield: 42 mg (24 %). 1H-NMR (D6-DMSO): δ (ppm) = 2.65 (s, 4 H)1 3.75 (m, 2 H), 4.25 (m, 2 H), 7.48 (m, 2 H), 7.50 - 7.65 (m, 1 H), 7.98 (m, 1 H), 8.05 (m, 1 H), 8.22 (d, 1 H), 8.33 (s, 1 H). MS: M+H+ = 349.
HPLC retention time: 1.72 min (method HPLC A).
According to the method described in example 50, by replacing the 3-chloro-4- fluorophenylboronic acid employed in step b) with the respective boronic acid of the formula R50-B(OH)2, the 1-(2-(6-R50-pyridin-3-yloxy)ethyl)pyrrolidine-2,5-diones of examples 51 to 87 were prepared which are compounds of the formula Ie wherein the aromatic or heteroaromatic group R50 is as specified in table 1.
Figure imgf000109_0001
The compounds of examples 51 to 87 were obtained in the form of their trifluoroacetic acid salts. The names of the prepared compounds are obtained by replacing the identifier R50 in the general name 1-(2-(6-R50-pyridin-3- yloxy)ethyl)pyrrolidine-2,5-dione of the compounds of formula Ie with the meaning of R50 given in table 1 , optionally allowing for a modification of the name according to the nomenclature rules. For example, in the case of example 51 , in which R50 is 6- fluoropyridin-3-yl, the prepared compound of the formula If
Figure imgf000109_0002
If ig thus is 1-(2-(6-(6-fluoropyridin-3-yl)pyridin-3-yloxy)ethyl)pyrrolidine-2,5-dione, trifluoroacetic acid salt, which can also be named as 1-(2-(6'-fluoro-[2,3']bipyridinyl-5- yloxy)ethyl)pyrrolidine-2,5-dione; trifluoroacetic acid salt or 1-(2-(6'-fluoro-[2,3'- bipyridin]-5-yloxy)ethyl)pyrrolidine-2,5-dione, trifluoroacetic acid salt, and in the case of example 60 the prepared compound of the formula Ig is 1-(2-(6-(2,3-dichloro- phenyl)pyridin-3-yloxy))ethyl)pyrrolidine-2,5-dione, trifluoroacetic acid salt, and in the case of example 64 the prepared compound is 1-(2-(6-(3-cyanophenyl)pyridin-3- yloxy))ethyl)pyrrolidine-2,5-dione, trifluoroacetic acid salt, which can also be named as 3-(5-(2-(2,5-dioxopyrrolidin-1-yl)ethoxy)pyridin-2-yl)benzonitrile, trifluoroacetic acid salt. The HPLC retention times given in table 1 were determined according to method HPLC A.
Table 1. Example compounds of formula Ie
Example R50 MS HPLC retention no. M+H+ time (min)
51 6-fluoropyridin-3-yl 316 1.45
52 4-methylthiophen-2-yl 317 1.64
53 3,4,5-trifluorophenyl 351 1.77
54 3-trifluoromethoxyphenyl 381 1.77
55 2-trifluoromethoxyphenyl 381 1.66
56 6-methoxypyridin-3-yl 328 1.38
57 pyridin-3-yl 298 0.61
58 quinolin-8-yl 348 1.32
59 4-trifluoromethoxyphenyl 381
60 2,3-dichlorophenyl 365 1.75 Example R50 MS HPLC retention no. M+H+ time (min)
61 2,4-difluorophenyl 333 1.66
62 3,4-dimethoxyphenyl 357 1.38
63 4-cyanophenyl 322 1.66
64 3-cyanophenyl 322 1.65
65 naphthalen-2-yl 347 1.70
66 naphthalen-1-yl 347 1.57
67 3-acetylaminophenyl 354 1.33
68 2-trifluoromethylphenyl 365 1.69
69 4-trifluoromethylphenyl 365 1.81
70 3,5-dichlorophenyl 365 1.87
71 3-trifluoromethylphenyl 365 1.75
72 4-methylsulfonylaminophenyl 390 1.29
73 3,4-difluorophenyl 333 1.74
74 3,5-difluorophenyl 333 1.78
75 4-tert-butylphenyl 353 1.72
76 4-ethoxyphenyl 341 1.53
77 2-fluoropyridin-3-yl 316 1.43
78 2,5-difluorophenyl 333 Example R50 MS HPLC retention no. M+H+ time (min)
79 4-dimethylaminophenyl 340 1.32
80 3-chloropyhdin-4-yl 332 1.39
81 3-methylsulfonylaminophenyl 390 1.32
82 5-cyanothiophen-2-yl 328 1.70
83 3,5-dimethylisoxazol-4-yl 316 1.26
84 3-fluoropyridin-4-yl 316
85 4-fluoro-2-methylphenyl 329 1.37
86 4-fluoro-3-methylphenyl 329 1.36
87 pyrimidin-5-yl 299 0.96
Sample 1H-NMR data of compounds of formula Ie (determined in D6-DMSO): Example 60: δ (ppm) = 2.65 (s, 4 H), 3.75 (m, 2 H), 4.25 (m, 2 H), 7.45 (m, 1 H), 7.5 (m, 2 H), 7.64 (d, 1 H), 7.68 (m, 1 H), 8,34 (s, 1 H). Example 73: δ (ppm) = 2.65 (s, 4 H), 3.75 (m, 2 H), 4.25 (m, 2 H), 7.45-7.55 (m, 2 H), 7.38 (m, 1 H), 7.96 (d, 1 H), 8.06 (m, 1 H), 8,30 (s, 1 H).
Example 86: δ (ppm) = 2.28 (s, 3 H) 2.65 (s, 4 H), 3.78 (m, 2 H), 4.22 (m, 2 H), 7.20 (t, 1 H), 7.46 (d, 1 H), 7.83 (m, 1 H)1 7.90 (d, 1 H), 7.94 (m, 1 H), 8.30 (s, 1 H).
Determination of the biological activity
A) Activation of eNOS transcription
Activation of eNOS transcription was measured as described in detail by Li et al., "Activation of protein kinase C alpha and/or epsilon enhances transcription of the human endothelial nitric oxide synthase gene", MoI. Pharmacol. 53 (1998) 630. Briefly, a 3.5 kB long fragment 5' of the starting codon of the eNOS gene was cloned, sequenced and cloned in firefly luciferase expression plasmids to monitor activation of the eNOS promoter by reporter gene activity. A human endothelial cell line stable transfected and expressing this promoter-reporter construct was used for compound testing. Cells were incubated for 18 h with the compounds.
All compounds were dissolved in sterile dimethyl sulfoxide (DMSO). A final concentration of 0.5 % DMSO in complete medium was allowed. Induction of reporter gene expression in these cells was measured using a standard luciferase assay system (Promega, Cat. No. E150) according to the manufacturer's instructions. Luciferase induction in cells incubated with compounds were compared to those incubated with solvent alone. The ratio of both activities (transcription induction ratio, TIR) was plotted as a function of compound concentration. Typically, TIR values started at low concentrations at a ratio of 1 , indicating no compound effect, and extended up to a maximum TIR value TIR(max) which indicates the increase of the eNOS transcription. EC50 values of transcription induction ratios as a function of compound concentration were determined graphically.
Numerous compounds of the instant invention were tested by the above-described assay and found to increase protein transcription. Generally, the tested compounds exhibited EC50 values of less than about 50 μM. Preferred compounds, including the compounds of examples 7, 17, 34, 64, 66, for example, exhibited EC50 values of from about 5 μM to about 0.5 μM. More preferred compounds, including the compounds of examples 18, 25, 50, 52, 86, for example, exhibited EC50 values of less than about 0.5 μM.
The effect of compounds on eNOS-transcription was confirmed in a second assay based on eNOS protein detection. Primary human umbilical vein cord endothelial cells (HUVEC) were isolated and cultivated according to standard procedures. Confluent cells were incubated with compounds for 18 h and the effect on eNOS protein expression determined by a quantitative Western blotting procedure. After compound incubation, HUVEC were lysed in ice-cold lysis buffer containing 10 mM Tris-HCI, pH 8.0, 1 % SDS and protease inhibitors. The lysate was subjected to a standard denaturating polyacrylamide gel electrophoresis and blotted to nitrocellulose membranes. Using a specific primary monoclonal antibody (Transduction Laboratories, UK) and alkaline phosphatase labelled secondary antibody (Jackson Labs), a specific eNOS protein band was visualized and quantified based on a chemofluorescence detection method.
The effect of the compounds of the formulae I and Ia can also be investigated in the following animal models (animal experiments are performed in accordance with the German animal protection law and the guidelines for the use of experimental animals as given by the Guide for the Care and Use of Laboratory Animals of the US National Institutes of Health).
Animals and treatment (experiments B - D)
ApoE and eNOS deficient mice (C57BL/6J background, Jackson Laboratory, Bar Harbor, Me) are used. All animals are 10 to 12 weeks of age and weigh 22 to 28 g. Three days before surgery mice are divided into 4 groups (apoE control, n = 10 to 12; apoE with test compounds, n = 10 to 12; eNOS control, n = 10 to 12; eNOS with test compounds, n = 10 to 12) and receive either a standard rodent chow (containing 4 % of fat and 0.001 % of cholesterol; in the following designated as placebo group) or a standard rodent chow + test compound (10 or 30 mg/kg/day p.o.).
B) Anti-hypertensive effect in ApoE knockout mice
Blood-pressure is determined in conscious mice using a computerized tail-cuff system (Visitech Systems, Apex, Nc). After treatment of ApoE deficient mice and eNOS deficient mice with the test compounds the blood pressure is compared to the results obtained with a placebo treatment.
C) Inhibition of neointima formation and atherogenesis (femoral artery cuff) After 3 day treatment of ApoE deficient mice with the respective compound (10 mg/kg/day pressed in chow), animals are anesthetized with an intraperitoneal injection of pentobarbital (60 mg/kg) followed by an intramuscular injection of xylazin (2 mg/kg) and a cuff is placed around the femoral artery as described in Moroi et al. (J Clin. Invest. 101 (1998) 1225). Briefly, the left femoral artery is dissected. A non- occlusive 2.0 mm polyethylene cuff made of PE 50 tubing (inner diameter 0.56 mm, outer diameter 0.965 mm, Becton Dickinson, Mountain View, Ca) is placed around the artery and tied in place with two 7-0 sutures. The right femoral artery is isolated from the surrounding tissues but a cuff is not placed. Treatment with the respective compound is continued for 14 days after surgery. Then the animals are sacrificed. The aorta are taken for determination of vascular eNOS expressions by quantitative western blotting. Both femoral arteries are harvested, fixed in formalin and embedded in paraffin. 20 cross sections (10 μm) are cut from the cuffed portion of the left femoral artery and from the corresponding segment of the right artery. Sections are subjected to standard hematoxylin and eosin staining. Morphometric analyses are performed using an image analysis computer program (LeicaQWin, Leica Imaging Systems, Cambridge, GB). For each cross section the area of the lumen, the neointima and the media are determined. To this end, the neointima is defined as the area between the lumen and the internal elastic lamina and the media is defined as the area between the internal and the external elastic lamina. The ratio between the area of the neointima and the area of the media is expressed as the neointima/media ratio. The results obtained in the compound group are compared to those obtained in the placebo group.
D) Prevention of atherosclerotic plaque formation in chronic treatment
ApoE deficient mice are treated for 16 weeks with the respective compound pressed in chow and finally sacrificed. Aortas are removed from each mouse, fixed in formalin and embedded in paraffin. Plaque formation is measured via lipid lesions formation in the aortas (from aortic arch to diaphragm) and is analyzed by oil red O staining. For quantifying the effect of the respective compound on vascular eNOS expression the femoral arteries are used in this experiment. The results obtained in the compound group are compared to those obtained in the placebo group.
D) Improvement of coronary function in diseased ApoE deficient mice
Old Male wild-type C57BL/6J mice (Charles River Wiga GmbH, Sulzfeld), and apoE deficient mice (C57BL/6J background, Jackson Laboratory, Bar Harbor, Me) of 6 month of age and weighing 28 to 36 g are used in the experiments. Mice are divided into 3 groups (C57BL/6J, n = 8; apoE control, n = 8; apoE with respective compound, n = 8) and receive for 8 weeks either a standard rodent chow (containing 4 % of fat and 0.001 % of cholesterol) or a standard rodent chow + respective compound (30 mg/kg/day p.o.). Mice are anesthetized with sodium pentobarbitone (100 mg/kg i.p.), and the hearts are rapidly excised and placed into ice-cold perfusion buffer. The aorta is cannulated and connected to a perfusion apparatus (Hugo Sachs Electronics, Freiburg, Germany) which is started immediately at a constant perfusion pressure of 60 mm Hg. Hearts are perfused in a retrograde fashion with modified Krebs bicarbonate buffer, equilibrated with 95 % O2 and 5 % CO2 and maintained at 37.5 °C. A beveled small tube (PE 50) is passed through a pulmonary vein into the left ventricle and pulled through the ventricular wall, anchored in the apex by a fluted end, and connected to a tip-micromanometer (Millar 1.4 French). The left atrium is cannulated through the same pulmonary vein and the heart switched to the working mode with a constant preload pressure of 10 mm Hg and an afterload pressure of 60 mm Hg. Aortic outflow and atrial inflow are continuously measured using ultrasonic flow probes (HSE/Transonic Systems Inc.). Coronary flow is calculated as the difference between atrial flow and aortic flow. All hemodynamic data are digitized at a sampling rate of 1000 Hz and recorded with a PC using spezialized software (HEM, Notocord).
Hearts are allowed to stabilize for 30 min. All functional hemodynamic data are measured during steady state, and during volume and pressure loading. Left ventricular function curves are constructed by varying pre-load pressure. For acquisition of preload curves, afterload is set at 60 mm Hg and preload is adjusted in 5 mm Hg steps over a range of 5 to 25 mm Hg. Hearts are allowed to stabilize at baseline conditions between pressure and volume loading.

Claims

Patent claims
1. A compound of the formula I,
Figure imgf000118_0001
in which
A is chosen from -CH2-CH2-, -CH2-CH2-CH2- and -Y-CH2-CH2-, wherein all CH2 groups can be substituted by one or more identical or different substituents R4, and wherein Y is chosen from O, S and NR11 and Y is bonded to the group Het;
Het is a 5-membered or 6-membered, monocyclic aromatic group which contains one or two identical or different hetero ring members chosen from N, NR13, O and S and which can be substituted by one or more identical or different substituents R5;
X is chosen from a direct bond, CH2, O and NH;
R1 and R2, together with the N-CO group which carries them, form a 4-membered to 10-membered, monocyclic or bicyclic, saturated or unsaturated ring which, in addition to the ring nitrogen atom being part of the N-CO group, can contain one or two further hetero ring members chosen from N, NR12, O, S, SO and SO2 which can be identical or different, with the proviso that two ring members from the series O, S, SO and SO2 cannot be present in adjacent ring positions, wherein the ring formed by R1 and R2 and the N-CO group which carries them can be substituted by one or more identical or different substituents R8;
R3 is chosen from phenyl, naphthalenyl and heteroaryl which can all be substituted by one or more identical or different substituents chosen from halogen, (Ci-C4)-alkyl, (Ci-C4)-alkyloxy-(C1-C2)-alkyl-, OH, (d-C4)-alkyloxy which can be substituted by one or more fluorine atoms, (Ci-C2)-alkylenedioxy which can be substituted by one or more fluorine atoms, (Ci-C4)-alkylmercapto, NH2, (Ci-C4)-alkylamino, di((Ci-C4)- alkyl)amino, ((Ci-C4)-alkyl)-CONH-, di((Ci-C4)-alkyl)aminocarbonyl-, ((C1-C4)- alkyl)aminocarbonyl-, ((d-C4)-alkyloxy)carbonyl-, COOH, CONH2, CN, CF3, H2NSO2- and (d-C4)-alkyl-SO2-;
R4 is chosen from (Ci-C4)-alkyl and fluorine;
R5 is chosen from halogen, (Ci-C4)-alkyl,
Figure imgf000119_0001
OH, (C1-C4)- alkyloxy which can be substituted by one or more fluorine atoms, (Ci-C4)- alkylmercapto, NH2, (Ci-C4)-alkylamino, di((Ci-C4)-alkyl)amino, ((Ci-C4)-alkyl)- CONH-, di((C1-C4)-alkyl)aminocarbonyl-,
Figure imgf000119_0002
((CrC4)- alkyloxy)carbonyl-, COOH, CONH2, CN, CF3 and (d-C4)-alkyl-SO2-;
R8 is chosen from halogen, (CrC4)-alkyl, (C3-C7)-cycloalkyl-CnH2n-, phenyl-CnH2n-, heteroaryl-CnH2n-, (Ci-C4)-alkyloxy-(Ci-C2)-alkyl-, OH, oxo, (d-C4)-alkyloxy which can be substituted by one or more fluorine atoms, (d-C2)-alkylenedioxy which can be substituted by one or more fluorine atoms, (Ci-C4)-alkylmercapto, NH2, (C1-C4)- alkylamino, di((Ci-C4)-alkyl)amino, ((Ci-C4)-alkyl)-CONH-, di((d-C4)- alkyl)aminocarbonyl-, ((Ci-C4)-alkyl)aminocarbonyl-, ((Ci-C4)-alkyloxy)carbonyl-,
COOH, CONH2, CN, CF3, H2NSO2- and (Ci-C4)-alkyl-SO2-, wherein all phenyl groups and heteroaryl groups can independently of each other be substituted by one or more identical or different substituents chosen from halogen, (Ci-C4)-alkyl, CF3 and (C1- C4)-alkyloxy;
R11 is chosen from hydrogen, (Ci-C4)-alkyl and ((Ci-C4)-alkyl)-CO-;
R12 is chosen from hydrogen, (Ci-C4)-alkyl, (C3-C7)-cycloalkyl-CnH2n-, phenyl-CnH2n-, heteroaryl-CnH2n-, ((Ci-C4)-alkyl)-CO-, (C3-C7)-cycloalkyl-CnH2n-CO-, phenyl-CnH2n- CO-, heteroaryl-CnH2n-CO-, ((Ci-C4)-alkyl)-O-CO- and phenyl-CnH2n-O-CO-, wherein all phenyl groups and heteroaryl groups can be substituted by one or more identical or different substituents chosen from halogen, (Ci-C4)-alkyl, CF3 and (C1-C4)- alkyloxy;
R13 is chosen from hydrogen, (CrC4)-alkyl and phenyl-CnH2n-, wherein the phenyl group can be substituted by one or more identical or different substituents chosen from halogen, (Ci-C4)-alkyl, CF3 and (Ci-C4)-alkyloxy, where all groups R13 are independent of each other and can be identical or different;
heteroaryl is a 5-membered or 6-membered, monocyclic aromatic group which contains one, two or three identical or different hetero ring members chosen from N1 NR13, O and S;
n is 0, 1 or 2, where all numbers n are independent of each other and can be identical or different;
in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof;
provided that the group -N(R2)-CO-R1 cannot be an unsubstituted 2-oxopyrrolidin-1-yl group or an unsubstituted 2-oxoimidazolin-1-yl group if simultaneously the group R3-X-Het- is a group of the formula
Figure imgf000120_0001
in which the bond via which the group is connected to the group A is depicted by the line starting in the 2-position of the pyridine ring, and in which R90 is chosen from imidazol-1-yl, isoxazol-5-yl, isothiazol-5-yl, 1 ,2,4-triazoM-yl, pyrazin-2-yl and pyrazol- 3-yl which can all be substituted by (Ci-C4)-alkyl, and which can be substituted in the pyridine ring by up to four substituents chosen from (Ci-C4)-alkyl, (Ci-C4)-alkyloxy and halogen; and provided that the group -N(R2)-CO-R1 cannot be a 1 ,3-dioxoisoindol-2-yl group of the formula
Figure imgf000121_0001
in which the bond via which the group is connected to the group A is depicted by the line starting at the nitrogen atom.
2. A compound as claimed in claim 1 , in which
R3 is chosen from phenyl, naphthalenyl, pyridinyl, pyrimidinyl, isoxazolyl and thiophenyl which can all be substituted by one or more identical or different substituents which are chosen from halogen, (C-i-C4)-alkyl, (Ci-C4)-alkyloxy-(C-i-C2)- alkyl-, (Ci-C4)-alkyloxy which can be substituted by one or more fluorine atoms, (Cr C4)-alkylmercapto, (d-C^-alkylamino, di((Ci-C4)-alkyl)amino, CONH2, CN, CF3 and (Ci-C4)-alkyl-SO2-; or a physiologically acceptable salt thereof.
3. A compound as claimed in any of claims 1 to 2, in which R3 is phenyl which can be substituted by one or more identical or different substituents which are chosen from halogen, (Ci-C4)-alkyl, (Ci-C4)-alkyloxy-(CrC2)- alkyl-, (Ci-C4)-alkyloxy which can be substituted by one or more fluorine atoms, (Ci- C4)-alkylmercapto, (CrC^-alkylamino, di((Ci-C4)-alkyl)amino, CONH2, CN, CF3 and (Ci-C4)-aHcyl-SO2-; or a physiologically acceptable salt thereof.
4. A compound as claimed in any of claims 1 to 3, in which A is chosen from -CH2-CH2-CH2- and -Y-CH2-CH2- wherein Y is chosen from O and NH and Y is bonded to the group Het;
Het is chosen from the pyridinediyl, thiazolediyl, oxazolediyl, imidazolediyl and thiophenediyl which can all be substituted by one or more identical or different substituents R5 and wherein one of the ring nitrogen atoms of the imidazolediyl group carries a group chosen from hydrogen and (Ci-C4)-alkyl;
X is chosen from a direct bond and O;
R1 and R2, together with the N-CO group which carries them, form a saturated or unsaturated, monocyclic 4-membered to 7-membered ring which, in addition to the ring nitrogen atom being part of the N-CO group, can contain one further hetero ring member chosen from NR12, O and S, wherein the ring formed by R1 and R2 and the N-CO group which carries them can be substituted by one or more identical or different substituents R8;
R3 is phenyl which can be substituted by one or more identical or different substituents which are chosen from halogen, (Ci-C4)-alkyl, (Ci-C4)-alkyloxy-(Ci-C2)- alkyl-, (Ci-C4)-alkyloxy which can be substituted by one or more fluorine atoms, (C-i- C4)-alkylmercapto, (Ci-C4)-alkylamino, di((d-C4)-alkyl)amino, CONH2, CN, CF3 and (Ci-C4)-alkyl-SO2-;
R5 is chosen from halogen, (Ci-C4)-alkyl, (Ci-C4)-alkyloxy-(Ci-C2)-alkyl-, OH, (Ci-C4)- alkyloxy which can be substituted by one or more fluorine atoms, (Ci-C4)- alkylmercapto, NH2, (Ci-C4)-alkylamino, di((Ci-C4)-alkyl)amino, ((CrC4)-alkyl)- CONH-, CONH2, CN, CF3 and (Ci-C4)-alkyl-SO2-;
R8 is chosen from (Ci-C4)-alkyl and oxo;
R12 is chosen from H and (Ci-C4)-alkyl-; or a physiologically acceptable salt thereof.
5. A compound as claimed in any of claims 1 to 4, in which X is a direct bond, or a physiologically acceptable salt thereof.
6. A compound as claimed in any of claims 1 to 5, in which Het is a pyridinediyl or thiazolediyl group which can all be substituted by one or more identical or different substituents R5, or a physiologically acceptable salt thereof.
7. A compound as claimed in any of claims 1 to 6, in which A is chosen from -CH2-CH2-CH2- and -Y-CH2-CH2- wherein Y is chosen from O and NH and Y is bonded to the group Het;
Het is a pyridinediyl or thiazolediyl group which can all be substituted by one or more identical or different substituents R5;
X is a direct bond;
R1 and R2, together with the N-CO group which carries them, form a saturated or unsaturated, monocyclic 4-membered to 7-membered ring which, in addition to the ring nitrogen atom being part of the N-CO group, can contain one further hetero ring member chosen from NR12, O and S, wherein the ring formed by R1 and R2 and the N-CO group which carries them can be substituted by one or more identical or different substituents R8;
R3 is phenyl which can be substituted by one or more identical or different substituents which are chosen from halogen, (Ci-C4)-alkyl, (Ci-C4)-alkyloxy-(Ci-C2)- alkyl-, (Ci-C4)-alkyloxy which can be substituted by one or more fluorine atoms, (C-i- C-O-alkylmercapto, (CrC^-alkylamino, di((Ci-C4)-alkyl)amino, CONH2, CN, CF3 and (Ci-C4)-alkyl-SO2-;
R5 is chosen from halogen, (Ci-C4)-alkyl, (Ci-C4)-alkyloxy-(CrC2)-alkyl-, OH, (CrC4)- alkyloxy which can be substituted by one or more fluorine atoms, (Ci-C4)- alkylmercapto, NH2, (Ci-C4)-alkylamino, di((Ci-C4)-alkyl)amino, ((d-C4)-alkyl)- CONH-, CONH2, CN, CF3 and (d-C4)-alkyl-SO2-;
R8 is chosen from (Ci-C4)-alkyl and oxo,
R12 is chosen from H and (Ci-C4)-alkyl-; or a physiologically acceptable salt thereof.
8. A compound as claimed in claim 7, in which Het is a pyridinediyl group which can be substituted by one or more identical or different substituents R5; or a physiologically acceptable salt thereof.
9. A compound as claimed in any of claims 1 , 2, 5 and 6, chosen from 1-(3-(6-(2-fluorophenyl)pyridin-3-yl)propyl)-1 H-pyridin-2-one, 1 -(3-(6-(2-fluorophenyl)pyridin-3-yl)propyl)piperidin-2-one, 4-(3-(6-phenylpyhdin-3-yl)propyl)thiomorpholin-3-one, 1-(3-(6-(2-fluorophenyl)pyridin-3-yl)propyl)pyrrolidin-2-one, 1-(3-(6-(2-fluorophenyl)pyridin-3-yl)propyl)piperidine-2,6-dione) 1-(3-(6-(2-fluorophenyl)pyridin-3-yl)propyl)azepan-2-one, 4-(3-(6-(2-chlorophenyl)pyridin-3-yl)propyl)thiomorpholin-3-one, 4-(3-(6-(4-fluorophenyl)pyridin-3-yl)propyl)thiomorpholin-3-one, 4-(3-(6-(2-fluorophenyl)pyridin-3-yl)propyl)thiomorpholin-3-one, 1-(3-(6-(2-fluorophenyl)pyridin-3-yl)propyl)pyrrolidine-2,5-dione, 3-(3-(6-(2-fluorophenyl)pyridin-3-yl)propyl)thiazolidine-2,4-dione, 1-(3-(6-(4-fluorophenyl)pyridin-3-yl)propyl)pyrrolidin-2-one,
1-(3-(6-(4-fluorophenyl)pyridin-3-yl)propyl)pyrrolidine-2,5-dione, 3-(3-(6-(4-fluorophenyl)pyridin-3-yl)propyl)imidazolidine-2,4-dione, 1-(3-(6-(4-fluorophenyl)pyhdin-3-yl)propyl)azetidin-2-one, 1-(3-(6-(4-fluorophenyl)pyridin-3-yl)propyl)piperidin-2-one, 1 -(3-(6-(4-fluorophenyl)pyridin-3-yl)propyl)azepan-2-one,
4-(3-(6-(2-fluorophenyl)pyridin-3-yl)propyl)-4H-[1 ,4]thiazin-3-one, 3-(3-(6-(2-fluorophenyl)pyridin-3-yl)propyl)imidazolidine-2,4-dione, 1-(3-(6-(4-fluorophenyl)pyridin-3-yl)propyl)piperidine-2,6-dionel 3-(3-(6-(4-fluorophenyl)pyridin-3-yl)propyl)thiazolidine-2,4-dione, 1-(3-(6-(2-fluorophenyl)pyridin-3-yl)propyl)azetidin-2-one, 1-(3-(6-(4-fluorophenyl)pyridin-3-yl)propyl)-1H-pyridin-2-one, 4-(3-(6-(4-fluorophenyl)pyridin-3-yl)propyl)-4H-[1 ,4]thiazin-3-one, 1-(2-(6-(2-fluorophenyl)pyridin-3-yloxy)ethyl)piperidin-2-one, 1-(2-(6-(2-fluorophenyl)pyridin-3-yloxy)ethyl)azetidin-2-one, 1-(2-(6-(2-fluorophenyl)pyridin-3-yloxy)ethyl)pyrrolidine-2,5-dione, 3-(2-(4-(4-fluorophenyl)thiazol-2-ylamino)ethyl)imidazolidine-2,4-dione, 3-(2-(6-(2-fluorophenyl)pyridin-3-yloxy)ethyl)imidazolidine-2,4-dione, 1-(2-(5-(2-fluorophenyl)pyridin-2-yloxy)ethyl)pyrrolidin-2-one, 1-(2-(4-(4-fluorophenyl)thiazol-2-ylamino)ethyl)pyrrolidine-2,5-dione, 1-(2-(6-(4-fluorophenyl)pyridin-3-yloxy)ethyl)pyrrole-2,5-dione, 1-(2-(6-(4-fluorophenyl)pyridin-3-yloxy)ethyl)pyrrolidine-2,5-dione, 1 -(2-(6-(4-fluorophenyl)pyridin-3-yloxy)ethyl)-1 H-pyridin-2-one, 1-(2-(4-(4-fluorophenyl)thiazol-2-ylamino)ethyl)imidazolidin-2-one, 3-(2-(6-(4-fluorophenyl)pyridin-3-yloxy)ethyl)imidazolidine-2,4-dione, 3-(3-(6-(4-fluorophenyl)pyridin-3-yl)propyl)-5,5-dimethylimidazolidine-2,4-dione, 3-(3-(6-(4-fluorophenyl)pyridin-3-yl)propyl)oxazolidin-2-one, 1-(2-(6-(3-chloro-4-fluorophenyl)pyridin-3-yloxy)ethyl)pyrrolidine-2,5-dione, 1-(2-(6-(6-fluoropyridin-3-yl)pyridin-3-yloxy)ethyl)pyrrolidine-2,5-dione, 1-(2-(6-(4-methylthiophen-2-yl)pyridin-3-yloxy)ethyl)pyrrolidine-2,5-dione, 1-(2-(6-(3,4,5-trifluorophenyl)pyridin-3-yloxy)ethyl)pyrrolidine-2,5-dione, 1-(2-(6-(3-trifluoromethoxyphenyl)pyridin-3-yloxy)ethyl)pyrrolidine-2,5-dione, 1-(2-(6-(2-trifluoromethoxyphenyl)pyridin-3-yloxy)ethyl)pyrrolidine-2,5-dione, 1-(2-(6-(6-methoxypyridin-3-yl)pyridin-3-yloxy)ethyl)pyrrolidine-2,5-dione, 1-(2-(6-(pyridin-3-yl)pyridin-3-yloxy)ethyl)pyrrolidine-2,5-dione, 1-(2-(6-(4-trifluoromethoxyphenyl)pyridin-3-yloxy)ethyl)pyrrolidine-2,5-dione, 1-(2-(6-(2,3-dichlorophenyl)pyridin-3-yloxy)ethyl)pyrrolidine-2,5-dione, 1-(2-(6-(2,4-difluorophenyl)pyridin-3-yloxy)ethyl)pyrrolidine-2,5-dione, 1-(2-(6-(3,4-dimethoxyphenyl)pyridin-3-yloxy)ethyl)pyrrolidine-2,5-dione, 1-(2-(6-(4-cyanophenyl)pyridin-3-yloxy)ethyl)pyrrolidine-2,5-dione, 1-(2-(6-(3-cyanophenyl)pyridin-3-yloxy)ethyl)pyrrolidine-2,5-dione, 1-(2-(6-(naphthalen-2-yl)pyridin-3-yloxy)ethyl)pyrrolidine-2,5-dione, 1-(2-(6-(naphthalen-1-yl)pyridin-3-yloxy)ethyl)pyrrolidine-2,5-dione, 1-(2-(6-(3-acetylaminophenyl)pyridin-3-yloxy)ethyl)pyrrolidine-2,5-dione, 1-(2-(6-(2-trifluoromethylphenyl)pyridin-3-yloxy)ethyl)pyrrolidine-2,5-dione) 1-(2-(6-(4-trifluoromethylphenyl)pyridin-3-yloxy)ethyl)pyrrolidine-2,5-dione, 1-(2-(6-(3,5-dichlorophenyl)pyridin-3-yloxy)ethyl)pyrrolidine-2,5-dione, 1-(2-(6-(3-trifluoromethylphenyl)pyridin-3-yloxy)ethyl)pyrrolidine-2,5-dione) 1-(2-(6-(3,4-difluorophenyl)pyridin-3-yloxy)ethyl)pyrrolidine-2,5-dione, 1 -(2-(6-(3,5-difluorophenyl)pyridin-3-yloxy)ethyl)pyrrolidine-2,5-dione, 1-(2-(6-(4-tert-butylphenyl)pyridin-3-yloxy)ethyl)pyrrolidine-2,5-dione, 1-(2-(6-(4-ethoxyphenyl)pyridin-3-yloxy)ethyl)pyrrolidine-2,5-dione, 1-(2-(6-(2-fluoropyridin-3-yl)pyridin-3-yloxy)ethyl)pyrrolidine-2,5-dione, 1-(2-(6-(2,5-difluorophenyl)pyridin-3-yloxy)ethyl)pyrrolidine-2,5-dione, 1-(2-(6-(4-dimethylaminophenyl)pyridin-3-yloxy)ethyl)pyrrolidine-2,5-dione, 1-(2-(6-(3-chloropyridin-4-yl)pyridin-3-yloxy)ethyl)pyrrolidine-2,5-dione, 1-(2-(6-(5-cyanothiophen-2-yl)pyridin-3-yloxy)ethyl)pyrrolidine-2,5-dione, 1-(2-(6-(3>5-dimethylisoxazol-4-yl)pyridin-3-yloxy)ethyl)pyrrolidine-2,5-dione, 1-(2-(6-(3-fluoropyridin-4-yl)pyridin-3-yloxy)ethyl)pyrrolidine-2,5-dione, 1-(2-(6-(4-fluoro-2-methylphenyl)pyridin-3-yloxy)ethyl)pyrrolidine-2,5-dione, 1-(2-(6-(4-fluoro-3-methylphenyl)pyridin-3-yloxy)ethyl)pyrrolidine-2,5-dione, and 1-(2-(6-(pyrimidin-5-yl)pyridin-3-yloxy)ethyl)pyrrolidine-2,5-dione, or a physiologically acceptable salt thereof.
10. A process for the preparation of a compound as claimed in any of claims 1 to 9, or a physiologically acceptable salt thereof, in which A is -Y-CH2-CHb- (compound of formula Ib)1 comprising reacting a compound of the formula IV and compound of the formula V,
Figure imgf000127_0001
wherein Het, X, Y, R1, R2 and R3 are defined as in claims 1 to 9 and, in addition, any functional groups can be present in protected form or in the form of precursor groups, and L1 is a nucleophilically substitutable leaving group.
11. A compound as claimed in any of claims 1 to 9, or a physiologically acceptable salt thereof, for use as a pharmaceutical.
12. A pharmaceutical composition, comprising an effective dose of at least one compound as claimed in any of claims 1 to 9 and/or a physiologically acceptable salt thereof, and a pharmaceutically acceptable carrier.
13. The use of a compound of the formula Ia,
Figure imgf000127_0002
in which
A is chosen from -CH2-CH2-, -CH2-CH2-CH2- and -Y-CH2-CH2- wherein all CH2 groups can be substituted by one or more identical or different substituents R4, and wherein Y is chosen from O, S and NR11 and Y is bonded to the group Het;
Het is 5-membered to 10-membered, monocyclic or bicyclic, aromatic group which contains one or more identical or different hetero ring members chosen from N, NR13, O and S and which can be substituted by one or more identical or different substituents R5;
X is chosen from a direct bond, CH2, O, S, NH and N((Ci-C4)-alkyl), or X is absent and in this case the phenyl, naphthalenyl or heteroaryl group representing the group R3 is fused to the group Het;
R1 and R2 are independently of each other chosen from (Ci-CiO)-alkyl, (C3-Ci0)- alkenyl, (C3-Ci0)-alkynyl, (C3-Ci o)-cycloalkyl-CnH2n-, phenyl-CnH2n-, naphthalenyl- CnH2n- and heteroaryl-CnH2n-, and R2 can in addition be hydrogen, wherein the groups (Ci-Cio)-alkyl, (C3-Ci0)-cycloalkyl, (C3-Ci0)-alkenyl and (C3-Ci0)-alkynyl can all be substituted by one or more identical or different substituents R6, and the groups CnH2n can all be substituted by one or more identical or different substituents chosen from fluorine and (Ci-C4)-alkyl, and all phenyl, naphthalenyl and heteroaryl groups can independently of each other be substituted by one or more identical or different substituents R7, or R1 and R2, together with the N-CO group which carries them, form a 4-membered to 10-membered, monocyclic or bicyclic, saturated or unsaturated ring which, in addition to the ring nitrogen atom being part of the N-CO group, can contain one or two further hetero ring members chosen from N, NR12, O, S, SO and SO2 which can be identical or different, with the proviso that two ring members from the series O, S, SO and SO2 cannot be present in adjacent ring positions, wherein the ring formed by R1 and R2 and the N-CO group which carries them can be substituted by one or more identical or different substituents R8;
R3 is chosen from phenyl, naphthalenyl and heteroaryl which can all be substituted by one or more identical or different substituents chosen from halogen, (Ci-C6)-alkyl, (Ci-C6)-alkyloxy-(Ci-C6)-alkyl-, OH, (CrC6)-alkyloxy which can be substituted by one or more fluorine atoms, (Ci-C3)-alkylenedioxy which can be substituted by one or more fluorine atoms, (Ci-C6)-alkylmercapto, NH2, (Ci-C6)-alkylamino, di((Ci-C6)- alkyl)amino, ((Ci-C6)-alkyl)-CONH-, ((Ci-C6)-alkyl)-SO2NH-, di((d-C6)- alkyl)aminocarbonyl-, ((Ci-C6)-alkyl)aminocarbonyl-, ((Ci-C6)-alkyloxy)carbonyl-, COOH, CONH2, CN, CF3, ((Ci-C6)-alkyl)NHSO2-, di((Ci-C6)-alkyl)NSO2-, H2NSO2- and (d-C6)-alkyl-SO2-;
R4 is chosen from (Ci-C6)-alkyl, fluorine and oxo;
R5 is chosen from halogen, (Ci-C6)-alkyl, phenyl-CnH2n-, (Ci-C6)-alkyloxy-(Ci-C3)- alkyl-, OH, (Ci-C6)-alkyloxy which can be substituted by one or more fluorine atoms, (CrC6)-alkylmercapto, NH2, (Ci-C6)-alkylamino, di((CrC6)-alkyl)amino, ((Ci-C6)- alkyl)-CONH-, di((Ci-C6)-alkyl)aminocarbonyl-, ((Ci-CβJ-alkyOaminocarbonyl-, ((Ci- C6)-alkyloxy)carbonyl-, COOH, CONH2, CN, CF3, H2NSO2-, ((Ci-C6)-alkyl)NHSO2-, di((Ci-C6)-alkyl)NSO2- and (Ci-C6)-alkyl-SO2-, wherein the phenyl group can be substituted by one or more identical or different substituents chosen from halogen, (Ci-C4)-alkyl, CF3 and (Ci-C4)-alkyloxy;
R6 is chosen from fluorine, OH, oxo, (Ci-C6)-alkyloxy, (Ci-CβJ-alkylmercapto, di((Ci- C6)-alkyl)amino, ((Ci-C6)-alkyl)-CONH-, di((C1-C6)-alkyl)aminocarbonyl-, ((CrC6)- alkyloxy)carbonyl-, COOH, CONH2, CN and CF3;
R7 is chosen from halogen, (Ci-C6)-alkyl, (Ci-C6)-alkyloxy-(CrC3)-alkyl-, OH, (CrC6)- alkyloxy which can be substituted by one or more fluorine atoms, (CrC3)- alkylenedioxy which can be substituted by one or more fluorine atoms, (CrC6)- alkylmercapto, NH2, (Ci-C6)-alkylamino, di((Ci-C6)-alkyl)amino, ((CrC6)-alkyl)- CONH-, di((Ci-C6)-alkyl)aminocarbonyl-, ((Ci-C6)-alkyl)aminocarbonyl-, ((CrC6)- alkyloxy)carbonyl-, COOH, CONH2, CN, CF3, SF5, H2NSO2-, ((Ci-C6)-alkyl)NHSO2-, di((Ci-C6)-alkyl)NSO2- and (Ci-C6)-alkyl-SO2-;
R8 is chosen from halogen, (Ci-C6)-alkyl, (C3-C7)-cycloalkyl-CnH2n-, phenyl-CnH2n-, heteroaryl-CnH2n-, (Ci-C6)-alkyloxy-(CrC3)-alkyl-, OH, oxo, (Ci-C6)-alkyloxy which can be substituted by one or more fluorine atoms, (Ci-C3)-alkylenedioxy which can be substituted by one or more fluorine atoms, (Ci-C6)-alkylmercapto, NH2, (CrC6)- alkylamino, di((Ci-C6)-alkyl)amino, ((CrC6)-alkyl)-CONH-, di((CrC6)- alkyl)aminocarbonyl-, ((Ci-C6)-alkyl)aminocarbonyl-, ((Ci-C6)-alkyloxy)carbonyl-, COOH, CONH2, CN, CF3, SF5, H2NSO2- and (d-C6)-alkyl-SO2-, wherein all phenyl groups and heteroaryl groups can independently of each other be substituted by one or more identical or different substituents chosen from halogen, (d-C4)-alkyl, CF3 and (Ci-C4)-alkyloxy;
R11 is chosen from hydrogen, (Ci-C6)-alkyl, (C3-C7)-cycloalkyl-CnH2n-, phenyl-CnH2n-, heteroaryl-CnH2n-, ((d-C6)-alkyl)-CO-, (C3-C7)-cycloalkyl-CnH2n-CO-, phenyl-CnH2n- CO- and heteroaryl-CnH2n-CO-, wherein all phenyl groups and heteroaryl groups can be substituted by one or more identical or different substituents chosen from halogen, (Ci-C4)-alkyl, CF3 and (d-C4)-alkyloxy;
R12 is chosen from hydrogen, (Ci-CβJ-alkyl, (C3-C7)-cycloalkyl-CnH2n-, phenyl-CnH2n-, heteroaryl-CnH2n-, ((d-C6)-alkyl)-CO-, (C3-C7)-cycloalkyl-CnH2n-CO-, phenyl-CnH2n- CO-, heteroaryl-CnH2n-CO-, ((CrC6)-alkyl)-O-CO- and phenyl-CnH2n-O-CO-, wherein all phenyl groups and heteroaryl groups can be substituted by one or more identical or different substituents chosen from halogen, (Ci-C4)-alkyl, CF3 and (Ci-C4)- alkyloxy;
R13 is chosen from hydrogen, (Ci-C4)-alkyl and phenyl-CnH2n-, wherein the phenyl group can be substituted by one or more identical or different substituents chosen from halogen, (d-C4)-alkyl, CF3 and (Ci-C4)-alkyloxy, where all groups R13 are independent of each other and can be identical or different;
heteroaryl is a 5-membered to 10-membered, monocyclic or bicyclic aromatic group which contains one or more identical or different hetero ring members chosen from N, NR13, O and S;
n is 0, 1 , 2 or 3, where all numbers n are independent of each other and can be identical or different; in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, for the manufacture of a medicament for the stimulation of the expression of endothelial NO synthase.
14. The use of a compound as defined in claim 13 or a physiologically acceptable salt thereof, for the manufacture of a medicament for the treatment of cardiovascular diseases, stable or unstable angina pectoris, coronary heart disease, coronary artery disease, Prinzmetal angina, acute coronary syndrome, cardiac insufficiency, heart failure, myocardial infarction, stroke, thrombosis, peripheral artery occlusive disease, endothelial dysfunction, atherosclerosis, restenosis, endothel damage after PTCA, hypertension, essential hypertension, pulmonary hypertension, secondary hypertension, renovascular hypertension, chronic glomerulonephritis, erectile dysfunction, ventricular arrhythmia, diabetes, diabetes complications, nephropathy, retinopathy, angiogenesis, asthma bronchiale, chronic renal failure, cirrhosis of the liver, osteoporosis, restricted memory performance or a restricted ability to learn, or for the lowering of cardiovascular risk of postmenopausal women or after intake of contraceptives.
15. The use as claimed in any of claims 13 to 14, wherein in the compound of the formula Ia or a physiologically acceptable salt thereof
A is chosen from -CH2-CH2-CH2- and -Y-CH2-CH2- wherein all CH2 groups can be substituted by one or more identical or different substituents R4, and wherein Y is chosen from O, S and NR11 and Y is bonded to the group Het; Het is chosen from pyridinediyl and thiazolediyl which can all be substituted by one or more identical or different substituents R5; X is a direct bond.
16. The use as claimed in any of claims 13 to 14, wherein the compound of the formula Ia is a compound of the formula I as defined in any of claims 1 to 9 or a physiologically acceptable salt thereof.
PCT/EP2006/005706 2005-06-28 2006-06-14 Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals WO2007000246A1 (en)

Priority Applications (19)

Application Number Priority Date Filing Date Title
SI200631277T SI1899321T1 (en) 2005-06-28 2006-06-14 Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals
NZ565041A NZ565041A (en) 2005-06-28 2006-06-14 Aryl substituted pyridinediyl and thiazolediyl amides comprising a saturated linker group
CA002611953A CA2611953A1 (en) 2005-06-28 2006-06-14 Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals
AU2006264049A AU2006264049B2 (en) 2005-06-28 2006-06-14 Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals
EP06754352A EP1899321B1 (en) 2005-06-28 2006-06-14 Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals
JP2008518663A JP5149794B2 (en) 2005-06-28 2006-06-14 Heteroaryl-substituted amides containing saturated linker groups and their use as pharmaceuticals
BRPI0613717-2A BRPI0613717A2 (en) 2005-06-28 2006-06-14 heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals
RS20120131A RS52266B (en) 2005-06-28 2006-06-14 Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals
ES06754352T ES2378894T3 (en) 2005-06-28 2006-06-14 Heteroaryl substituted amides comprising a saturated binding group and its use as pharmaceuticals
AT06754352T ATE539072T1 (en) 2005-06-28 2006-06-14 HETEROARYL SUBSTITUTED AMIDES WITH SATURATED COMPOUNDING GROUP AND THEIR USE AS PHARMACEUTICALS
MX2008000044A MX2008000044A (en) 2005-06-28 2006-06-14 Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals.
PL06754352T PL1899321T3 (en) 2005-06-28 2006-06-14 Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals
CN2006800228986A CN101208328B (en) 2005-06-28 2006-06-14 Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals
DK06754352.0T DK1899321T3 (en) 2005-06-28 2006-06-14 Heteroaryl-substituted amides comprising a saturated linker group and its use as drugs
US11/958,483 US8518976B2 (en) 2005-06-28 2007-12-18 Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals
IL188382A IL188382A0 (en) 2005-06-28 2007-12-24 Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals
NO20080523A NO20080523L (en) 2005-06-28 2008-01-28 Heteroaryl substituted amides comprising a saturated linking group and their use as pharmaceutical agents
HK08113552.5A HK1122551A1 (en) 2005-06-28 2008-12-12 Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals
HR20120167T HRP20120167T1 (en) 2005-06-28 2012-02-20 Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05013870.0 2005-06-28
EP05013870A EP1741709A1 (en) 2005-06-28 2005-06-28 Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/958,483 Continuation US8518976B2 (en) 2005-06-28 2007-12-18 Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals

Publications (1)

Publication Number Publication Date
WO2007000246A1 true WO2007000246A1 (en) 2007-01-04

Family

ID=35478793

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/005706 WO2007000246A1 (en) 2005-06-28 2006-06-14 Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals

Country Status (33)

Country Link
US (1) US8518976B2 (en)
EP (2) EP1741709A1 (en)
JP (1) JP5149794B2 (en)
KR (1) KR20080027801A (en)
CN (1) CN101208328B (en)
AR (1) AR054800A1 (en)
AT (1) ATE539072T1 (en)
AU (1) AU2006264049B2 (en)
BR (1) BRPI0613717A2 (en)
CA (1) CA2611953A1 (en)
CY (1) CY1112869T1 (en)
DK (1) DK1899321T3 (en)
DO (1) DOP2006000146A (en)
ES (1) ES2378894T3 (en)
GT (1) GT200600274A (en)
HK (1) HK1122551A1 (en)
HR (1) HRP20120167T1 (en)
IL (1) IL188382A0 (en)
MA (1) MA29552B1 (en)
MX (1) MX2008000044A (en)
NO (1) NO20080523L (en)
NZ (1) NZ565041A (en)
PA (1) PA8683901A1 (en)
PE (1) PE20070102A1 (en)
PL (1) PL1899321T3 (en)
PT (1) PT1899321E (en)
RS (1) RS52266B (en)
RU (1) RU2412181C2 (en)
SI (1) SI1899321T1 (en)
TW (1) TWI378095B (en)
UY (1) UY29640A1 (en)
WO (1) WO2007000246A1 (en)
ZA (1) ZA200710002B (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1939181A1 (en) * 2006-12-27 2008-07-02 sanofi-aventis Heteroaryl-substituted carboxamides and use thereof for the stimulation of the expression of NO synthase
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
US8815772B2 (en) 2012-06-29 2014-08-26 E I Du Pont De Nemours And Company Fungicidal heterocyclic carboxamides
WO2014168522A1 (en) 2013-04-12 2014-10-16 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives
WO2015072893A1 (en) 2013-11-14 2015-05-21 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Pharmaceutical composition containing glutarimide derivatives, and application thereof for treating eosinophilic diseases

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1913471A1 (en) 1968-04-01 1969-11-13 Ici Ltd Heterocyclic compounds and processes for their preparation
US3655684A (en) 1968-09-19 1972-04-11 Hoffmann La Roche Novel substituted-oxadiazoles and a process for the manufacture thereof
GB1341375A (en) 1969-11-19 1973-12-19 Smith Kline French Lab Aminoalkylimidazoles and process for their production
EP0200024A2 (en) 1985-04-30 1986-11-05 ARZNEIMITTELWERK DRESDEN GmbH 3-Cyano-pyridines, process for their preparation and their pharmaceutical use
US5190589A (en) 1988-04-18 1993-03-02 Cedona Pharmaceuticals B.V. Compounds and process preparing a substituted or an unsubstituted 4(5)-(ω-aminoalkyl)imidazole
US5292732A (en) 1991-07-02 1994-03-08 Hoffmann-La Roche Inc. Pyrrolopyrazine derivatives
US5547972A (en) 1991-12-23 1996-08-20 The Boots Company Plc Therapeutic agents useful for treating inflammatory diseases
WO2002070520A1 (en) 2001-03-07 2002-09-12 Bayer Aktiengesellschaft Substituted 2,6-diamino-3,5-dicyano-4-aryl-pyridines and their use as adenosine receptor-selective ligands
US20030055093A1 (en) * 2001-02-13 2003-03-20 Hartmut Strobel Acylated indanyl amines and their use as pharmaceuticals
WO2003094845A2 (en) * 2002-05-08 2003-11-20 Bristol-Myers Squibb Company Pyridine-based thyroid receptor ligands
WO2004014842A1 (en) * 2002-08-07 2004-02-19 Aventis Pharma Deutschland Gmbh Acylated arylcycloalkylamines and their use as pharmaceuticals
WO2004060890A1 (en) * 2002-12-27 2004-07-22 Amgen Inc. 2-oxopyridin-3-yl thia (di) azole derivates for use in the treatment of cell proliferation and apoptosis related diseases
JP2004262890A (en) 2003-03-04 2004-09-24 Taisho Pharmaceut Co Ltd Azole derivative having 20-hete production inhibiting action
WO2004089903A1 (en) 2003-04-10 2004-10-21 Warner-Lambert Company Llc Piperidine derivatives as renin inhibitors for the treatment of hypertension
WO2004094425A1 (en) 2003-04-24 2004-11-04 Sanofi-Aventis Deutschland Gmbh Triaza- and tetraaza-anthracenedione derivatives, their preparation and their use as pharmaceuticals

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4429656Y1 (en) 1967-03-16 1969-12-08
FR2510997A1 (en) 1981-08-10 1983-02-11 Sanofi Sa NOVEL DERIVATIVES OF METHYL-4-PHENYL-6-PYRIDAZINE, PROCESS FOR THEIR PREPARATION AND ACTIVE MEDICINES ON CENTRAL NERVOUS SYSTEM CONTAINING THE SAME
CA1218655A (en) 1983-01-28 1987-03-03 Kathleen Biziere Process for the preparation of pyridazine derivatives having a psychotropic action
US4710502A (en) 1985-11-04 1987-12-01 American Cyanamid Company 3-heteroarylalkyl-4-quinazolinones
US4701502A (en) * 1985-12-13 1987-10-20 E. I. Du Pont De Nemours And Company Chip resistant primer composition V'
WO1996018616A1 (en) * 1994-12-12 1996-06-20 Merck & Co., Inc. Substituted 2-aminopyridines as inhibitors of nitric oxide synthase
NZ335810A (en) 1996-12-10 2001-03-30 Abbott Lab 3-(2-azetidinyl-methoxy)-pyridine derivatives useful as analgesics and azetidinyl intermediates
US6180597B1 (en) 1998-03-19 2001-01-30 Brigham And Women's Hospital, Inc. Upregulation of Type III endothelial cell nitric oxide synthase by rho GTPase function inhibitors
AU4990599A (en) 1998-07-14 2000-02-07 Brigham And Women's Hospital Upregulation of type iii endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization
SE9803518D0 (en) * 1998-10-15 1998-10-15 Astra Pharma Prod Novel compounds
AU3511500A (en) * 1999-03-05 2000-09-21 Trustees Of University Technology Corporation, The Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide-induced clinical conditions
DE19947154A1 (en) * 1999-10-01 2001-10-04 Bayer Ag Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and their use
AU2001244608A1 (en) 2000-03-31 2001-10-15 Takeda Chemical Industries Ltd. Fused heterocyclic derivatives, their production and use
JP2002255971A (en) * 2000-03-31 2002-09-11 Takeda Chem Ind Ltd Fused heterocyclic derivative, method for manufacturing the same and usage of the same
MXPA03000436A (en) * 2000-07-18 2003-06-24 Yamanouchi Pharma Co Ltd Medicine comprising dicyanopyridine derivative.
PE20020856A1 (en) 2001-02-13 2002-11-11 Aventis Pharma Gmbh 1,2,3,4-TETRAHYDRONAFTIL ACILATED AMINES
MY136316A (en) 2001-02-13 2008-09-30 Sanofi Aventis Deutschland Acylated 6,7,8,9-tetrahydro-5h-benzocycloheptenyl amines and their use as pharmaceutical.
TWI241190B (en) 2001-02-13 2005-10-11 Aventis Pharma Gmbh 4-Fluoro-N-indan-2-yl benzamide and its use as pharmaceutical
PL367130A1 (en) * 2001-05-29 2005-02-21 Schering Aktiengesellschaft Cdk inhibiting pyrimidines, production thereof and their use as medicaments
WO2003022821A1 (en) * 2001-09-06 2003-03-20 Taisho Pharmaceutical Co., Ltd. Heterocycle derivative having 20-hete-producing enzyme inhibitory activity
UY27487A1 (en) * 2001-10-17 2003-05-30 Boehringer Ingelheim Pharma PIRIMIDINE DERIVATIVES, MEDICATIONS CONTAINING THESE COMPOUNDS, THEIR EMPLOYMENT AND PROCEDURE FOR PREPARATION
DE10201240A1 (en) 2002-01-15 2003-07-24 Bayer Ag New 1-substituted fused bicyclic uracil derivatives, are poly-(ADP-ribose) synthase inhibitors useful for treating e.g. ischemia, reperfusion damage, cardiovascular diseases, arthritis, asthma and neurodegenerative diseases
FR2837201A1 (en) 2002-03-18 2003-09-19 Servier Lab New quinazoline derivatives are farnesyl transferase inhibitors, useful for treating cancer, restenosis following angioplasty or vascular surgery, and type 1 neurofibromatosis
JP2005531520A (en) * 2002-03-28 2005-10-20 メルク　エンド　カムパニー　インコーポレーテッド Substituted 2,3-diphenylpyridines
EP1388341A1 (en) 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals
EP1388342A1 (en) 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals
US7186735B2 (en) 2002-08-07 2007-03-06 Sanofi-Aventis Deutschland Gmbh Acylated arylcycloalkylamines and their use as pharmaceuticals
ES2338545T3 (en) * 2002-12-20 2010-05-10 Pfizer Products Inc. PIRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELLULAR GROWTH.
CN100360126C (en) * 2003-01-31 2008-01-09 港大科桥有限公司 Method for treating ischemic stroke with melatonin
JP2004269469A (en) * 2003-03-12 2004-09-30 Yamanouchi Pharmaceut Co Ltd Pyrimidine derivative or salt thereof
US7538233B2 (en) * 2003-09-05 2009-05-26 Aventis Pharmaceuticals Inc. Coumarins as iNOS inhibitors
AU2004291082A1 (en) * 2003-11-13 2005-06-02 The General Hospital Corporation Methods for treating pain
ZA200605624B (en) * 2004-01-12 2007-11-28 Applied Research Systems Thiazole derivatives and use thereof
GB0402809D0 (en) * 2004-02-09 2004-03-10 Glaxo Group Ltd Chemical compounds

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1913471A1 (en) 1968-04-01 1969-11-13 Ici Ltd Heterocyclic compounds and processes for their preparation
US3655684A (en) 1968-09-19 1972-04-11 Hoffmann La Roche Novel substituted-oxadiazoles and a process for the manufacture thereof
GB1341375A (en) 1969-11-19 1973-12-19 Smith Kline French Lab Aminoalkylimidazoles and process for their production
EP0200024A2 (en) 1985-04-30 1986-11-05 ARZNEIMITTELWERK DRESDEN GmbH 3-Cyano-pyridines, process for their preparation and their pharmaceutical use
US5190589A (en) 1988-04-18 1993-03-02 Cedona Pharmaceuticals B.V. Compounds and process preparing a substituted or an unsubstituted 4(5)-(ω-aminoalkyl)imidazole
US5292732A (en) 1991-07-02 1994-03-08 Hoffmann-La Roche Inc. Pyrrolopyrazine derivatives
US5547972A (en) 1991-12-23 1996-08-20 The Boots Company Plc Therapeutic agents useful for treating inflammatory diseases
US20030055093A1 (en) * 2001-02-13 2003-03-20 Hartmut Strobel Acylated indanyl amines and their use as pharmaceuticals
WO2002070520A1 (en) 2001-03-07 2002-09-12 Bayer Aktiengesellschaft Substituted 2,6-diamino-3,5-dicyano-4-aryl-pyridines and their use as adenosine receptor-selective ligands
WO2003094845A2 (en) * 2002-05-08 2003-11-20 Bristol-Myers Squibb Company Pyridine-based thyroid receptor ligands
WO2004014842A1 (en) * 2002-08-07 2004-02-19 Aventis Pharma Deutschland Gmbh Acylated arylcycloalkylamines and their use as pharmaceuticals
WO2004060890A1 (en) * 2002-12-27 2004-07-22 Amgen Inc. 2-oxopyridin-3-yl thia (di) azole derivates for use in the treatment of cell proliferation and apoptosis related diseases
JP2004262890A (en) 2003-03-04 2004-09-24 Taisho Pharmaceut Co Ltd Azole derivative having 20-hete production inhibiting action
WO2004089903A1 (en) 2003-04-10 2004-10-21 Warner-Lambert Company Llc Piperidine derivatives as renin inhibitors for the treatment of hypertension
WO2004094425A1 (en) 2003-04-24 2004-11-04 Sanofi-Aventis Deutschland Gmbh Triaza- and tetraaza-anthracenedione derivatives, their preparation and their use as pharmaceuticals

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
HAGEN ET AL., PHARMAZIE, vol. 45, 1990, pages 343
KOTHA ET AL., TETRAHEDRON, vol. 58, 2002, pages 9633
LIPINSKI ET AL., J. MED. CHEM., vol. 29, 1986, pages 2154
MEIJERE ET AL., ANGEW. CHEM. INT. ED., vol. 33, 1994, pages 2379
TILLEY ET AL., J. ORG. CHEM., vol. 53, 1988, pages 386

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1939181A1 (en) * 2006-12-27 2008-07-02 sanofi-aventis Heteroaryl-substituted carboxamides and use thereof for the stimulation of the expression of NO synthase
WO2008077507A1 (en) * 2006-12-27 2008-07-03 Sanofi-Aventis Heteroaryl-substituted carboxamides and use thereof for the stimulation of the expression of no synthase
US8188291B2 (en) 2006-12-27 2012-05-29 Sanofi-Aventis Heteroaryl-substituted carboxamides and their use as pharmaceuticals
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
US8815772B2 (en) 2012-06-29 2014-08-26 E I Du Pont De Nemours And Company Fungicidal heterocyclic carboxamides
US10155745B2 (en) 2013-04-12 2018-12-18 Obschestvo S Ogranichennoi Otvetstvennostiyu “Pharmenterprises” Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives
US10155743B2 (en) 2013-04-12 2018-12-18 Obschestvo S Ogranichennoi Otvetstvennostiyu “Pharmaenterprises” Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives
KR20160021092A (en) * 2013-04-12 2016-02-24 오브셰스트보 에스 오그라니첸노이 오트베트스트벤노스티주 “파름엔터프라지즈” Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives
US9815814B2 (en) 2013-04-12 2017-11-14 Obschestvo S Ogranichennoi Otvetstvennostiyu “Pharmenterprises” Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives
KR102296182B1 (en) * 2013-04-12 2021-09-02 엘티디 “발렌타-인텔렉트” Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives
US10155747B2 (en) 2013-04-12 2018-12-18 Obschestvo S Ogranichennoi Otvetstvennostiyu “Pharmenterprises” Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives
US10155744B2 (en) 2013-04-12 2018-12-18 Obschestvo S Ogranichennoi Otvetstvennostiyu “Pharmenterprises” Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives
KR20200069381A (en) * 2013-04-12 2020-06-16 오브셰스트보 에스 오그라니첸노이 오트베트스트벤노스티주 “파름엔터프라지즈” Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives
US10155746B2 (en) 2013-04-12 2018-12-18 Obschestvo S Ogranichennot Otvetstvennostiyu “Pharmenterprises” Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives
WO2014168522A1 (en) 2013-04-12 2014-10-16 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives
US10196377B2 (en) 2013-04-12 2019-02-05 Obschestvo S Ogranichennoi Otvetstvennostiyu “Pharmenterprises” Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives
KR102255929B1 (en) * 2013-04-12 2021-05-26 오브셰스트보 에스 오그라니첸노이 오트베트스트벤노스티주 “파름엔터프라지즈” Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives
EP3725785A1 (en) 2013-04-12 2020-10-21 Obschestvo S Ogranichennoi Otvetstennostiyu "Pharmenterprises" Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives
US10377739B2 (en) 2013-04-12 2019-08-13 Obschestvo S Ogranichennoi Otvetstvennostiyu “Pharmenterprises” Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives
EP3722290A1 (en) 2013-04-12 2020-10-14 Obschestvo S Ogranichennoi Otvetstennostiyu "Pharmenterprises" Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives
US10220029B2 (en) 2013-11-14 2019-03-05 Obschestvo S Ogranichennoi Otvetstvennostiyu “Pharmenterprises” Pharmaceutical composition comprising glutarimide derivatives and use thereof in the treatment of eosinophilic diseases
EA032955B3 (en) * 2013-11-14 2020-02-27 Общество С Ограниченной Ответственностью "Хемиммьюн Терапьютикс" Use of a glutarimide derivative in the treatment of eosinophilic diseases
EA032940B1 (en) * 2013-11-14 2019-08-30 Общество С Ограниченной Ответственностью "Рсв Терапевтикс" Method for treatment of eosinophilic diseases using a glutarimide derivative compound
EA032955B1 (en) * 2013-11-14 2019-08-30 Общество С Ограниченной Ответственностью "Хемиммьюн Терапьютикс" Use of a glutarimide derivative in the treatment of eosinophilic diseases
EP3466425A1 (en) 2013-11-14 2019-04-10 Obschestvo S Ogranichennoi Otvetstvennostiyu "Pharmenterprises" Pharmaceutical composition comprising glutarimide derivatives and use thereof in the treatment of eosinophilic diseases
EA037447B1 (en) * 2013-11-14 2021-03-30 Общество С Ограниченной Ответственностью "Атд Терапевтикс" Method of treating eosinophilic diseases
WO2015072893A1 (en) 2013-11-14 2015-05-21 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Pharmaceutical composition containing glutarimide derivatives, and application thereof for treating eosinophilic diseases
US9949962B2 (en) 2013-11-14 2018-04-24 Obschestvo S Ogranichennoi Otvetstvennostiyu “Pharmenterprises” Pharmaceutical composition comprising glutarimide derivatives and use thereof in the treatment of eosinophilic diseases

Also Published As

Publication number Publication date
RS52266B (en) 2012-10-31
ES2378894T3 (en) 2012-04-18
NO20080523L (en) 2008-01-28
UY29640A1 (en) 2007-01-31
RU2008102966A (en) 2009-08-10
PL1899321T3 (en) 2012-05-31
US20080171739A1 (en) 2008-07-17
AU2006264049B2 (en) 2012-04-12
JP5149794B2 (en) 2013-02-20
NZ565041A (en) 2011-03-31
PT1899321E (en) 2012-03-19
TW200738673A (en) 2007-10-16
AR054800A1 (en) 2007-07-18
RU2412181C2 (en) 2011-02-20
TWI378095B (en) 2012-12-01
US8518976B2 (en) 2013-08-27
HRP20120167T1 (en) 2012-03-31
IL188382A0 (en) 2008-04-13
PE20070102A1 (en) 2007-03-02
DK1899321T3 (en) 2012-04-16
CN101208328B (en) 2012-02-29
EP1899321A1 (en) 2008-03-19
CN101208328A (en) 2008-06-25
EP1899321B1 (en) 2011-12-28
CY1112869T1 (en) 2016-04-13
BRPI0613717A2 (en) 2011-02-08
ZA200710002B (en) 2008-11-26
AU2006264049A1 (en) 2007-01-04
PA8683901A1 (en) 2007-01-17
EP1741709A1 (en) 2007-01-10
GT200600274A (en) 2007-02-05
DOP2006000146A (en) 2006-12-31
ATE539072T1 (en) 2012-01-15
JP2008543958A (en) 2008-12-04
CA2611953A1 (en) 2007-01-04
HK1122551A1 (en) 2009-05-22
SI1899321T1 (en) 2012-04-30
MX2008000044A (en) 2008-03-19
MA29552B1 (en) 2008-06-02
KR20080027801A (en) 2008-03-28

Similar Documents

Publication Publication Date Title
ES2322964T3 (en) AMIDAS REPLACED WITH HETEROARILO UNDERSTANDING AN UNATURED OR CYCLIC UNION GROUP, AND ITS USE AS PHARMACEUTICAL AGENTS.
EP2121612B1 (en) Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals
US8304438B2 (en) Heteroarylacrylamides and their use as pharmaceuticals
ES2373651T3 (en) HETEROARIL-CONDENSED ACCESSED CYCLLOCHYLAMINES AND THEIR USE AS PHARMACEUTICAL COMPOUNDS.
MXPA05000697A (en) Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals.
US8188291B2 (en) Heteroaryl-substituted carboxamides and their use as pharmaceuticals
US8518976B2 (en) Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals

Legal Events

Date Code Title Description
DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 12007502682

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: DZP2007000737

Country of ref document: DZ

WWE Wipo information: entry into national phase

Ref document number: 2611953

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006754352

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006264049

Country of ref document: AU

Ref document number: 188382

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 200680022898.6

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2008518663

Country of ref document: JP

Ref document number: 07136622

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 6023/CHENP/2007

Country of ref document: IN

Ref document number: 1020077030929

Country of ref document: KR

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: MX/a/2008/000044

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 565041

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2008102966

Country of ref document: RU

WWE Wipo information: entry into national phase

Ref document number: 2006264049

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2006264049

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2006754352

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0613717

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20071228

WWE Wipo information: entry into national phase

Ref document number: P-2012/0131

Country of ref document: RS